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Abstract 
Background: Chronic kidney disease stage 5 (CKD5) with end-stage renal failure 
(ESRF) is not common but it is expensive to treat, despite advances in technology. 
Appropriate service provision requires good quality information on the population served 
and the services provided. In Romania this is in limited supply. 
Aim: To estimate current and future service needs for CKD5 in Romania.  
Methods:  Desktop research, surveys of a sample of Romanian treatment centres, and 
mathematical modelling. The baseline renal replacement therapy (RRT) stock was 
calculated using the capture-recapture method (CRM).  The reported % of cases with 
diabetic nephropathy was compared with the expected % based on population attributable 
risk (PAR%) and trends in disease precursors.  The acceptance rate was estimated using 
the Impact Fraction method. Needs for numbers of treatment places were calculated from 
service activity and clinical parameters (stock, acceptance and mortality) in a spreadsheet 
model. Estimates were made under variant scenarios for two periods: calibration and 
validation (1997-2006) and projection (2007-2016).  
Results: In Romania in 1997, the prevalence of chronic kidney disease (CKD) stages 1 to 
5 was estimated at 1,222.5 per million population (pmp). There was a strong association 
between CKD5 and diabetes plus hypertension (OR =7.73 [95% CI: 0.99 to 60.38]). 
Increasing trends in age, diabetes and hypertension suggest an increasing incidence of 
CKD5; but a downward trend in smoking will offset this. Reported national RRT stock in 
Romania was 139 pmp in 1997 and 250 pmp in 2003. The CRM suggested that the 
Centre Questionnaire and EDTA data covered 71% of the total stock at baseline (2,995 
patients). The % of CKD5 on RRT reported to have diabetic nephropathy was 10%, much 
less than the PAR%-based estimate of 30.5%. Acceptance and stock varied between the 
14 centres from 11 to 85 pmp, and 112 to 222 pmp respectively. In the calibration period, 
two of the scenarios tried gave figures for 2006 of 238 and 251, close to the observed 
figure of 250. (Other scenarios gave figures from 238 to 721).  Projecting the two chosen 
scenarios to 2016 gave 239 and 276 pmp. (Other scenarios gave up to 1,940 pmp.)   
Conclusions: The information base for this modelling exercise was weak. However there 
appears to be under-provision of care for CKD5 in Romania, particularly for diabetic 
nephropathy. 
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1  Introduction 
1.1  Planning health care  
One of the aims of any health care system is to improve efficiency by deriving increased 
benefits from scarce resources
1
. This challenge is particularly relevant to Romania, which 
has a lower GDP and devotes less of it to health care than most other European 
countries
2
.  
One priority area for planners of health care is the treatment of medical conditions that 
are costly to treat but have a substantial impact on morbidity and mortality, even though 
the absolute numbers of patients involved may be relatively low. This has to be balanced 
against care for other conditions that are more common but less damaging to health 
and/or less costly to manage.   
1.2  Chronic kidney disease (CKD) 
Chronic kidney disease does not rank high among causes of death
2
 but it is of concern to 
managers and health services researchers because in most cases, without treatment, 
surviving with this chronic condition has a poor outcome.  Moreover, treatment involves 
high technology and high costs of care, with an average of 12-15 hours treatment a week 
for a patient on haemodialysis
3,
 
4,
 
5
 or for very limited numbers of patients, a transplant. 
Improving technology and an increasing pool or ‘stock’ of prevalent renal disease means 
greater demands on both providers of care and third party payers.  
Health analysts have argued that in comparison with for example many cancers, treatment 
of end stage renal failure is effective in terms of avoiding years of life lost, and that in 
cost-benefit terms, more rational resource allocation decisions could be made 
6, 7, 8
. Some 
of the relevant considerations have been set out by Cameron 
6
: 
What is the impact of CKD on the health status and the quality of life of a renal patient? 
What is the impact on economic activity? 
What is the impact on the patient’s family? 
What future can be expected for these patients as individuals and from the societal point of view?  
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1.3  The research question and approach 
The research question is: 
How might epidemiological and health care systems data be used to inform the planning 
of services for renal replacement therapy in Romania? 
The approach is to:  
i) review and collect relevant information on the epidemiology of renal disease and 
its risk factors; 
ii) estimate future incidence and prevalence of renal disease and its risk factors;  
iii) review and collect information on health care effectiveness, provision, policies 
and guidelines; and 
iv) construct a health care system model to forecast future health care needs in the 
light of the future burden of renal disease, and to explore alternative service 
configurations. 
1.4  Research outline: aim, specific objectives, methodology and methods, design 
and setting, outcomes 
1.4.1  Aim 
This research aim was to investigate the future requirement for treatment of CKD5 in 
Romania.  
The intention was to provide evidence-based policy recommendations for the National 
RRT Programme under the political lead of the Ministry of Public Health and funded by 
the National Health Insurance Fund. The Romanian Society for Nephrology and Renal 
Registry were also stakeholders. 
1.4.2  Specific objectives  
The specific objectives of this research were: 
1 to estimate the recent and current burden of CKD and its precursor conditions in 
Romania and on this basis to estimate the future burden; 
2 to describe the baseline (1997) provision of services for CKD5 in Romania; 
3 to measure observed clinical outcomes (survival) for a sample of patients with 
CKD5 undergoing RRT) in Romania; 
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4 to estimate RRT annual operational costs in a sample of Romanian units as a basis 
for  a cost-effectiveness analysis (CEA); 
5 to identify and describe relevant Romanian policies and clinical protocols, and to 
assess local RRT provision against these; and 
6 to calibrate and validate an RRT treatment model for the Romanian national renal 
programme, and to make recommendations based on different model scenarios 
which may assist future service planning. 
1.4.3  Methodology and methods 
The methodology included:  
i) a review of the relevant literature on the epidemiology of kidney disease (CKD) 
and its precursor conditions, on CKD5 and RRT, on clinical outcomes, on health 
economics (CEA or cost-effectiveness and including CUA or cost-utility) and on 
treatment modelling for CKD;  
ii) collection of both quantitative and qualitative data, from both primary and 
secondary sources;  
iii) supplementary analytical methods including capture-recapture and survival 
analysis to provide estimates of parameters for the treatment model; and 
iv) a spreadsheet-based cohort model to estimate future needs for treatment for renal 
CKD5 in the light of changes in population, incidence of disease, survival and the 
availability of different treatment (RRT) modalities.  
1.4.4  Data 
Data were collected: 
 for Romania as a whole and other countries, using secondary sources ;  
 for Romania as whole using primary sources: a specially designed form (the Centre 
Questionnaire) and structured interviews with national key persons; and 
 for different areas within Romania, from sampled RRT centres, using a specially 
designed form for individual patients, but also including cost data from the annual 
centre RRT programme and interviews with local key persons.  These sources of data 
were mainly primary, but files and clinical notes were also consulted. 
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 Data collection from primary and secondary sources and preliminary analyses for the 
empirical part were carried out during a 12 month period, from April 1998 to March 
1999. Secondary sources of data were further used for follow-up by 2006 to 2008 for 
model validation purposes.  
1.4.5  Settings 
The setting for national level of information included nearly half of RRT adult centres in 
1998; the CRM allowed for two-thirds of crude estimates to be considered as national 
CKD5 baseline in the treatment model. The settings for outcome, such as survival in newly 
accepted patients on dialysis and cost measurements were two teaching units and one 
district unit and these were at the basis of CEA.  
1.4.6  Supplementary analyses 
In order to validate the baseline stock estimate for the model and to supplement the 
information with a potentially better ascertained number of patients on RRT a capture-
recapture method (CRM) was used with data from two quasi-independent data sources: 
the Centre Questionnaire and the European Dialysis and Transplantation questionnaire, 
both for 1997 data. Three historical cohorts from three centres were then used to calculate 
observed 1-, 2 and 3- year survival estimates. The Kaplan-Meier method was used and 
further, a Cox regression was used to identify possible variables which may influence 
survival of the Romanian CKD5-RRT patient. 
1.4.7  The model 
The model had a multi-centre historical cohort design.  It was based on the following data 
from the sampled centres: 
- age and gender profiles based on 38% of the CKD5 patient stock (source: Centre 
Questionnaire);   
- probabilities of survival at 1- , 2- and 3 years for the Romanian CKD5-RRT patient.  
(Five- year survival probabilities were taken from the literature for validation 
purposes); 
- differences in survival probabilities by modality of RRT (HD and CAPD); 
- average cost per patient’s treatment by modality in each of the three centres;  and 
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- the cost per one year of life gained for the Romanian CKD5-RRT patient. 
Estimated projections of precursor conditions were based on the population aged 15 years 
and over.  The model was used to estimate the burden of renal disease in Romania in 
2006 based on burden data for 1997, and a variety of scenarios for the other parameter 
values based on the evidence gathered during the study. The results were compared with 
Ministry of Health and National Health Insurance Fund data for 2006, and on this basis a 
reduced set of plausible parameter scenarios was chosen. This reduced set was then used 
to estimate the burden in 2016.  
1.5  The structure of the thesis 
Chapter 2 provides a review of the relevant literature. This covers epidemiology 
(definitions, natural history, indicators, mortality, morbidity including precursors and risk 
factors), the role of substitutive treatment and outcomes (survival and prognostic factors: 
complications, hospitalisation, and quality of life); and policy analyses (cost-of-illness 
and cost analyses, and model-based decision analyses). The chapter ends with a more 
detailed rationale for the study.  
Chapter 3 introduces the original research and presents the results for objective 1. The 
estimates for the epidemiology of renal disease and diseases associated with progression 
to chronic renal insufficiency and ESRF in Romania are described. This chapter describes 
the epidemiological model: the methodology, methods and data sources and results. The 
main source is the national health survey of Romania (1997) and information from the 
Information and Statistics Centre of the MoH.  Estimates for the leading causes of 
chronic kidney disease/chronic renal insufficiency and ESRF are placed in an 
international context, that of reported prevalence of primary renal diseases (PRD), 
hypertension (HT) and diabetes (DM). Strengths and weaknesses are discussed. 
Chapter 4 presents the methodology, methods, data sources, data analyses and results on 
activity in the RRT network in Romania, showing the structure and functions of the 
various services involved, and national estimates for acceptance and stock rates. These 
results were used for calibrating the treatment model. 
Chapter 5 presents the methodology used, methods, data sources and analyses with 
results from three sampled units for the following parameters: treatment activity based on 
acceptance and stock of patients; and clinical outcomes (survival). 
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Chapter 6 presents the methodology, methods and data source plus results on costs and 
cost-effectiveness analysis from the three sampled units. 
Chapter 7 presents the information on treatment protocols and access to RRT for CKD5, 
based on interviews with national and local key persons and from secondary sources. 
Results for specific objective 5 are described. 
Chapter 8 describes the treatment model, the type and methods used for its construction. 
Calibration and validation were carried out for a 10-year cycle from 1997 to 2006, using 
the 1997 baseline data. The model was then used to explore six scenarios in a second 
cycle from 2007 to 2016. Strengths and weaknesses are presented.  
Chapter 9 presents a summary of the findings. The broader context of CKD is considered 
to highlight prevention strategies as well as the treatment requirements for CKD5.  It 
consists of 3 main Sections:  Discussion, Conclusions and Recommendations. The last 
section includes recommendations for further research. 
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2  The Literature 
2.1  Introduction 
The research question set out in Chapter 1 is concerned with estimating the requirement 
for renal replacement therapy in Romania. The subject matter for this literature review is 
based on a number of propositions: 
 The requirement for renal replacement therapy is not necessarily related to historical 
patterns of resource allocation.  Data on catchment populations and on the 
epidemiology of renal disease are important.  
 Romanian data on the epidemiology of renal disease are sparse, but there are data from 
other Western societies which are relevant. 
 Data on risk factors for renal disease can supplement and to some extent substitute for 
data on disease itself. Also planning involves estimating future requirements. The 
evolution of chronic renal insufficiency in an individual can take years, and so 
estimates of future requirements should be based on the distribution of ‘upstream’ risk 
factors and risk factor trends. 
 Renal failure is a chronic condition. In the absence of a ‘cure’ or recovery, such as in 
the case of acute renal failure, it requires maintenance treatment (i.e. dialysis or a 
kidney transplant). Chronic functional failure develops in the context of chronic 
kidney disease. Thus planning the provision of services requires estimates and 
projections of prevalence. Projections of prevalence require projections of length of 
survival. Thus data on prognostic factors are needed.  
 There is more than one way of managing renal failure, from the (ideally) one-off 
transplant to alternative modalities for long-term dialysis.  Data on outcomes of 
treatment for the different modalities are needed. 
 Services for chronic renal failure with CKD5 are costly and are in competition for 
resources with services for other conditions. As part of the process of considering 
options for provision, the costs and cost-effectiveness of different options should be 
considered.  
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 One of the main objectives of this study is to build a renal care system model for 
Romania.  There are a number of these in the literature for other countries, and they 
will be reviewed. 
For these reasons, the scope of the literature review is very wide. After a description of 
the search methods used, this chapter consists of: 
 definitions of chronic kidney disease 
 risk factors and precursor conditions 
 disease progression and prognostic factors 
 treatment 
 outcomes   
 the population burden of chronic kidney disease 
 economic evaluation and cost-effectiveness studies; and 
 decision support modelling for policy and planning.  
Also in considering the extent to which existing services meet the needs, information is 
required on current levels of provision, and also on current policies and guidelines.  
These are topics for chapters 3 and 9. 
2.2  Search methods 
The following electronic libraries were searched: United States Renal Data System 
(http://www.usrds.org accessed in 1997; 2000; 2010 
9
; The Cochrane Library (2000 to 
2009 for end-stage kidney disease reviews under the Cochrane Renal Group) at 
http//www.thecochranelibrary.com 
10
; ANZDATA (New Zealand Renal Database) 
11
 ; 
this was accessed through the main European gateway to renal databases, the world-wide-
web page of the European Renal Association- European Dialysis and Transplant 
Association, ERA-EDTA; www.ncchta.org (hypertension) 
12
; www.uptodate.com 
13
; 
www.dh.gov.uk (NSF Renal Services) 
14
; BMC Nephrology (Open Access: 2000- 2007) 
15
 ; and most related journals through ADITUS (Athens library) for remote access of 
journals) 
16
.   
MeSH key words used in searches relevant for each section of the literature review 
included:  
 end stage renal disease OR failure (ESRD, ESRF for papers up to 2008; CKD 
from 2008) AND 
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 renal replacement therapy (RRT) AND :  
 natural history, primary renal disease, hypertension, diabetes, obesity, mortality, 
survival, quality of life, utilities, complications, co-morbidity, computer 
modelling, competitive risk analysis, decision making, costs, cost analyses.  
Each of these combinations of key words was searched (Appendix 1).  This revealed a 
total of 788 papers.  A further selection based on the abstracts reduced this to 250. Case 
reports and papers reporting case series with a very small number of patients, i.e. <30 per 
sample, were excluded (28 papers). Although some non-English-language research 
papers were considered, most were from the English and American literature. 
The following journals, from a full list of journals provided in Appendix 1, were also 
hand-searched. After 2003 three of these were accessed electronically through ToC alerts:  
1 American Journal of Kidney Diseases 1990 to 2011; 
2 Journal of the American Society of Nephrology 1990 to 2011;  
3 Kidney International 1990 to 2002; and 
4 Nephrology Dialysis and Transplantation 1993 to 2012 (main access through 
personal subscription). 
The initial literature search also yielded 33 relevant papers published before 1990, all 
related to haemodialysis. Publications have increased in number since the 1990s at least 
partly because of recent developments in dialysis technology, with a controversial 
literature on differences in effectiveness of different modalities: According to some 
studies, but not others, outcomes such as survival appear to be better with peritoneal 
dialysis than haemodialysis. A back search from references dating from 1997-2000 
produced 7 relevant earlier papers, the earliest related to renal services dated 1968 
17
. 
Most papers published before the 1990s based their research on small samples (< 30 
patients) and little comparative data and that is why they were excluded. Some Romanian 
grey literature was also consulted in the form of annual reports.  
 2.3  Definitions of chronic kidney disease  
2.3.1  Clinical definitions 
When kidneys are affected by a chronic disease their function is not impaired straight 
away. If one kidney is lost due to disease, surgery, etc, the other, if healthy, will fulfil the 
renal function at 100% efficiency. Chronic renal insufficiency, defined here as chronic 
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kidney disease (CKD) starts developing when less than 25% of the nephron population 
remains functional, regardless of whether the patient has one or two kidneys. Clinically it 
is described as mild when in an incipient phase (CKD1), and then moderate (CKD2 and 
CKD3a and 3b) progressing to severe (CKD4 and final CKD5). Although this study is 
concerned mainly with CKD5, the wider picture of chronic renal insufficiency and 
conditions leading to it is sketched in.  
The definition and staging of CKD over the decades have been through a variety of 
formulations. The first dates from the mid 1970s (Cockroft-Gault) 
18
. 
As a result there are several clinical terms for the condition or syndrome under study. 
Chronic kidney disease (CKD) has been the established terminology since 2009 
19
, but, 
chronic renal failure (CRF), chronic renal insufficiency (CRI), end-stage renal disease 
(ESRD), end stage renal failure (ESRF) were used widely in the 1970s throughout the 
1990s and even in the first decade of the new millennium. These latter terms were often 
used interchangeably by clinicians from Europe and North America 
20,
 
21
.  
When kidney function is chronically affected, the spectrum of insufficiency of their 
functionality and clinical abnormalities can be characterised as falling into one of five 
stages. Middleton, quoting K/DOQI of the US National Kidney Foundation gives the 
staging in Table 2.1 
22
 and Figure 2.1 adapted from Map of Medicine shows the flow 
diagram for assessment, investigation and management of CKD 
23
: 
Table 2.1:  Staging of Chronic Kidney Disease and biological functionality 
Stage Description GFR (ml/min/1.73 m
2
) 
1 Chronic kidney disease (normal GFR) (CKD1) ≥90 
2 Chronic kidney disease with mild decrease in GFR (CKD2) 60-89 
3 Chronic kidney disease with moderate decrease in GFR 
(CKD3a and 3b) 
a
 
30-59 (30-44 and 45-
59) 
4 Chronic kidney disease with severe decrease in GFR 
(CKD4) 
15-29 
5 Chronic kidney disease with function failure (CKD5) <15 
a
 some clinical differences were noticed in US patients with GFR at 45-59 ml/min/1.73m
2
 
compared with those at levels of 30-44 ml/min/1.73m
2
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Fig 2.1  Chronic kidney disease – detection and management from primary care to 
tertiary care – adapted from Map of Medicine, UK (1Romania’s health care 
system, 2011) 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
The five (or six) stages are commonly grouped as follows: 
 early or mild to moderate chronic insufficiency (stages 1-2): functionally the kidneys 
are still being controlled by compensatory mechanisms, but on investigation, clinical 
and pathological abnormalities can be found such as an altered glomerular filtration 
rate (GFR).  The patient usually seeks medical advice for general complaints such as 
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fatigue, headache etc. and renal insufficiency is discovered during routine biological 
check-up 
24
; and  
 late ( stages 3-4 or 3a, 3b and 4) and end stage renal failure, ESRF (stage 5): renal 
insufficiency is far enough advanced to be detected both clinically and pathologically. 
When CKD reaches stage 5, replacement therapy must be planned and access to a 
required RRT modality depends on many factors: age (but not solely), underlying 
precursor condition, co-morbidity, evolution and natural history. The extent of failure 
is usually defined by the levels of GFR. The great majority of epidemiological studies 
are at this “end” stage or CKD5, the “visible” tip of the larger iceberg of chronic 
kidney disease.  Many patients also suffer from secondary complications from 
conditions leading to CKD before they enter RRT 
25
; and the mild to moderate stages 
are an emerging area of research despite the fact that one classification dates since the 
mid-1970s 
18
. 
Early formulae for determining clinical chronic renal insufficiency stages were based on 
measurable proxy variables: age, sex, weight and serum creatinine 
18
. Later the Modified 
Diet in Renal Disease (MDRD) study established formulae which use between four and 
six variables (serum creatinine, serum urea nitrogen, serum albumin, age, sex and 
ethnicity) to predict the GFR and thus assign the stage of CKD 
26
.      
The latest formula, after the MDRD (Modification of Diet in Renal Disease), is the CKD-
EPI (Chronic Kidney Disease Collaboration). The two formulae, MDRD and CKD-EPI 
have been validated against each other and tried to standardise the criteria used in the 
definition of CKD. The authors (Earley et al) agree that neither the CKD-EPI nor the 
MDRD Study equation is optimal across all populations and GFR ranges. The authors 
conclude that using a single equation for reporting estimated GFR (marker of defining 
CKD stages) requires a tradeoff to optimize performance at either higher or lower GFR 
ranges. They further go on to say that “a general practice and public health perspective 
favors adopting the CKD-EPI equation in North America, Europe, and Australia and 
using it as a comparator for new equations in all locations”. Moreover they specify that 
“whether the precision of creatinine-based equations can be substantially improved 
without adding other variables remains uncertain”27. This is despite the fact that other 
authors report in a meta-analysis that “the CKD-EPI equation classified fewer individuals 
as having CKD and more accurately categorized the risk for mortality and ESRD than did 
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the MDRD Study equation across a broad range of populations”28. The use of K/DOQI 
criteria were deemed valid for this study which considers CKD5 with renal insufficiency 
or failure under replacement therapy (Table 2.1).  
2.3.2  Epidemiological definitions 
Descriptive epidemiological studies aim to measure the frequency of occurrence of a 
disease in a defined population and time period, so as to provide an estimate of the 
associated population “burden”29. This requires a clear, explicit definition that can be 
used reliably by different investigators in different contexts.  
The following selection of quotations helps to identify the relevant criteria: 
 “Chronic renal failure (CRF) is the progressive decline in glomerular filtrate rate 
(GFR) that is often irreversible owing to progressive loss of functioning nephrons... 
The most reliable evidence of CRF is previously sustained increases in serum 
creatinine (Cr). An X-ray or renal ultrasonography with documentation of bilateral 
renal size less than 9 cm suggests CRF. In all other cases an elevated serum Cr is 
assumed to be due to acute renal failure (ARF)” 22; 25;  
 “Renal injury of a more sustained nature which leads to progressive destruction of 
nephron mass;...proof of chronicity provided also by bilateral reduction of kidney size 
by plain X-ray, ultrasonograph exam, intravenous pyelography (BUN<100 mg/dl) or 
tomography; reliable, but not specific clinical and pathological proofs are: 
proteinuria, anaemia, hyperphosphatemia, hypocalcemia; specific signs in the urine 
sediment: broad casts, hematuria (deteriorated erythrocytes)” 30; 
 “Chronic renal failure is defined as the irreversible, substantial, and usually long-
standing loss of renal function causing ill-health, usually referred to as uraemia. End-
stage renal failure is the degree of chronic renal failure that without renal replacement 
treatment would result in death. The severity of chronic renal failure can be classified 
by sequences and proportion of renal function lost, as mild (GFR =30-50 ml/min), 
moderate (GFR =10-29 ml/min), severe (GFR =<10 ml/min), and end -stage <5 
ml/min)“ 31.  
In this research the focus was on CKD5 with its implication that kidneys have reached the 
final stage of an irreversible anatomical and functional deterioration, and the patient 
requires renal replacement therapy (RRT).  The epidemiological definition of the CKD5 
  
 
29 
case chosen for this study was adapted from the K/DOQI definition of CKD staging and 
includes criteria as follows: 
a patient who has:  
- received continual renal replacement therapy for over 90 days, irrespective of the  
primary underlying renal disease  
-     and at least one abnormal biochemical result of: 
- serum creatinine:    9 mg/dl; and 
- glomerular filtrate rate (GFR)  15 ml/min/ 1.73 m2 (stage 5); and/or  
-  bilaterally (or unilaterally if only one kidney), kidney sizes on a plain X-
ray film or  
- ultrasonographic examination to be  9 cm;  
-      and at least one clinically diagnosed co-morbidity of: 
-        anaemia 
-        gastro-intestinal disorders,  
-        neurological disorder,  
-        cardio-vascular disorders,  
-        raised blood pressure ( 140/90 mm Hg)  
One reason for choosing these parameters and measurements was that these were used by 
the Romanian renal centres and Renal Registry in the definition of the condition at the 
time when the field work started in 1998. 
2.4  Risk factors and precursor conditions  
2.4.1  Introduction 
Most of the patho-physiological factors that lead to renal damage are still not fully 
understood, and the relationship between uraemic syndrome and alteration of renal 
function varies from patient to patient. To summarise the literature, the emergence of 
chronic renal disease mostly depends on: 
 primary renal diseases (PRD) such as lupus nephritis, analgesic nephropathy, 
ADPKD, chronic obstructive uropathy, etc 
26
; 
32, 33
; 
 muscle mass (large, muscular patients tolerate high level of azotemia) and dietary and 
nutritional status, which are also linked with obesity and diabetes 
30
 ;   
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 co-morbidity (co-existing conditions) where precursor conditions such as high blood 
pressure, diabetes and proteinuria with/without albuminuria, analgaesic use are key 
markers 
10; 20; 32; 34
; 
 genetic determinants of diseases leading to nephropathy and renal insufficiency (e.g. 
type 1 diabetes which runs in families) 
35, 36
; 
 personal and behavioural attributes, the main ones being smoking and obesity with 
signs of macro-vascular atherosclerosis; with implications for the micro-
vascularisation (capillary) of organs playing an important role. Alcohol consumption 
has also been implicated, but the evidence for this is relatively weak. 
Information on precursor conditions and risk factors in Romanian kidney disease patients 
is very limited. The focus here will be on the links between kidney disease (CKD5 
especially, but also CKD) and: diabetes mellitus, hypertension, obesity and smoking.   
2.4.2  Diabetes mellitus 
Diabetes mellitus is a group of metabolic diseases characterised by hyperglycaemia 
resulting from defects in insulin secretion (type 1 diabetes mellitus or T1DM), insulin 
action (type 2 diabetes mellitus or T2DM; gestational diabetes mellitus (GDM); or both, 
(T2DM and/or other disorders). Chronic hyperglycaemia is associated with long-term 
organ damage, both vascular and tissue damage, dysfunction and failure. Kidneys are 
susceptible to such anatomical and physiological damage 
37
. 
Evidence for this association is given by the high proportion of patients with diabetic 
nephropathy on renal replacement therapy, and also by the increasing acceptance of these 
patients on renal replacement therapy in countries around the world, where treatment 
capacity allows it.  For example in the USA 36% of patients undergoing renal 
replacement therapy had diabetes mellitus as an underlying cause in 1991, increasing to 
40% by 2000 
37,
 
38, 39, 40,  41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58
. Table 2.2 
summarises findings from papers which illustrate the link between diabetes and end-stage 
renal failure from the world-wide literature 
48; 59, 60, 61, 62, 63, 64, 65, 66
: 
Also in the USA, of those born in 2000 an estimated 33% of men and 38% of women 
may develop diabetes mellitus in their lifetime 
67
.  Until the end of 1990s the majority of 
cases of diabetes among children and adolescents (< 20 years) were immune-mediated 
type 1 diabetes. However, the prevalence of obesity has more than doubled in the past 
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two decades in the USA and this has led to an increase of type 2 diabetes in this age 
group 
 37;
 
56; 64
.  The prevalence of diabetes is predicted to go on rising in the next two 
decades in all populations and so its impact as a leading cause for chronic kidney disease 
chronic renal insufficiency will be increasingly important when planning capacity for 
RRT 
64
.  
In Canada, 29% of patients with CKD had diabetes mellitus as the primary cause in 1997, 
rising to 33% in 2001. One centre (Ontario) reported that 51% of its new patients entering 
renal replacement therapy had diabetic nephropathy 
56
. After a follow-up for 8 years of 
96% of the population from one Health Insurance Plan (7.4 million population of which 
0.5 million had diabetes), those with diabetes were 12 times more likely to enter renal 
replacement therapy at the end of the 8 year observation period (an acceptance rate of 
1,300 per million population for patients with diabetes compared to 110 for those 
without). The risk of developing chronic kidney disease and end-stage CKD5 was higher 
in those with diabetes, as high as ten times more. The Canadian study gives a RR (risk 
ratio) of 12 for incidence of end-stage renal failure in those exposed (with diabetes 
mellitus) over those unexposed 
56
.  
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Table 2.2: Diabetes linked to chronic kidney disease and CKD5 
Diabetes Ref year Study Sample 
mean 
fu yrs 
Exposed baseline 
End point/case 
definition 
OR 95% CI a
g
e 
se
x 
sm
o
ki
n
g
 
o
b
es
it
y 
a
lc
o
h
o
l 
h
yp
er
te
n
si
o
n
 
so
ci
a
l 
cl
a
ss
 
ex
er
ci
se
 
Notes   
CKD 
Fox C et 
al49 
2004 
Framingham 
offspr 
2,585 US 
cohort 
18.5 
fasting 
glucose 
> 126 
mg/dl  or 
med 
GFR 
m< 64 
f<59 
ml/min/1
.73m2 
2.38 1.45 3.92 *
     *
   
GFR in 
lower 
%ile 
< 
59.25 
in men 
 
 
Domrongk
itchaiporn 
S et al 50 
2005 Employees 
3,499 
Thai 
cohort 
12 
fasting 
glucose 
 GFR 
< 60 
ml/min/1
.73m2 
1.74 0.95 3.19 *
 
*
 
*
 
*
  *
   no adjustment for age and sex 
 
Hallan SI 
et al  51 
2006 HUNT II 
65,181 
Norway 
 
plasma 
glucose 
>= 
200mg/d
l 
GFR 
< 60 
ml/min/1
.73m2 
1.5 1.3 1.7 *
        age only 
 New J et al 
52 
2007 GP list 
162,113 
UK 
 
GP 
recorded 
not 
recorded 
GFR 
< 60 
ml/min/1
.73m2 
6.14 5.7 6.5         unadjusted 
 
 
Coresh et 
al 53 
2007 NHANES III 13,233  
self-
reported 
absent GFR 
< 60 
ml/min/1
.73m2 
1.54 1.28 1.80 *
 
*
  *
  *
    
1588/ 
5072 
10911/ 
157041 
 
Shan54r et 
al 80 
2006 Wisconsin 
4,926 US 
XS 
 
plasma 
glucose 
>= 
200mg/d
l or 
treatment 
GFR 
< 60 
ml/min/1
.73m2 
3.58 2.63 4.86 *
 
*
 
*
 
*
 
*
 
*
 
E
  adjusted for education 
 
Chadban S 
et al55  
2003 
Australia 
AusDiab 
11,247 
XS 
 
WHO 
criteria 
absent eGFR 
< 60 
ml/min/1
.73m2 
0.9 0.07 1.1 *
 
*
    *
      
CKD5 Lok CE  56 2004 Ontario 
7.5 
million 
8 DM No-DM 
Acceptance on 
RRT (CRF Stage 5) 
12            
 
Brancati F 
et al 57 
1996 MRFIT 
US men 
332,544 
16 
self-
reported 
absent 
Dialysis or KD on 
death cert 
9.9 7.4 11 *
     *
 
*
   
 
Haroun et 
al 58  
2003 CLUE 
23,534 
US cohort 
20 Treated absent 
Dialysis or KD on 
death cert 
7.5 4.8 11.7 *
  *
       
  
 
33 
In the UK Prospective Diabetes Study (UKPDS 64) over 5,000 patients with type 2 diabetes 
were studied. On the basis of observed and modelled data it was estimated that 25% of these 
patients will experience diabetic nephropathy within 10 years of diagnosis 
44;60
. The 
proportion of those on renal replacement therapy with diabetes was 16% and 33% for white 
and Afro-Caribbean patients respectively, rising from 2% overall in 1976-78 to 19% in 1998 
61
.  
Studies of the association between diabetes mellitus and CKD (stages 3 to 5) have reported 
ORs from 1.5 to 6.1 while studies of the ORs for diabetes and CKD5 have reported values of 
between 7.5 and 12 (Table 2.2).  
2.4.3  Hypertension 
In the USA, 29% of patients undergoing renal replacement therapy had hypertension as an 
underlying cause in 1991, and this remains an important leading cause of chronic kidney 
disease and end-stage renal failure, second after diabetes, whether directly (essential 
hypertension) or indirectly through other cardiovascular involvement 
65, 66
.  Results from a 
number of studies are summarised in Table 2.3. 
“At the end of the day we still don’t have a clear understanding why even minor elevation of 
blood pressure increases the risk of end-stage renal disease. This fascinating problem with 
considerable public health implications will undoubtedly keep nephrologists busy in the years 
to come.” 68  And although kidneys are target organs from raised blood pressure, there are no 
clear cut-off values of blood pressure at which organs such as the brain, heart or kidneys are 
more commonly affected.  Nonetheless the recognised threshold for diagnosing essential 
hypertension (i.e. raised blood pressure with no other recognised cause) in adults is ≥140/90 
mm Hg. These values are defined as “high normal”. This stage is preceded by the optimal and 
normal stages and is followed by four stages (1-4) of raised BP of >140/90 mm Hg (JNC-VI: 
Joint National Committee on Prevention, Detection Evaluation and Treatment of high BP 
criteria for hypertension – Sixth Revision as quoted by USRDS) 9.  
Essential hypertension shows a consistent but weaker association with chronic kidney disease 
and chronic renal failure than diabetes mellitus, with ORs ranging from 1.11 to 3.12 in 
different studies. The association between hypertension and end-stage renal failure may be 
slightly closer, with ORs from different studies ranging from 1.47 to 5.7 
49, 50, 51; 55, 56,
 
57 ; 58;
 
69, 
70,
 
71,
 
72, 73, 74 
 (Table 2.3). 
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Individuals with hypertension are at even higher risk of chronic kidney disease if 
hypertension is associated with diabetes mellitus.  This risk has not yet been robustly 
quantified 
66;
 
73; 75
 but in the UK around 6% of people with hypertension develop chronic 
kidney disease when in age group 50-74 year olds, but if the patient has both diabetes and 
hypertension, 17% go on to develop chronic kidney disease 
70
.  
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Table 2.3:  Hypertension linked to chronic kidney disease and CKD5 
Hyper-
tensio
n 
Ref year Study Sample 
mean 
fu yrs 
Exposed Baseline End point/case definition OR 95% CI a
g
e 
se
x 
sm
o
ki
n
g
 
O
b
es
it
y 
a
lc
o
h
o
l 
d
ia
b
et
es
 
so
ci
a
l 
cl
a
ss
 
ex
er
ci
se
 
Notes  
CKD Fox C et al 49 2004 
Framingham 
offspr. 
2,585 US 
cohort 
18.5 
140/90 or 
medication 
< 140 GFR 
m< 64 f<59 
ml/min/1.73m2 
1.57 1.17 2.12 *     *
   GFR in 
lower %ile 
< 59.25 
in men 
 
Domrongkitchai
porn S et al  50 
2005 Employees 
3,499 Thai 
cohort 
12 > 160 < 140  
< 60 
ml/min/1.73m2 
1.01 0.56 1.81 *
 
*
 
*
 
*
  *
   no adjustment for age 
and sex 
 
Kurella M et al 
69 
2005 ARIC 
10,096 US 
cohort 
9 
waist > 88f 
102m 
waist < eGFR 
< 60 
ml/min/1.73m2 
1.99 1.69 2.35 *
 
*
         
 
Retnakaran R et 
al 70   
2006 UKPDS 
2,392 UK 
diabetics 
15 Ever < 140 GFR 
< 60 
ml/min/1.73m2 
1.11 1.06 1.16 *
 
*
 
*
 
*
  *
     
 Hallan SI et al 51 2006 HUNT II 
6,5181 
Norway 
 
140/90 or 
medication 
< 140 GFR 
< 60 
ml/min/1.73m2 
1.5 1.3 1.6 *
          
 
Chadban S et al 
55 
2003 
Australia 
AusDiab 
11,247 XS  
140/90 or 
medication 
< 140 eGFR 
< 60 
ml/min/1.73m2 
1.4 1.2 1.6 *
 
*
    *
     
 Shankar et al  54 2006 Wisconsin 
4,926 US 
XS 
 
140/90 or 
medication 
< 140 GFR 
< 60 
ml/min/1.73m2 
3.12 2.46 3.96 *
 
*
 
*
 
*
 
*
 
*
 
e  
adjusted for 
education 
 
 Coresh et al 53 2007 NHANES III 13,233 XS  
self-
reported 
< 140 GFR 
< 60 
ml/min/1.73m2 
1.98 1.73 2.67 *
 
*
  *
  *
     
CKD5 Klag M et al 71 1996 MRFIT US men 
332,544 
16 140/90 
< 
140/90 
Dialysis or KD on death 
cert 
3.10 2.3 4.3 *
  *
        
 Colhoun et al 72  2001 
WHO 
MSVDD 
3558 type 
II DM 
8.4 160 < 120 
Dialysis or KD on death 
cert 
1.0 0.7 1.4 *
 
*
 
*
   *
     
 
Haroun et al 58 2003 CLUE 
23534 US 
cohort 
20 
160/100 
< 
120/80 
Dialysis or KD on death 
cert 
5.7 1.7 18.9 *
  *
        
 140/90 
< 
120/80 
Dialysis or KD on death 
cert 
3.2 1 10.4 *
  *
        
 Ishani et al 73 2006 MRFIT US men 
12866 
25 SBP 
per 
10mm 
Dialysis or KD on death 
cert 
1.31 1.19 1.43 *
  *
 
*
       
 
Reynolds K et 
al 74 
2007 CNHS fu 
China 
158,365 
8.3 140/90 
< 
140/90 
Dialysis or KD on death 
cert 
1.47 1.06 2.06 *
 
*
 
*
 
*
 
*
 
*
  *
 
  
 
Reynolds K et 
al  74 
2007 CNHS fu 
China 
158,365 
8.3 
160/100 or 
medication 
< 
140/90 
Dialysis or KD on death 
cert 
2.60 1.89 3.57 *
 
*
 
*
 
*
 
*
 
*
  *
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2.4.4  Obesity 
The relationship between height and weight in adult populations is commonly measured 
using the Quetelet Index or BMI (Body Mass Index). Four categories are defined: 
underweight, normal weight, overweight and obesity. Overweight is defined as a BMI from 
25 to 29.99 and obese as a BMI = 30 and above. (The obese category is further 
subcategorised from I to IV, with IV being morbid obesity.) 
The effect of obesity as an independent risk factor for chronic kidney disease is inconsistent 
and depends on whether it is studied prior to renal damage or after it, and particularly if 
replacement therapy has been initiated. In most of the studies reviewed the ORs were 
between 1.2 and 1.7.  The ORs for obesity and CKD5 were similar (Table 2.4). Increasingly 
chronic kidney disease in the setting of pre-diabetes “is considered as an additional 
complication of macro-vascular atherosclerosis, thus accelerating the progress towards end-
stage renal failure” 73; 76, 77, 78.  
Obesity is also a risk factor for diabetes and hypertension, and data on these risks are given 
in Table 2.4 and 2.5. The strength of the association was shown with the ORs for 
overweight (BMI <29.9) of 3.44 and for obesity (BMI ≥ 30) from 3.44 to 6.30.  One study 
of overweight gave OR of 8.1 but this was unadjusted for other risk factors. 
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Table 2.4: Obesity linked to chronic kidney disease and CKD5. 
Obesity Ref year Study Sample 
mean 
fu 
yrs 
Exposed baseline 
End point/case 
definition 
OR 95% CI a
g
e 
se
x 
sm
o
ki
n
g
 
a
lc
o
h
o
l 
d
ia
b
et
es
 
h
yp
er
te
n
si
o
n
 
so
ci
a
l 
cl
a
ss
 
ex
er
ci
se
 
Notes   
CKD 
Chen J et 
al.75 
2003 PHS 
11,104 
US 
cohort 
 
BMIb > 
26.6 
BMIb < 
22.7 
GFR 
< 60 
ml/min/1.73m2 
1.45 1.19 1.76            
 
Fox C et al 
49 
2004 
Framingha
m offspr. 
 18.5 
BMI 
baseline 
per unit GFR 
m< 64 f<59 
ml/min/1.73m2 
1.23 1.06 1.41 * * *  *
 
*
   
GFR 
in 
lower
%ile 
< 59.25 
men 
<  
64.25  
women 
 
Gelber R et 
al 76 
2005 PHS 
11,104 
US men 
14 
BMIb > 
26.6 
BMIb < 
22.7 
GFR 
< 60 
ml/min/1.73m2 
1.45 1.19 1.76 *
 
*
 
*
 
? ?       
 
Kurella M et 
al  69 
2005 ARIC 
10,096 
US 
cohort 
9 
waist > 
88f 102m 
waist < 
eGF
R 
< 60 
ml/min/1.73m2 
1.18 1 1.4 *
 
*
          
 
Domrongkit
chaiporn S 
et al 50 
2005 Employees 
3,499 
Thai 
cohort 
12 BMI > 25 
BMI <= 
25 
 
< 60 
ml/min/1.73m2 
1.68 1.02 2.77 *
 
*
 
*  * *      
 
Ejerblad E et 
al 77 2006 
Population 
register 
1,924 
Sweden 
CC 
 
BMI > 25 
at 20 
BMI <= 
25 
Seru
m 
creat 
> 3.4 mg/dl 
(M) or 2.8 (F) 
3.1 2.1 4.8 *
  * *   e  
wome
n: 3.0 
(1.4-
6.1) 
  
 
Shankar et al 
54 
2006 Wisconsin 
4,926 
US XS 
 BMI > 25 
BMI <= 
25 
GFR 
< 60 
ml/min/1.73m 
1.2 0.83 1.73 *
 
*
 
* * * * e  
adj for 
educati
on 
  
CKD5 
Stengel 
et al  78 
2003 
NHANES 
II 
9082 US 
cohort 
12-
16 y 
BMI > 35 BMI < 25 
Dialysis or KD on 
death cert 
1.3 0.6 2.9 *
 
*
 
*
 
 * *      
 
Ishani 
et al 73 
2006 MRFIT 
US men 
12866 
25 per 5 units BMI 
Dialysis or KD on 
death cert 
1.17 0.95 1.44 *
  *
 
  *      
 
Hsu C 
et al.7 
2006 Kaiser 320,252 26.1 
BMI 30-
34 
BMI < 25 
Dialysis or KD on 
death cert 
2.98 2.54 3.49 *
 
*
 
*
 
 * *      
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Table 2.5: Obesity linked to diabetes and hypertension. 
Obesity Ref year Study Sample 
mean 
fu 
yrs 
Exposed baseline 
End point/case 
definition 
OR 
95% 
CI a
g
e 
se
x 
sm
o
ki
n
g
 
a
lc
o
h
o
l 
d
ia
b
et
es
 
h
yp
er
te
n
si
o
n
 
so
ci
a
l 
cl
a
ss
 
ex
er
ci
se
 
 Notes 
Diabetes 
Colditz et al 
199579 
1995 
nurses 
health 
114,281 
US  
cohort 
14 
BMI 25-
26.9 
BMI 
< 22 
self-reported 
diabetes ++ 
8.1 6.2 10.5 *         
 
Mokdad A 
et al 89 2003 
telephone 
survey 
195,005  
BMI 30-
39 
BMI 
< 25 
self-reported 
diabetes 
3.44 3.17 3.74 * * *      
adjustment for age, sex, 
education, smoking & ethnicity 
 
Wannameth
ee G et al 80 
1998 
BRHS 
cohort 
study  
7,176  20  
BMI 
27.5-29.9 BMI 
< 25 
 
GP reports 
3.64 2.74 4.83 * * *   *
 
*
 
*
 
adjusted for age, social class, 
smoking, alcohol, phys activity 
etc  BMI 30+ 6.30 4.67 8.51 * * *    *
 
* 
Hyper-
tension 
Mokdad A 
et al 89 
2003 
telephone 
survey 
195,005 
XS 
 
BMI 30-
39 
BMI < 25 
self-reported 
hypertension 
3.50 3.31 3.70 * * *  *   *
 adjustment for age, sex, 
education, smoking & ethnicity 
 
John U et al 
200681  
2006 
national 
survey 
6,903 
German
y XS 
 BMI 30+ BMI < 25 
SBP, DBP 
mild >140 or > 90 
2.80 2.30 3.40 * *   *   *
 adj: age, sex, CHD, alcohol, 
smoking, exercise etc 
 
treated hypertension 8.60 6.70 11.1 * * *  *   *
 adj: age, sex, CHD, alcohol, 
smoking, exercise etc 
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2.4.5  Smoking 
Smoking has been associated with increased risk of chronic kidney disease in two 
longitudinal studies in the USA, a case series in the UK and a case-control study in Sweden 
(Table 2.6). All these studies were representative of the adult populations in their countries. 
ORs for smoking and end-stage renal failure ranged from 1.84 to 2.60. They, and others, all 
concluded that smoking affects blood vessels via arteriosclerosis and may act as an 
independent risk factor for chronic kidney disease 
49, 50;54; 70; 77
.  
In one systematic review of 17 studies it was found that smoking remained a risk factor for 
the development of chronic renal disease in men (RR= 2.4, 95%CI from 1.2 to 4.5), in 
those smoking over 20 cigarettes a day (OR= 1.51, 95%CI from 1.06 to 2.15) and in those 
smoking for more than 40 years (OR= 1.45, 95%CI from 1.00 to 2.09). The review could 
not provided a pooled estimated relative risk due to heterogeneity of studies 
82
.  
 The ORs for chronic renal failure associated with smoking were reported as from 1.34 to 
2.1 
 54; 70; 77
.  However a Thai study found no effect 
50
.  The systematic review by Jones-
Burton et al found values from 1.45 to 2.4 
82
. 
Smoking is also a risk factor for diabetes (OR =1.44) and possibly for hypertension 
83
.  
Data on these risks are given in Table 2.7. However there is mounting evidence that any 
links between smoking and hypertension are, in fact, the product of confounding between 
smoking and obesity, possibly via another factor, such as a sedentary lifestyle. Thus for 
people with a BMI in the normal range there is very little evidence that smoking carries an 
excess risk of hypertension 
81;
 
84,
 
85, 86
.  
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Table 2.6: Smoking linked to chronic kidney disease and CKD5 
Smoking Ref year Study Sample 
mea
n fu 
yrs 
Exposed baseline 
End point/case 
definition 
OR 95% CI a
g
e 
se
x 
sm
o
ki
n
g
 
o
b
es
it
y 
a
lc
o
h
o
l 
d
ia
b
et
es
 
h
yp
er
te
n
si
o
n
 
so
ci
a
l 
cl
a
ss
 
ex
er
ci
se
 
Notes   
CKD 
Fox C et 
al 49 
2004 
Framingha
m offspr. 
2,585 
US 
cohort 
18.5 
smokers at 
baseline 
non-
smokers 
GFR 
m< 64 
f<59 
ml/min/1.
73m2 
1.42 1.06 1.91 *     *
 
*
   
GFR in 
lower 
%ile 
< 
59.25 
in 
men 
<64.25 
in 
women 
 
Domron
gkitchai
porn S 
et al 50 
2005 Employees 
3,499 
Thai 
cohort 
12 Smokers 
non-
smokers 
 
< 60 
ml/min/1.
73m2 
1 0.7 1.45    *
  *
 
*
   
no 
adjustme
nt for age 
and sex 
  
 
Retnaka
ran R et 
al 70 
2006 UKPDS 
2,392 
UK 
diabetic
s 
15 Ever 
non-
smokers 
GFR 
< 60 
ml/min/1.
73m2 
1.34 1.28 1.4 * *  *  *
 
*      
 
Ejerblad 
E et al 
77 
2004 
Population 
register 
1,924 
Sweden 
CC 
 > 20/day 
non-
smokers 
Seru
m 
creat 
> 3.4 
mg/dl 
(M) or 
2.8 (F) 
1.51 1.06 2.15 *
 
*
   *
   e     
 
Shankar 
et al 54 
2006 Wisconsin 
4,926 
US XS 
 smokers 
non-
smokers 
GFR 
< 60 
ml/min/1.
73m2 
2.1 1.57 2.81 *
 
*
  * *
 
*
 
*
 
e  
adjusted 
for 
education 
  
CKD5 
Colhoun 
et al 72 2001 
WHO 
MSVDD 
2,559 
type II 
DM 
8.4 smokers 
non-
smokers 
Dialysis or KD on 
death cert 
1.2 0.8 1.8 *
 
*
    *
 
*
   RRs   
 
Stengel 
et al 78 
2003 
NHANES 
II 
9,082 
US 
cohort 
12-
16 y 
<20/day 
non-
smokers 
Dialysis or KD on 
death cert 
1..4 0.7 2.7 *
 
*
  *
  *
 
*
      
 >=20/day 
non-
smokers 
Dialysis or KD on 
death cert 
2.3 1.2 4.3 *
 
*
  *
  *
 
*
      
 
Ishani 
et al 73 
2006 MRFIT 
US men 
12,866 
25 smokers 
non-
smokers 
Dialysis or KD on 
death cert 
1.84 1.35 2.51 *
   *
   *
      
 
Haroun 
et al 58 
2003 CLUE 
23,534 
cohort 
20 smokers 
non-
smokers 
 
Dialysis or KD on 
death cert 
2.6 1.8 3.7 *
     *
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Table 2.7: Smoking linked to diabetes and hypertension. 
Smoking Ref year Study Sample 
mean 
fu 
yrs 
Exposed baseline 
End point/case 
definition 
OR 95% CI a
g
e 
se
x 
o
b
es
it
y 
a
lc
o
h
o
l 
d
ia
b
et
es
 
h
yp
er
te
n
si
o
n
 
so
ci
a
l 
cl
a
ss
 
ex
er
ci
se
 
Notes 
Diabetes 
Willi C et 
al 83 
2007 25 studies 
1,2 
million 
 smokers 
non-
smokers 
 
Diabetes 
1.44 1.31 1.58 *  *      
All but 3 studies adjusted for 
age and BMI; 14 biologically 
screened, 10 questionnaire, 1 
med exam 
Hyper-
tension 
Fogari R et 
al 84 
1996 Employees 
7,109 
Italy XS 
 smokers 
non-
smokers 
SBP difference 
in mean 
NS 
 
 
 *  *      
No difference in BP between 
smokers/non smokers with 
normal weight; for obese 
smokers had higher bp in 18-
30 only 
 
Primatesta 
et al 85 
2001 HSE 
33,860 
England 
XS 
 smokers 
non-
smokers 
SBP linear NS 
 
 
 *  * *   *  
"any independent chronic 
effect of smoking on BP is 
small"  " increase in BP with 
smoking only seen in age 
45+ overweight men, and 
also linked to alcohol 
consumption" 
 
Halimi JM 
et al 86 
2002 Population 
12,417 
France 
XS 
 current never SBP NS   *  * *     1.31 for unadjusted by BMI 
 
John U et al 
81 
2006 
national 
survey 
6,903 
German
y XS 
   
SBP: 
mild >140 and 
DBP: > 90 or 
treatment 
(treated HT) 
1.1 0.9 1.4 * * * * 
M
I 
  * 
Smoking hypertension 
paradox may be explained by 
obesity and overweight. No 
trend in Ht with smoking 
among those with normal 
weight 
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 2.5  Disease progression and prognostic factors 
Apart from the few who are given a transplant, most people with end stage renal failure will 
continue on dialysis until they die. Thus the requirement for dialysis depends on length of survival 
as well as disease incidence, and any changes over time in the factors that affect survival will need 
to taken into account when estimating the capacity required to meet future needs.  Prognostic 
factors also affect policies relating to patient selection by treatment centres 
5; 26; 87, 88
 and methods 
of case-mix adjustment in observational studies of outcome, such as comparisons between 
treatment modalities or centres.  However according to Williams and Mallick 
89
: 
“The natural history of renal disease in which there is a primary structural, metabolic, or 
immunological abnormality is … complex since there are few occasions when progression due 
to the underlying disease can be differentiated from progression due to adaptive factors”. 
Among adaptive factors is the secondary hypertension triggered by sub-normal functioning of the 
kidneys. Secondary hypertension is a separate topic and is not considered further here. 
Nonetheless a number of patients’ attributes have been associated with progression of chronic 
kidney disease and reduced survival on RRT. Age, primary renal disease and co-morbidity mix 
have received most attention 
60; 66; 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 
  For example: 
 ‘...age at entry on RRT, type of RRT, hypertension and diabetes increase the risk of death...’ 
60;66; 91, 92
; 
 ‘.age, sex and race are useful predictors of mortality...initial diagnoses at time of first dialysis, 
such as: diabetes, hypertension, glomerulonephritis, polycystic kidney and collagen diseases 
(diagnostic aggregations) are reasonably predictive, but there is likely to be substantial 
unmeasured severity within these diagnostic cells...’ 92; 
 ‘...age, race, cause of renal failure, nutritional impairment, and, the presence of cardiovascular 
disease are the main predictive mortality risk factors in patients receiving dialysis...treatment 
time was found to be inversely related to mortality’ 94,95,96,97; 
 ‘...serum creatinine concentration, urea reduction ratio (URR), albumin, anion gap...are the 
most important associates of death risk...’ 100, 101, and cholesterol levels...’102; 
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 ‘...risk group classification of patients under RRT in: low, medium, high risk, according to 
primary renal disease and co-morbidities was the strongest predictor of  mortality 93...diabetes 
and myeloma were also associated with a significantly high risk of death...each additional year 
in age at the commencement of RRT increased the risk of death by 3.1%...
102
;  
Age profiles in patients undergoing renal replacement therapy have changed in the past 30 years.  
One study shows that in the UK 1% were aged 65 years or older in 1976-78. By 1998 this 
proportion had risen to 47% 
60
.  
According to the National Institute for Clinical Excellence (NICE) in England and the National 
Collaborating Centre for Chronic Conditions: ‘the evidence on the effects of obesity on the risk of 
progression of renal disease is un-convincing’ 103, 104.  However there is evidence from several 
large studies that obesity actually has a protective effect among people who are on haemodialysis: 
 ‘ …. the effect of overweight (BMI: 25–30) or obesity (BMI: >30) in patients with chronic 
kidney disease (CKD) undergoing maintenance haemodialysis (MHD) is paradoxically in the 
opposite direction; i.e., a high BMI is associated with improved survival or, so called “reverse 
epidemiology”… 105, 106.  
and there is: 
 :  ‘… no evidence supporting the intuition that smaller patients require proportionately lower 
dialysis dose than larger patients [BMI related], that is once a patient is under HD…’ 103. 
Type 1 and type 2 diabetes mellitus progress differently.  After diagnosis of type 1 diabetes, the 
incidence of chronic kidney disease rises from 2.2% at 20 years and 7.8% at 30 years. Although 
overall survival has improved markedly (by 50%) in cases diagnosed in the 1970s compared with 
those diagnosed in the 1960s, type 1 diabetes has shown a steady and relatively slow natural 
progression towards end-stage renal failure 
40; 45, 46, 47
.  
Because type 2 diabetes has only been increasing since the late 1990s, survival studies have yet to 
demonstrate an impact on need for renal replacement therapy.  
One Austrian study, with small samples of type 1 and type 2 diabetes, suggested that survival in 
treated type 2 diabetes patients was worse than for type 1: 80% vs. 100% at 1 year but 82% vs. 
29% at 5 years. The difference is partially explained by the difference in age; the type 2 diabetes 
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patients were much older. However, apart from age, the study observed that the prevalence of 
cardio-vascular morbidity and peripheral vascular disease was significantly higher in the type 2 
diabetes patients than non-diabetic patients. Most importantly, an increase in the proportion of 
type 2 diabetes patients entering treatment was noted and also because of co-morbidity and 
complications, these patients were less likely to receive a transplant 
64
. 
Finally, ‘…early referral to nephrology services has been shown to be a prognostic factor e.g. in 
the UK 
107
.  
Despite the importance of prognostic factors, research in this area has many challenges. Among 
the recommendations are: better definition of primary outcomes; and improvements in 
methodological standards and on reporting standards by using guidelines
108
.  
To summarise, the prognostic factors for end-stage renal failure that will be considered in here are: 
primary renal disease, diabetes and hypertension. Age, sex, obesity and smoking are considered in 
discussion as likely to be influential in future. These variables should be considered in future 
epidemiological models as prognostic factors for outcome as well as risk factors for disease 
9 ; 
48;58;60 
. 
2.6  Treatment  
Once a patient has developed CKD with renal insufficiency the course of the disease can be 
affected by: 
“…conservative therapy (non-dialytic, non-transplant therapy), which, if instituted early, could 
control symptoms, minimise complications, prevent long term sequelae and slow the 
progression of renal insufficiency…” 30. 
Modification of diet and compliance with modified dietary regimes are of great importance, as 
they can delay the need for renal replacement therapy 
26;32;89
. However, if a primary renal disease 
(or a systemic disease) leads to renal insufficiency that in time becomes chronic and progresses 
into end stage renal failure. Eventually, without renal replacement therapy the patient will die 
89; 97; 
109
.  
The possible modalities for of renal replacement therapy in end-stage renal failure include:  
 in-centre haemodialysis (HD), whether staff dependent or self-care;  
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 home haemodialysis, where the home environment is adapted to use a HD station, a common 
approach in the  USA;  
 home continuous ambulatory peritoneal dialysis (CAPD); and  
 home continuous cycling peritoneal dialysis (CCPD). 
Patients for whom CAPD is favoured over the in-centre HD modality in end-stage renal failure 
include: patients with severe cardio-vascular disease; patients with difficult vascular access (e.g. 
diabetics); patients who desire greater freedom to travel; and patients who wish to perform home 
dialysis, but do not have a suitable partner or resources to be assisted. Home HD is frequently 
used in the USA 
9
, whereas in Europe, hospital or in-centre HD and CAPD are the main 
modalities 
110; 111; 112
.  
If a patient suffers from acute fluid overload, which may happen between haemodialysis sessions, 
then dialysis is supplemented with ultra-filtration which removes the excess fluid. Special HD 
stations are used, called haemo-dia-filtration (HDF) stations. The predilution variant of HDF is 
gaining better quality of treatment status according to most recent studies, with achievement of 
better creatinine clearance during HD sessions of same length of time and frequency 
112
. HD has 
evolved in a combination of methods which are tailored to suit the patients’ needs. Outcomes are 
promising in terms of survival and quality of life although results come from small cohorts of 
patients. 
Transplantation is a third modality, with first and second haemodialysis and peritoneal dialysis. 
Usually one kidney is placed in the lower abdomen of the recipient. Transplantation can be 
performed with a kidney from a living related donor or someone who has a very good HLA 
(genetic) match or with a cadaver donated kidney, again matched by HLA properties. The A 
stands for antigen and the closer the match between donor and recipient, the lower the level of 
antibodies which may reject the transplanted organ
113
.   
The complexity of cases can results in patients moving from one modality to another 
32
. Patient 
preferences and clinical decisions about type of therapy have been much debated over the years, 
and vary from country to country 
93
.  In the mid 1990s Canadians reported better survival on PD, 
while a study from the USA reported better survival on HD 
113
. However, Kjellstrand and others 
have taken the view that: 
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“...the influence of dialysis technology on mortality is meaningless, and most of the 
differences can be explained by different patient populations and transplant rates...” 114, 115. 
and  
“case-mix differences may underlie these paradoxical results and registry data should be 
careful interpreted.....There is no convincing proof that true differences in mortality rates exist 
between haemodialysis and peritoneal dialysis....The modalities should be viewed as 
complementary, and attention to detail in patient care should be emphasised for both”114. 
Two later reports in 2003 showed that different risks of mortality between peritoneal dialysis and 
haemodialysis were obtained when the data were analysed using different statistical models.  The 
differences found in the estimated hazard ratio (HR) between the modalities were not related to the 
therapies themselves, but were instead determined by the variables included in the analysis 
116
, 
117
: 
 “…there was no randomness; timeframe and sample size played a role…”;  
One point on which the published literature is agreed is that survival and quality of life of 
transplant patients is better than patients undergoing dialysis at all ages. In 2009 a study from a 
large cohort of patients (25,287) in Australia and New Zealand suggested that treatment with 
peritoneal dialysis may be advantageous initially, but may be associated with higher mortality 
after 12 months 
118, 119
. 
2.7  Supply 
Increasingly, research supports the hypothesis that factors related to the supply and provision of 
renal replacement therapy such as referral time or access to a nephrologist, waiting time and/or 
inclusion on a transplantation list, and formal multi-disciplinary clinic (MDC) based care, can 
influence survival and some clinical guidance includes strategies of delaying the onset of RRT
 60;  
87; 107; 109; 120,
 
121, 122, 123, 124
.  For example: 
 ‘…referral to nephrologist as “time in nephrological care” in the predialysis phase; age and, 
also being a male – the patient is more affected and overall prognosis is poorer…’ 60; ; 87; 107;109; 
 ‘...NICE recommends the use of ACE-I when there is hypertension to maintain BP below 140 
(systolic) and 90(diastolic); NICE divides stage 3 of CKD in 3a and 3b and recommend testing 
for bone disease and anaemia in stage 3b (eGFR 30 to 44), as well as stage 4 and 5’ 120. This 
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suggests some rationing during the progression of disease, but monitoring of kidney damage 
through clinically monitoring proteinuria and blood pressure have been defined good practice 
by 2012. 
The problem is that: 
“....there is no universally agreed-upon index to summarise the severity of illness...and which 
would have value in adjusting the case mix...” It has been suggested that “the Khan, Davies 
and the Charlson indices will adjust to the same extent for the potential confounding effect of 
comorbidity in studies with health status as an outcome. Separate co-morbidity diagnoses will 
adjust best for co-morbidity and treatment referral” 5; 91; 97; and it has been identified that: 
“...macroeconomic and renal service factors are more often associated with RRT incidence 
rates (or acceptance on RRT) than measured demographic or general population health status 
factors in this 46 country analysis...” 121; and that 
“...The global burden of ESKD (end-stage kidney disease) or CKD5 is concealed behind 
statistics which reflect only the number of people treated, not those who die of kidney failure or 
cardiovascular complication…” 115; thus the issue of equity is also raised when treatment 
supply is addressed. 
It is clear from clinical practice and the literature that any form of RRT may improve survival, 
depending on a variety of circumstances and factors.  However, by mid-2000s none of renal 
replacement therapy, let alone the role of population estimated glomerulo-filtrate rate (eGFR) 
screening in reducing the incidence of stage 5 of the condition, has ever been subjected to a large 
phase III clinical trial. For example, haemodiafiltration as new procedure (new in comparison with 
the ‘simple’ haemodialysis itself) is the only one to have undergone such a trial after a decade of 
case series studies 
112
. In the absence of a definitive proven method of risk adjustment it is difficult 
to determine which treatment modality is most effective for which patient groups or what 
benchmarking can be used when variations in the timing of dialysis initiation may explain some 
variations in RRT incidence 
123
. This is despite the fact that one country seems to have found an 
optimum RRT combination for good outcomes and quality of life associated with affordability in 
supply, yet this country also addresses an equitable supply 
112;124
.  
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Romania has changed its levels of RRT supply from 1990 to 2004 with little documented 
analysis of association with treatment outcomes or equity 
122
.  
2.6.1  Specific technologies  
There is a growing health technology assessment literature which tends to be based on 
intermediate, ‘proxy’ or surrogate outcomes such as haemoglobin or haematocrit levels, dialysis 
adequacy, lipid profile, and adverse symptoms during a dialysis session. Most of these could 
affect downstream outcomes such as survival and quality of life. One of the most comprehensive 
groups of systematic reviews was published by MacLeod 
125
; other papers have also been 
reviewed, particularly in the light of the quality of evaluations of interventions 
120
. The UK 
systematic review gave recommendations for the English National Service Framework (NSF) for 
Renal Services in 2002. Some of the factors found to affect outcomes include
 14
: 
Synthetic vs modified cellulose membranes:  in a UK led meta-analysis, the use of synthetic 
membranes significantly ameliorated HD treatment; Romanian data show that between 1996 and 
2003 the use of synthetic membranes rose from 5% to 63% 
122
; 
Bicarbonate-buffered vs acetate-buffered dialysate in HD for CKD5; Romanian data show that 
between 1991 and 2003 the use of bicarbonate-buffered dialysate rose from 0% to 63% 
122
; and 
Y-set/ modified Y-set versus standard spike as CAPD delivery system for patients with end-stage 
renal failure; Romanian data show that all patients since CAPD was introduced in 1996 are treated 
on Y-sets or modified Y-sets 
41; 122
.  
2.7  Need 
Need for a treatment has many definitions. Spassof quotes Stevens and Raftery in the way they 
place “the conceptualization of need in a broader context and based on Bradshaw’s approaches" to 
define need: 
- Normative need: “objectively” measured by professionals; 
- Felt need: equivalent of want or expectation; “subjective”; 
- Expressed need: in seeking care; this need is related to demand or requirement; the individual 
would utilise the service at a given cost; 
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- Comparative need: a lower use of services than enjoyed by some comparable population. 
In public health, the generic term ‘need’ is used in relation to both the illnesses or health shortfall 
that people experience (need for ‘health’) and for the treatment appropriate to their  illness (need 
for ‘health care’). A key role of public health practitioners is to assess both the health and the 
health care needs  of a given population. Such health needs assessments can at best ensure that 
health-care provision, RRT for CKD5 in this case, is evidence based. The findings of health needs 
assessments should then guide allocation of resources,  with the main aim of improving health 
care efficiency and reducing population health inequalities.  
The definitions of need most useful for  this research are the expressed need or requirement for 
RRT, and comparative need, which relates to evidence-based provision, equity and thus addresses 
health inequalities. The affordability of RRT is a concern in most countries which have cash 
limited health care systems. As a result an evidence-based needs assessment (EBM), a cost-
effectiveness analysis (CEA) and the development of a valid and reliable treatment model could 
be the starting point for evidence-based provision of care for CKD in Romania.  
2.8  Outcomes 
2.8.1  Survival and case fatality under RRT 
Since end-stage renal disease is fatal without treatment which conserves the renal function or 
RRT, survival is: 
“...the ultimate outcome measure of the success of RRT and may increasingly be used as a 
quality assurance tool to compare the performance of centres providing such treatment and to 
determine funding...” 99. 
The 1997 USRDS and later Annual Reports and EDTA reports compare 1-, 2-, and 5-year survival 
rates for various incident cohorts of dialysis patients. The USRDS for 1993 reported an all-age 
survival rate of 75.3%, (i.e. ≈ 25 deaths per 100 renal patients on RRT), increasing to 80-82% for 
1999 
9
.This is quite low when compared with some cancers, such as breast cancer, which have a 5- 
year survival of 80% 
82
. However, the USA reports high met need for RRT and non-selective 
acceptance on to RRT may result in a complex case mix in terms of co-morbidity, advanced age, 
etc. 
9
.  The 1-year and 5-year estimates for 1997 for the European Registry were 82% and 47% 
slightly better than in 1992 
122; 126
 .   
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Most of the improvement in years of life under treatment occurs in the early years of therapy, 
apart from the first 3 to 6 months when survival is relatively poor. Japan reports a quarter of their 
patients surviving at 10 years or more 
112
.Occasionally patients survive for longer than 20 years 
101
. 
Since the mid 1990s, severity of case mix has been estimated by measuring case fatality in the first 
90 days on RRT. It has been reported that between 1.8 and 11.4% of patients die during this 
period; among the causes, cardiac and social causes are commonly quoted in the literature. The 
extent of late referral, as a predictor of early death on treatment, may also vary very widely across 
countries, depending on the definition of ‘late’. This is a possible explanation for the variation in 
early case fatality on RRT 
103
.  
However, researchers have agreed to exclude these deaths from the counts and indicators 
measuring the annual national renal replacement therapy acceptance and stock, as well as when 
measuring survival, in order to provide meaningful information on rates for chronic replacement 
therapy.  The 90- day mortality is reported as significant if more than 10% of those who enter 
RRT die within the 90- day period 
107
.    
Survival for 5 years was shown to be better for an American 1990 cohort than for the 1985 cohort 
in one study. However, estimates may be unreliable, and sources of data, and methods of analysis 
(e.g. life tables vs product limit Kaplan-Meier) should be checked 
108
.  
In 1992 McClellan reported an increasing fatality rate with age: 8.6% in patients aged 20 to 45 vs. 
17% in those aged 46 to 65, and 24.1% in those aged over 65 years 
9; 66
.   
In the 1991 EDTA Report it was found that after careful analysis, “a relatively constant 16-19 fold 
increase in mortality exists in renal replacement therapy patients compared with the general 
population in the UK and Italy” 110. 
The WHO HFA Database of cause-specific standardised mortality rates does not contain 
information on end-stage renal failure as a specific cause of death 
2
. Also the use of population 
mortality rates as indicators of the wider morbidity of renal failure is controversial, particularly 
because end-stage renal failure is seldom given as cause of death amongst people on renal 
replacement therapy 
9; 107
.  Despite these difficulties, in Australia chronic or unspecified renal 
failure was reported as being the 7
th
 leading cause of death in 2000.  Other studies have also 
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reported kidney disease as an endpoint on death certificates since 2001 
2; 127
 and references in 
Table 2.4. 
In a report from Romania in 2003, 1- and 5- year survival rates were surprisingly high at 91% 
(95% CI 89 to 92%); and 62% (95% CI 59 to 65%). Diabetic nephropathy accounted for 13% 
compared to 2% in 1997 
122
. Previous European data shows that predictive survival models have a 
low accuracy, especially for 1-year information 
128
.  
2.8.2  Causes of death for patients with CKD5 on RRT 
Although CKD5 is seldom registered as the cause of death, analyses of proportional mortality 
from the USRDS and EDTA Registries indicate that in 1990 cardio-vascular disease accounted for 
36-53% of deaths as primary cause or as a co-morbid condition if the onset of cardio-vascular 
disease was registered later than the diagnosis of end-stage renal failure. The main causes 
registered are complications of the disease. These were myocardial ischaemia and/or infarction 
(more common in transplant patients) followed by cardiac failure and cardiac arrest in HD 
patients, and then cerebro-vascular and “other cardiac” 110; 118; 124. Infections account for 
approximately 12-19% of deaths, primarily for transplant patients also for dialysed (peritoneal) 
patients 
124
. 
Approximately 25-35% of deaths are accounted for by causes registered as “others”. This pattern 
of causes of death among end-stage renal failure patients has changed recently with a breakdown 
into: “social deaths” (suicide, withdrawal) accounting for 5-12%, and 10-12% remaining 
“unknown” causes of deaths. In the Dialysis Outcomes and Practice Patterns Study (DOPPS), 
depression was independently associated with higher risks of mortality and hospitalisation among 
HD patients, both in the USA and Europe 
114; 115
. 
Some researchers argue that the registered cause of death following medical certification of cause 
of death (MCCD) is biased.  Deaths from cardio-vascular diseases could be overestimated among 
end-stage renal failure patients, and deaths from its progression and its consequences could be 
underestimated 
129
.  
Perneger  and others stress the importance of validity, reliability and concordance of information 
in relation to different sources of data 
127, 129, 130,
 
131, 132
:  
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“Selection of a cause of death in end-stage renal disease patients deserves more attention 
from renal disease nosologists and information managers.  Adjustments to the Renal Data 
system database may include coding of multiple cause-of death data and separate reporting of 
cause-of death and quality control information. Clarification of ICD-9 coding (note: by 2010 
this is ICD-10) for kidney diseases is also warranted. Increased compatibility between the two 
information systems may greatly increase their usefulness…….[A] plausible explanation is 
that death certificates and registry reports do not measure the same concept of ’cause of death’. 
The registry reporting system emphasises possible indicators of quality of care withdrawal 
from therapy, vascular access haemorrhage, or hyperkalemia...which may be poorly reported 
on standard death certificates. These are mechanisms of death rather than underlying causes.” 
133
 
European Registry data also suggest that total and cardio-vascular mortality is higher in Northern 
than in Southern Europe, and this was confirmed by an in-depth age-stratified analysis of 
myocardial ischaemia and infarction as causes of death in the UK and Italy 
110
.  
One other explanation of cardio-vascular factors being often recorded as causes of death in 
patients undergoing renal replacement therapy could be the most frequently recorded primary 
diseases leading to end-stage renal failure: hypertension and diabetes mellitus. These conditions 
can develop cardio-vascular complications independently of the alteration of the renal function, 
and for this reason the cause of death can be misclassified 
97
.   
Other data show that total and cardio-vascular mortality in patients with end-stage renal failure 
due to diabetic nephropathy show higher rates than in non-diabetic patients (standardised rates for 
age, sex, cardio-vascular cause of death). With information being not directly comparable from 
various sources conclusions are difficult to draw 
130, 131
. 
Currently there is no information on registered causes of mortality for patients with end-stage 
renal failure in Romania. 
2.9 Intermediate (surrogate) outcomes  
The large and unstructured literature does not clearly distinguish between different types of 
complications (nosocomial infections, vascular access complications, etc) developed by patients 
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with CKD5 under renal replacement therapy (RRT). It often refers only to ‘RRT- related 
complications’. However, any complications developing after treatment started could be: 
- an event due to the primary cause which led to end-stage renal failure, and/or 
- an event due to some co-morbidity, and/or 
- an event due to the renal replacement therapy (RRT).   
Literature searches were grouped into infectious and non-infectious complications. Both types can 
be encountered in HD, CAPD and transplant patients. They can also be explored indirectly 
through other indirect intermediate outcome measurements such as hospitalisations. However, 
given the very limited data available from Romania, this part of the critical appraisal of the 
literature was not pursued in any more depth.  
2.10 Quality of life 
In the dawn of the renal replacement therapy era both patients and professionals focused on adding 
years to life. Levy quotes a landmark paper
134
: 
“The absence of behavioral observations in the very early days of dialysis is underscored in the 
1964 presidential address of Belding Scribner to the American Society for Artificial Internal 
Organs: ‘Because patients and physicians were allies in a continual fight for survival, there 
was no time to worry about much else. Patients were basically happy, and the dire predictions 
of emotional breakdowns and suicide made so easy because of the ever-present arterio-venous 
shunt usually did not materialize. As long as the struggle for survival was the main issue, 
emotional problems were suppressed.”  
However, nearly forty-five years on, quality of life, or health-related quality of life, ultimately 
counts more for the chronic patient than simple survival. It is a multidimensional construct and it 
includes life-satisfaction, self-esteem, health and functioning, socio-economic status and social 
role 
135
. 
Research in this area, in respect of patients on renal replacement therapy, goes back to 1971, when 
the psychosocial aspects of patients on dialysis and kidney transplantation began to be addressed. 
However, it took researchers decades to develop and apply a range of reliable and valid quality-of-
life indicators. Now a wide range of instruments is available.  The most widely used in patients 
under renal replacement therapy are 
136
: 
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 the SF-36 
 the Karnofsky Performance Scale (KPS) 
 the Kidney Disease Quality of Life (KDQOL) as a disease specific instrument (KDCS in 
short); and 
 the Spitzer QL-Index. 
Other instruments that have been used include the Nottingham Health Profile (NHP) and the 
Sickness Impact Profile (SIP). Some authors have suggested that for renal patients under renal 
replacement therapy and associated renal anaemia the NHP provided a “measure of perceived 
health” and the SIP provided a more “functional measure”137.  
Health-related quality of life specialists and researchers attach different meanings to the term 
when it comes to its measurement
138
. In particular, health psychologists and some researchers 
prefer to look at health-related quality of life (HRQoL) with either generic (all aspects of health, 
all health conditions) or specific tools (e.g. Cognitive Depressive Index- CDI, Kidney Disease 
Quality of Life -KDQoL).  Some prefer to use health profiles (e.g. SIP, NHP, SF-36), some to use 
more than one instrument 
139,
 
140
. They also use measurements of compliance with treatment. SF-
36 has been widely used since 1995.  Health economists, on the other hand, use HRQoL measures 
from the perspective of utility or ‘preference’ measures, often based on satisfaction with life (e.g. 
EuroQoL/ EQ-5D) for cost-utility studies.  
The SF-36 was once validated in Romania (general population) in the mid 1990s 
141
 and the 
questionnaire was used for the first time in haemodialysis patients in 2000 with results published 
in 2004 
142
. Another study was published in 2008 
143
. The summaries of the physical components 
score and the mental components score, or PCS and MCS scores, from the single centre study 
were 42.6 ±18.9 and 46.3± 21.1; the 2008 reported results from a multicentre study (12 RRT 
centres) showed values of 46.3 ± 19.2 and 55.1 ± 19.3 (cut off points of 43 and 51 were chosen 
and 64.4±21.1 and 63.8±22.5 were the Romanian general population norms respectively published 
by Mihaila et al in 2000 
141
; the kidney disease components score or KDCS score showed a value 
of 68.3 ± 11.3 (with no other reference).  
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Dutch researchers led by de Wit looked at the value of using both profiles (SF-36 and EuroQoL/ 
EQ- 5D) and preference-based measures such as the standard gamble (SG) and time trade-off 
(TTO) in dialysed patients. They concluded that: 
“Health profiles and health preferences represent different aspects of HRQoL. An impaired 
health status may not be reflected in the preference scores. Coping strategies and other 
attitudes towards health may affect the preference scores more than they influence health 
profile outcomes. The added value of health preferences methods in clinical research is 
limited.” 144 
Salek gives a very comprehensive list of over 40 QoL instruments that have been used with 
peritoneal dialysis patients 
145
. However, none of them were specifically developed for this 
purpose (CAPD). 
The tendency recently has been to measure QoL with at least two instruments; one generic and 
one disease specific, which makes the measurement of quality of life almost an independent area 
of study. The most commonly used generic instrument with patients on renal replacement therapy 
is the SF-36. It is easy to apply whether by the patient or an interviewer, easy to compute scores 
on its 8-item scale, and it allows computation of summary or ‘domain’ scores, distinguishing for 
example between mental and physical components, and benchmarking. 
Disease specific instruments for end-stage kidney disease have been developed since the 1990s 
and are still being validated. Hays reported in the mid-1990s from a study which he developed a 
new renal disease specific instrument: the KDQoL. It uses a 36-item health survey scale (the 
RAND version), as a generic core combined with 11 kidney disease-targeted grouped scales 
(KDCS) and when expanded in analyses, reporting on a total of 107 items is possible. In general, 
the instrument looks promising, but there are possible difficulties with its application and hence a 
Romanian version was validated very late for this research, in 2007 
146, 147
: 
 it is complex, and validation in languages other than English will take a long time; 
 its length and variety of items requires a trained team of interviewers with substantial cost 
implications. 
Two disease-specific instruments are the Kidney Disease Questionnaire (KDQ) and the Renal 
Quality-of-Life Profile (RQLP). At the end of 2008, there was little information on the internal 
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consistency, reliability and translation of these two instruments. Therefore disease specific 
measures pose major problems in their application 
144
. 
To summarise, the impact of treatment on quality of life from the literature shows that: 
 The health-related quality of life of patients undergoing renal replacement therapy is a very 
important outcome, responsive to quality of care, and a good deal of effort has been put into 
developing instruments for measuring it 
34; 91; 135; 144
; 
 For some dimensions of health–related quality of life, transplantation gives similar values to 
those in the general population 
92; 140
; 
 For most dimensions of quality of life patients on hospital HD or continuous ambulatory 
peritoneal dialysis score lower than the general population or transplant patients 
34; 91; 141
. 
In the Romanian study from 2008, the physical components score (PCS) and mental components 
score (MCS) in haemodialysed patients were again lower than in the Romanian population, but 
compared with two international studies the outcomes appear significantly better 
122; 143
.  These 
results seemed inconsistent with survival analyses and results from the single centre study by 
Covic et al (2004) which had a poorer MCS score than the multicentre result (46.3 vs. 55.1), 
despite patients being younger (48 years vs. 52 years) 
142
. As for the comparison with international 
values, one explanation could be that Romanian HD patients were overall younger than their 
Western counterparts.  
The study of QoL needs to be further reproduced for establishing a reliable baseline and further 
with individual patient trend, rather than sub-sampling a cohort of patients 
141
.  Also, standard 
deviations were similar in all 3 studies: general population (sample of 1,192, representative 18 
years and above), single centre (82 patients, mean age 47.9 ±12.1 years) and multicentre (709 
patients, mean age 51.7±12.6 years). The general population sample was randomly selected, only 
once 
141
 and the renal patient samples are subsequently self-selected, thus comparison in scores is 
difficult. This merits further attention when scores are measured and compared 
142, 143
.  
Unfortunately it was not possible to collect primary data on quality of life outcomes for RRT in 
Romania as part of the current study.    
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2.11 The burden of chronic kidney disease 
2.11.1  Chronic kidney disease (CKD): prevalence 
The relative burden of chronic kidney disease is measured as a prevalence rate.  In a study based 
on primary care records in SE England, Stevens et al reported the % prevalence rates for chronic 
kidney disease stages 3-5 given in Table 2.8. A Romanian study of two regional renal biopsy 
databases showed results from a 10-year period (1995-2004) on prevalence of biopsies which were 
analysed at 11/per million population/ year for two Romanian regions (6 million population) and 
the proportion (%) of CKD was 10%; the MPGN (membrano-proliferative glomerulo-nephritis) as 
an important CKD precursor showed a substantial decline during the period 
148
.  
Table 2.8:  The prevalence of chronic kidney disease stages 3-5 in SE England (Stevens et al 2007 
149
 and Australia (Chadban et al 2003)
81
  
 Age 
groups 18- 25- 35- 45- 55- 65- 75- 85+ 
England Males 0.01 0.17 0.71 3.08 6.89 17.65 33.16 44.75 
 Females 0.18 0.79 2.69 2.79 13.09 27.86 41.68 48.61 
Australia Males  0 (0 - 1.0) 1.8 (1.0 - 2.6) 51.8 (47.1 - 56.5) 
 Females  0 3.2 (1.9 - 4.4) 57.2 (51.4 - 63.0) 
2.11.2  CKD3 to 5 
Coresh et al 
53
, in data from the USA NHANES survey 1999-2004, reported a prevalence of stage 
3-4 chronic kidney disease of 0.7% for those aged 20-39 and 37.8% for those aged 70+,  a marked 
increase since NHANES 1988-94 (OR 1.47). According to the KDQI definition, the overall 
prevalence was 13% 
38
. 
In a 2008 press release by the Ministry of Public Health and the National Health Insurance Fund, 
Romania reported an estimate of CKD of 10% 
150
. Specific stages or how this was measured, were 
not given. 
In a study in the south of England Drey et al, defining chronic kidney disease as serum creatinine 
>150 micro-mol/L for 6 months, found 1,701 cases per million population (pmp) aged < 80 
151
.  In 
Australia Chadban S, et al 2003 reported the figures shown in Table 2.8 
55
.  
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2.11.2.1   CKD5: incidence and prevalence  
In the United States the Renal Data System (USRDS) has provided a focus for the collection and 
analysis of information on the incidence, prevalence, treatment and mortality for end-stage-renal-
disease in the USA ever since the mid-1980s 
9; 109
. The European Dialysis and Transplant 
Association - European Renal Association (EDTA-ERA) has had a similar history, except that it 
was only in late 1995 that the new constitution embraced the epidemiological along with the 
clinical aspects of end-stage renal failure and its treatment 
3
. The ICD-9 panel revisited chronic 
kidney disease end-stage renal disease and recommended new coding to be introduced from 
January 2007, but so far no reports have been produced based on the new codes 
132
. 
It is very difficult to capture all incident cases, and the literature usually reports the number of new 
patients beginning treatment for end-stage renal failure during a certain year. However, American 
and European terminologies differ.  In the USA, ‘reported incidence’ is taken as synonymous with 
starting on renal replacement therapy, on the basis that all newly diagnosed cases will be offered a 
treatment immediately they reach stage 5 
9; 125.  In Europe ‘acceptance’ excludes incident cases 
who are alive but not on renal replacement therapy, recognising that there may be unmet incident 
or new need, detected or not. Incidence may be expressed as crude rates (new end-stage renal 
failure patients per million population per year); or as specific rates for population subgroups (by 
age, sex, area of residence, etc., and combinations of these) 
9; 53; 78; 110; 125; 152
. 
Incidence rates can also be based on population screening, or inferred from pre-diabetic conditions 
such as impaired fasting glucose (IFG) and searches of routinely collected general practitioners’ 
(GP) computer data. Screening should generally increase detection rates 
70; 90; 153
. GP and Register 
data can be used for triangulation. The latter includes specialist diagnosis, including biopsy 
information in cases when biposy is performed 
148
. 
The number of patients with CKD5 within a given year provides an indicator of ‘prevalence’ 
(USA) or ‘stock’ (Europe) although this may only be the tip of the iceberg of the actual prevalence 
(see Section 8.1). Conventionally, and in line with the definition in section 1.2, stage 5 includes 
only patients who have completed at least 90 days on treatment, either in a dialysis programme or 
with a functioning kidney transplant 
107
. In recent years eGFR measurements at GP level led to 
high CKD prevalence estimates in the general population in the UK and fears of an increase in 
needs for treatment 
154
. However, other researchers followed-up over 3,000 individuals with 
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sustained reduced eGFR and discovered that the epidemiology of CKD 3b-5 is complex and that,  
individual risk (incidence of a defined stage), then relative risk and absolute risk are important 
measures when assessing the epidemiology of the condition over a period of follow-up 
155
. They 
identified in the followed-up cohort of more than 3,000 patients with CKD3 and above, that: 5% 
required and initiated RRT during the 6 years of follow-up, 59% died without initiating treatment 
and that 36% did not require RRT at the end of the 6 years and remained under observation. This 
merits further attention when considering the age and case-mix at initiation of treatment. 
The definition in section 2.3 consists of: at least one co-morbidity, such as: anaemia, gastro-
intestinal disorder, neurological disorder, cardio-vascular disorder or raised blood pressure ( 
140/90 mm Hg).  In Romania, unless the end-stage renal failure patient was known to the renal 
specialist prior to entry on renal replacement therapy, discriminating between a primary renal 
disease, hypertension and/or diabetes mellitus as a precursor when the patient presents with end-
stage renal failure remains a problem and this makes the condition’s staging difficult even though 
most patients would have reached stage 5 at this point and would also have at least one co-
morbidity 
9; 11
.  
In this study the terms incidence and prevalence will be used to cover the spectrum of chronic 
kidney disease (CKD), and acceptance and stock for CKD5 on renal replacement therapy (RRT)
1
.   
Table 2.9 sets out the main epidemiological indicators.  CKD covers stages 1 to 5 and CKD5 is the 
stage when renal replacement therapy is required. 
  
                                                 
 
 
1
 Since stock ≈ acceptance *survival, changes in case-mix, technology or capacity in a treatment 
facility can affect stock in two ways: an increasing acceptance rate on RRT (with expansion of 
facilities and/or their capacities); or an increase in survival of those treated. 
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Table 2.9:  Epidemiological indicators of CKD and CKD5 on RRT 
Indicator Formula 
CKD Incidence 
 (risk, cumulative incidence, any stage) 
New patients with CKD/  
Population at mid-year * 10
6
 for a given year 
CKD5 Acceptance  
(rate, newly on RRT) 
New patients with CKD5 on RRT/  
Population at mid-year * 10
6
 for a given year 
CKD Prevalence  
(rate)  
New and old patients with CKD at 31 December/  
Population at mid-year * 10
6
 for a given year 
CKD5 stock  
(rate, all on RRT) 
New and old patients with CKD5 on RRT at 31 December/  
Population at mid-year * 10
6
 for a given year 
 
Table 2.10 presents results from some population-based epidemiological studies, first reported 25 
years ago by Challah and Wing, mainly involving comprehensive, primary care data on chronic 
renal insufficiency (CKD) and end-stage renal disease (CKD5) 
90
, and some more recent surveys 
77; 156, 157
. This table summarises studies which have been considered at the conceptualisation of 
the research as the approach in designs underlie a public health approach to renal disease. 
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Table 2.10: Epidemiological studies of the incidence and prevalence of ESRD 
 
Ref Country Setting & Methods CKD Incidence (pmp) CKD Prevalence (pmp) 
 
 
 
 
 
 
90 
 
 
United 
Kingdom 
1971 
400 beds hospital 
(urea>71 mg%) 
39  
(<60y & appropriate for 
dialysis 
 
Northern 
Ireland 
1972 
GP questionnaire 
(urea>100 mg%) 
 424 CRF/3y & 222 
CKD5/3y 
Scotland 
1972 
GP questionnaire 
(urea>100 mg%) 
and death 
certificates 
52 
(<65y & appropriate for 
RRT) 
 
S-E Scotland 
1973 
GP questionnaire 
(urea>100 mg%) 
 190 
England 
1975 
Pathology register 
(urea >100 mg%) 
45 
(<65y & appropriate for 
RRT) 
 
 
 
 
 
 
England 
(Devon and 
Blackburn) 
1990 
Pathology register 
(serum creatinine 
>500 μmol/l) 
over 2 years 
148 
117 (>70 years) 
58 (20-49 years)… 
588 (> 80 years) 
78 initiated on RRT 
 
156 France 
(INSERM 
study) 
1992 
Various sources: 
-mortality statistics 
-sickness fund 
-PMSI 
-EDTA 
75 409 
(1982  206) 
 
 
157 
 
 
 
Ile-de-France 
(1998 data) 
Special form (all 
patients entering 
RRT including  
Failed transplants) 
100 
- 14 (< 18 years) 
- 55 (18-39 years) 
- 100 (40-59 years) 
- 190 (60-74 years) 
- 259 (≥75 years) 
108 including failed Tx 
 
417 to 433 
(3.8% increase over one 
year) 
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Table 2.10 shows how old the community based studies of the incidence and prevalence of 
chronic renal insufficiency are, with most of them from the 1970s.  Stages 3-5 of chronic renal 
insufficiency are difficult to measure, and such studies are difficult and expensive, making the real 
burden of renal disease, with renal insufficiency in all stages 1-5 (i.e. not just those on renal 
replacement therapy or stage 5) very difficult to determine.  Also these studies give a wide range 
of values that are difficult to compare, with differing age-groups and typically without a common 
or standardised methodology. One study has followed up patients with CKD 3b-5 for 6 years and 
although it looked prospectively at assessing the CKD staging through eGFR, only about 40% of 
patients were alive at the end of follow-up, thus making it even more difficult in assessing lifetime 
indicators 
118; 155
.  
A paper on the progression of chronic renal failure by Yu, 2003 describes in detail an updated 
review of known, but multiple, factors which contribute to the evolution of chronic renal failure 
showing that many complex associations between exposure factors remain to be explored 
158
.  
In 2006, the Incident ESRD Study Group published one paper in an attempt to provide better 
estimates of the incidence of ESRD, by capturing all new cases in countries where access to 
treatment to publicly funded renal replacement therapy was restricted only by medical 
contradictions and not by socio-economic or geographic circumstances. The recording of incident 
cases was believed to be complete for persons normally resident in the country or region 
152
. A 
summary of results is shown in Table 2.11. 
Most recently, CKD and its stages are measured with eGFR, thus defining the prevalence in 
various populations. The latest formulae are those developed by the MDRD Study and the CKD-
EPI Collaboration. These were briefly described in the clinical definition of CKD, in Section 
2.3.1. 
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Table 2.11:  Incidence of CKD5 in European population 
152
 
 All diabetic CKD5 All non-diabetic CKD5 
 30-44 years 45- 64 years 30-44 years 45- 64 years 
 ASR 99% CI ASR  99% CI ASR 99% CI ASR 99% CI 
Lowest 
value 
7 5 to 9 
(Netherlands) 
2-13 (Spain, 
Basque Reg) 
20 15 to 27 
(Norway) 
26 20 to 33 
(Finland) 
95 83 to 106 
(Finland) 
Highest 
value 
36 29 to 45 
(Finland) 
70 62 to 79 
(Austria) 
50 
 
 
 
53 
44 to 57 
(Greece) 
 
 
43 to 64 
(Spain, 
Valencia) 
132 
 
 
 
182 
119 to 146 
(Belgium, 
Flanders) 
163 to 202 
(Spain, 
Valencia) 
ASR = age and sex standardised [incidence] rate (pmp) 
Furthermore, established databases in Europe (ERA-EDTA), USA (USRDS), Australia and New 
Zealand (ANZDATA) have also published estimates of acceptance and stock. These are 
summarised in Table 2.12 
9; 11; 117
. Since the 1990s the primary research effort has been directed 
towards better information on the leading causes: primary renal disease, hypertension, and 
diabetes mellitus and to allow for benchmarking, which may only have been successful from as 
recently as 2007.  
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Table 2.12:  Measures of acceptance and stock for end-stage renal failure under renal 
replacement therapy world-wide 
Ref. Area Year Acceptance    (Rate pmp) Stock     (Rate pmp) 
EDTA-ERA 
152
 
Europe 1992 79.1 median 
(9.4-118.2)* 
437 median 
(28-579)* 
ANZDATA 
37
 
Australia 1992 79 482 
New 
Zealand 
1992 105 450 
USRDS 
35
 USA 1993 214** 824*** 
Lok CE 
82
 Canada 2001 1,300 diabetic ESRD 
110 non-diabetic ESRD 
n/a 
DH 
40
 UK 1998 96  (76 to 128)
~
 529  (439 to 693)^ 
Romanian 
Register 
27
 
Romania 1996 20 57 
*Ranges of acceptance and stock within the EDTA Registry; 
~
Anglia Oxford Region and Wales;^ Northern Ireland 
and North Thames. 
**   Reported incidence; not called acceptance;  
***Stock is prevalence in the USA renal replacement therapy 
In Table 2.12 the Canadian acceptance rate (incidence) for diabetic CKD5 was the highest found 
in the literature and measured by a prospective observational study 
56
. However, this is also an 
estimate assessed after 2000, whereas most other studies assessed theirs in the early 1990s.  
There are similar increases in overall incidence or acceptance of end-stage renal diseases in 
various European populations, For acceptance standardised rates (ASRs) in diabetic CKD5 in the 
30 to 44 year olds, the Netherlands has the lowest value (7 pmp) and Finland the highest (36 pmp). 
Finland has a high prevalence of diabetes in the general population (3.3%) and close to that of 4% 
in Romania. For non-diabetic end-stage renal disease, Finland has the lowest values of ASRs in 
both reported age groups: 26 pmp in 30 to 44 year olds and 95 pmp in 45 to 64 year olds. The 
highest values were reported from 2 Mediterranean countries as 50 pmp and 182 pmp respectively, 
in same age groups 
78; 149
. 
Incidence and prevalence as well as acceptance and stock are technical indicators and reflect 
exclusion or inclusion on RRT. These become comparable when measured in various populations 
only when numerators and denominators are clearly defined. This is for example reflected in the 
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variation of CKD from 4 to 11% from a 2010 review 
159
 and the variation noted in acceptance 
and stock in various countries (Table 2.11). 
Acceptance and stock (CKD5 on RRT) were low in Romania in 1996: 20 pmp and 57 pmp when 
the European median values were 79 pmp and 437 pmp in 1992; the UK figures were 96 pmp and 
529 pmp in 1998 (i.e. an acceptance four times higher and a stock ten times higher than in 
Romania) 
122; 160
.  
2.12 Prevalence of precursors  
2.12.1  Diabetes 
Data on regional variations and trends in the precursors of kidney disease can be useful for 
estimating the current and future prevalence in Romania 
70; 78
.   
In the USA the prevalence of diabetes in the general population rose from 4.9% in 1990 to 6.5% in 
1998 
81, 82
.  In another study in the USA from 2002, the disease prevalence was 6.3% in the general 
population, with <5% in the 20-39 years age group, 7-18% in the 40-59 years age group, and 13-30% 
in the ≥ 60 year olds.  The figures were higher in black, Hispanic, and American Indian groups than 
in the white population 
35; 58
. The American trends, by major age groups, are shown in Table 2.13. 
  Table 2.13:  USA trends in the prevalence of diabetes mellitus 
 Year 25-44 45-64 65-74 75+ 
 
White men 
1984 0.6 4.6 8.5 9.3 
1994 0.7 5.7 10.7 10.7 
2004 1.2 9.8 20.2 16.4 
 
White women 
1984 0.7 5 9.2 8.3 
1994 0.8 5.3 10.2 9.9 
2004 1.4 8.3 14.6 13.5 
Data from England and Wales are summarised in Table 2.14 
46
.  The overall figures for the Health 
Survey of England (HSE) in 2003 were 4.3% for men and 3.4% for women. (Furthermore 3% of 
men and 0.7% of women above the age of 35 years were found to have impaired fasting glucose 
(IFG)). In 1999 the UK Joint Health Survey Unit reported prevalence rates for England and Wales 
of <0.5% for type 1 diabetes and 3% for type 2 diabetes, so that type 2 represented 90% of all 
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diabetes cases 
46,47,48
.  Results from the two 2003 UK studies appear consistent. However the 
2003 results show a nearly 3-fold increase in 35-44 year old men for 2003 compared with 1994, 
and a 30% increase in men aged 55+ years; for women, the overall estimate nearly doubled from 
1.9% to 3.4%. 
Comparing the UK and USA data for those aged 45- 64, the white male American population in 
1984 had a rate (4.6%) which was twice as high as the UK male rate in 2001 (2.2%); and results 
for women showed a three-fold difference (5% compared with 1.5%).  Comparing the USA in 
2003 with the UK in 2003, rates in the 65-74 year olds were still higher in the USA: 20.2% and 
14.6% compared with 11.9% and 8.4% in the UK.  
Table 2.14:  Summary of UK prevalence studies for diabetes mellitus  
* 75-84 years    ** weighted 
 
Figures published recently by the European Commission show the population prevalence of 
diabetes mellitus in different countries ranging from 3.3% in Finland to 7.3% in Cyprus 
48
.   
In 2008 an estimate for the Romanian population was published and reported in the media by the 
Romanian Ministry of Public Health for the year of 2007.  The numbers of cases in the general 
Prevalence 
% 
Source 16-24 25-34 35-44 45-54 55-64 65-74 75+ Overall 
Men HSE 1994 0.8 0.8 1 2.5 6.4 5.8 7.5 2.9 
HSE 1998 0.1 0.7 1.6 2.9 5.8 7.0 8.7 3.3 
GPMS 2001 0.24 0.49 2.17 4.28 4.75*  
UKPDS 2003 <1 <1 2 3 6 7 9  
HSE 2003**  0.4 0.3 2.8 3.6 8.1 11.9 10.0 4.3 
HSE 2006** 0.8 1.2 2.4 6.0 8.5 15.7 13.5 5.6 
Women HSE 1994 0.6 0.3 0.9 1.5 2.5 4.8 5.2 1.9 
 HSE 1998 0.8 0.7 0.9 1.6 3.1 6.6 6.6 2.5 
GPMS 2001 0.15 0.34 1.54 3.37 3.74*  
UKPDS 2003 <1 <1 1 2 3 11.9 10  
HSE 2003**  0.9 0.9 1.5 2.6 4.7 8.4  8.9 3.4 
HSE 2006** 0.9 1.2 1.2 3.6 6.0 10.4 10.6 4.2 
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population were given as up to 570,000, of whom 2,500 were under 15 years old. This implied 
disease rates of 3.4% in the general population and up to 5.5 per 100,000 in the 0 to 15-year-olds. 
These figures were confirmed by a paper reported from the EuroDiab survey 
161
. The prevalence 
of diabetes mellitus in Romania (2008) is thus estimated to be around 4% 
162
. The Romanian rates 
in the younger population ranged from 1.43/100,000 in 0-4 years to 4.37/100,000 in those aged 
10-14 years. Geographically, the north-west of the country has seen an increase between 1988 and 
1997 
162
. 
To summarise: estimates of the current prevalence of diabetes mellitus rank Romania lower than 
the USA, but similar to other Western European countries. Impaired fasting glucose (IFG) data 
and proportion by type of DM were not available from Romania for the adult population of over 
15 years. Romania consists mainly of white individuals and no data were available for ethnic 
minorities.  
With regard to trends in diabetes, there are limited data for Romania; point prevalence rates have 
been measured in national health surveys and increased from 2.7% in 1989 to 4% in 2007.  The 
estimates from the Health Insurance Fund for 2003, 2004 and 2005 were 1.98%, 2.12% and 2.23% 
respectively. Part of this increasing trend may be explained changes in the structure of the 
population 
122; 147; 161, 162; 163
.  The percentage of patients on renal replacement therapy with diabetic 
nephropathy rose sharply from 1% in 1997 and to 13% in 2003, but this is still is lower than the 
19% recorded in the UK in 1998
 60 
and can be expected to increase further. More details are given 
in Chapter 3.   
2.12. 2 Hypertension 
The prevalence of hypertension varies widely geographically and increases with age 
164, 165, 166, 167
.  
Table 2.15 from the US NHANES survey, Table 2.16 from the Health Survey for England and 
Table 2.17 from two studies in Spain all show this age-related increase, starting younger for men 
than women but converging by the age of around 65.  
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Table 2.15:  Hypertension: on treatment or > 140/90 mm Hg in the USA (NHANES) 
168
 
 Period 20–34. 35–44 45–54 55–64 65–74 75+ 
Male 1988–1994 7.1 17.1 29.2 40.6 54.4 60.4 
2001–2004 7.0 19.2 35.9 47.5 61.7 67.1 
Female 1988–1994 2.9 11.2 23.9 42.6 56.2 73.6 
2001–2004 *2.7 14.0 35.2 54.4 72.9 82.0 
 
Table 2.16:   Hypertension: controlled or uncontrolled
2
 in England (HSE) 
167
 
 
 
 
 
 
 
 
 
Table 2.17:  Hypertension in Spain (Banegas 1998
169
, Ramos 2004 
166
) 
HT (%) All Men Women 
Age group 35-64 25-54 55-74 25-54 55-74 
Hypertension 47 19 53 12 60 
Treated hypertension n/a 3 22 6 27 
                                                 
 
 
2
 The top part of the table includes those with a history of hypertension but whose blood pressure is being 
controlled by treatment; the bottom part is those whose blood pressure is high, including some who are on 
treatment for it. 
   16-24 25-34 35-44 45-54 55-64 65-74 75+ 
All with 
high blood 
pressure 
Men 1998 16.0 20.5 26.1 42.3 59.8 69.9 72.8 
 2003
e
 10.5 13.3 21.2 37.1 53.0 65.3 67.2 
 2003
f
  6.4 11 19.5 34.7 50.6 64.1 64.4 
 2008 7.5 12.5 17.9 32.9 52.1 61.6 68.4 
Women 1998 4.2 6.9 13.2 30.8 51.6 72.8 77.6 
 2003
e
 1.9 4.9 10.2 24.5 47.1 68.1 77.2 
  2003
f
 1.9 5.2 11.3 23.4 46.5 64.3 74.9 
  2008 1.9 5.3 13.4 24.6 41.5 61.6 73.0 
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The US rates in the period 1988 to1994 appear to be much lower than those for England in 1998, 
except in the 75+ age group. However by 2003 the English rates had dropped and the American 
rates had increased to slightly above the English rates. It is possible that some of these changes 
may be due to blood pressure measurement bias, but some may be attributable to other factors, 
such diet and smoking and exercise. 
The Spanish studies report much lower values than either England or the US.  Precise comparison 
is impossible because the classification of age groups is different. Also some of the differences in 
reported prevalence may be attributable to different methods of measuring blood pressure.    
The European Commission’s 2007 report on major and chronic diseases gives data on the 
prevalence of hypertension in European countries, summarising studies from 1994 to 2003 
62
. 
Different studies used different definitions of hypertension as well as different methods of data 
collection such as questionnaire administration or physical measurement. However these studies 
and a WHO database suggest that the prevalence of hypertension doubles after the age of 50 years 
in line and that 50% of the population will be hypertensive after age of 55 years 
54; 65; 162; 165,166
. 
For Romania the source of the prevalence data in the European Commission report was the WHO 
MONICA study for 1997 
2; 62
. The prevalence of hypertension for the population aged 15 to 64 
years was reported as 4.9% in men and 4.5% in women. In 2008 the Romanian Ministry of Public 
Health also reported levels of around 6.5% in the general population for 2006 
162
.  
Rates of hypertension by JNCI-VII stage were not available from any of the Romanian sources, 
although recording of general information on hypertension was started in 2003 by the Ministry of 
Public Health after a gap since the latest MONICA WHO study which recorded Romanian data 
for 1997 
163
. The MoH data reported overall prevalence rates in the general population of 6.6% for 
2004 and 7.1% for 2005. There is no reported breakdown by age and sex, but there has clearly 
been an increase since 1997. In broad terms these are similar to the UK rates. 
2.12.3  Obesity 
The link between obesity, diabetes and chronic renal failure were shown in Table 2.4. Data on this 
are limited for Romania 
170
 as 7.6% for men and 9% for women (BMI>30, all ages). It is assumed 
that similar risks would apply across the Romanian population.  
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The US 1999-2002 National Health and Nutrition Examination Survey (NHANES) indicated that 
10% of 2-5 year olds and 16% of 6-19 year olds were overweight 
69
, and that 18% of the 12-19 
year olds had Impaired Fasting Glucose (IFG) test results signalling pre-diabetes (insulin 
resistance) status 
171, 172
. 
Table 2.19 gives data on obesity in the USA, England and Romania from national health interview 
surveys.  A BMI greater than 25 is generally considered overweight, and greater than 30 obese 
(see Section 2.4.2 on Diabetes and 2.4.4 on Obesity).  
To summarise: 
 levels of overweight and obesity in the USA have increased markedly since the 1970s, and 
continued to increase until around 2000.  Obesity in women has changed relatively little since 
then; obesity in men seems to have levelled off if around 2005-6 
63; 167,168;  
 this has also happened in England. Current levels of obesity in men are very similar to those in 
the USA, but for women American levels are higher in all age groups except those aged 75+;  
 although England has much higher levels of actual obesity (BMI > 30) than Romania, the 
levels of overweight (BMI > 25) are of similar orders of magnitude; 
 levels of obesity in England have increased markedly between 1994 an 2003 in all groups 
except older women. 
 Romania is benefiting from a cohort of people aged 75 or more that are less likely to be 
overweight than any other group aged 35 or more.  Later cohorts are more likely to be obese. 
A summary of this information is shown in the table below (Table 2.18), with more detailed 
information in Tables 2.19 and 2.20: 
Table 2.18: Summary of condition precursor prevalence rates in 3 populations: 
 DM HT* Obesity Smoking 
USA 7 30 30 25 
UK 3 25 23 23 
Romania 3 16 10 33 
*Note: most unreliable parameter
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Table 2.19: Body Mass Index for the USA, England and Romania 
    15-24 25-34* 35-44 45-54 55-64 65-74 75-84 
BMI >25 Men USA 1976–80  41.2 57.2 60.2 60.2 54.2 --- 
   1988–94  47.5 65.5 66.1 70.5 68.5 56.5 
   2001–04  59.0 72.9 78.5 77.3 76.1 66.8 
  England 1994 30.4 49.6 61.7 67.9 69.2 71.0 62.9 
   2003 31.8 59.5 71.9 75.8 77.1 77.5 70.7 
  Romania 2000 17.2 39.6 52.9 61.0 57.3 53.2 40.0 
 Women USA 1976–80  27.9 40.7 48.7 53.7 59.5 --- 
   1988–94  37.0 49.6 60.3 66.3 60.3 52.3 
   2001–04  51.6 60.1 67.4 69.9 71.5 63.7 
  England 1994 28.2 37.6 44.8 54.1 64.2 66.0 52.4 
   2003 32.1 47.1 55.2 59.1 66.8 71.4 66.5 
  Romania 2000 8.0 26.0 43.0 54.8 54.9 48.7 34.9 
BMI >30 Men  1976–80  8.9 13.5 16.7 14.1 13.2 --- 
   1988–94  14.1 21.5 23.2 27.2 24.1 13.2 
   2001–04  23.2 33.8 31.8 36.0 32.1 19.9 
  England 1994 5.7 9.8 15.5 17.2 17.8 17.9 14.7 
   2003 8.6 17.8 25.0 28.1 26.8 28.7 20.9 
  Romania 2000 0.6 5.7 9.8 11.7 10.5 9.7 5.2 
 Women USA 1976–80  11.0 17.8 19.6 22.9 21.5 --- 
   1988–94  18.5 25.5 32.4 33.7 26.9 19.2 
   2001–04  28.6 33.3 38.0 39.0 37.9 23.2 
  England 1994 7.9 12.9 16.9 17.8 25.5 25.3 16.3 
   2003 13.3 18.7 21.7 26.5 27.8 29.9 26.1 
  Romania 2000 1.2 5.3 10.6 15.5 14.9 11.2 8.7 
* 20–34 for the USA data. 
If subsequent generations of older Romanians follow England and most other European countries 
in their patterns of obesity, it seems likely that the pressure on services for CKD5 in younger age 
groups will increase markedly as a result 
173,
 
174
.  
2.12.4  Smoking 
Data from interview surveys on current smoking (occasional as well as daily) are given in Table 
2.20  
169
. 
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Table 2.20:  Prevalence (%) of smokers: trends in the USA and England 
 Country year 18–24* 25–34 35–44 45–54 55–64 65-74 75+ 
Overall
*** 
Men 
USA** 
 
1974 40.8 49.5 50.1 41.2 24.3  
1985 28.4 37.3 36.6 32.1 18.9  
1995 28.4 29.9 31.2 26.3 14.1  
2005 29.7 27.7 26.3 24.5 7.9 26 
England 1984        35 
 
1994 42 36 31 30 22 21 12 28 
2004 37 37 26 25 19 10 7 24 
Romania 2003 36 52.8 22 9 41 
Women 
USA 
 
1974 34.0 38.6 39.3 33.0 12.3  
1985 31.8 32.0 31.0 29.7 13.3  
1995 24.9 27.3 27.0 24.3 11.7  
2005 22.6 23.1 22.2 18.9 8.4 23 
England 1984        32 
 
 
1994 34 33 28 29 24 19 11 27 
2004 30 29 27 25 20 14 4 23 
Romania 2003 19 21.2 3 4 25 
*15-24 for Romania, 20-24 for England             ** white men and women for the USA   *** for adults 
The prevalence of smoking has gone down in young men in England whilst it has remained almost 
unchanged in the USA.  Data from the WHO in 15 year olds and older show the prevalence of 
smoking is higher in Romania (41%) than the USA (26%), New Zealand (30%) or England (37%). 
Romania’s data show that smoking continues in men aged 25+ with a rate almost double that of 
the USA or UK figures in the 25-64 years and that is despite a lower uptake of smoking at the age 
of 15 
175
. For the population of 15 years and older, the World Health Organisation data, show that 
smoking prevalence for Poland is 44% and Hungary has a 46% rate; these are higher than 
Romania’s 173.  However women, and particularly young ones, smoke less in Romania than 
American or English counterparts. Thus smoking remains an important risk factor for chronic 
kidney disease and end-stage renal failure in Romanian men.  
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2.12.5  Prevalence of risk factors: relative risks and attributable risks 
Table 2.18 summarises individual prevalence rates in 3 populations for the 4 main condition 
precursors. While needs assessment (expressed need and comparative need) refers to possibilities 
of providing RRT to the Romanian population, epidemiology also goes on measuring not only the 
prevalence of precursor conditions, but also assess their risk (hazard x exposure) in a given 
population. This has proven particularly difficult to measure in the case of CKD due to the 
complexity around precursor conditions: 1. they can act as single hazards; and 2. or as multiple 
hazards. In either situation the duration of exposure can vary. Epidemiology goes on to assist in 
this case with indicators such as: relative risk and odds ratio (RR and OR), already covered in the 
Section of CKD and association with the four condition precursors. Other indicators are PAR% 
(population attributable risk percent) and the Impact Fraction. These have been used in Chapter 3 
to assist with the epidemiological assessments of CKD 5 in Romania and are further discussed in 
Chapter 9 
174
.   
2.13 Cost of illness and economic evaluation of treatment for CKD5 
2.13.1  Costing frameworks 
Romanian data are limited in this area.  One paper with mid 1990s data did not report empirical 
cost measurements, but gave an overall budget estimate for 1993 quoted from a secondary source 
176
, 
177
.   
Approaches to costing end-stage renal failure in the literature are complex and very varied, and the 
results probably less generalisable to Romania than some epidemiological parameters 
25; 90; 95, 
102;159; 178, 179,
 
180
. However decisions on investment of scarce capital and labour are required, and 
these require data on costs.  
There is no single costing framework recommended by health economists.  However, some rules 
have been universally agreed, e.g.: 
 distinguish between direct and indirect costs, and between fixed and variable costs 1.   
 include as many types of cost as possible and acknowledge those that are left out; 
 consider opportunity costs where available; 
 state what the components of each type of cost are; and  
 think in terms of the marginal costs of producing more or less of an output. 
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Economic theory provides a basis for constructing cost functions for any quantity of products or 
services for which a price is given.  From these we can derive marginal economic costs 
1
. 
2.13.2  Economic measurements of benefits 
If costs are seen as ‘investments’ (which could otherwise earn interest, or be spent on housing, 
education, etc.) then, what is expected in return? What types of benefits are there, and what units 
are they measured in? 
The units of benefit used are: 
 natural units (e.g. life years gained) which measure the (opportunity) costs of buying a unit of 
effect  (e.g. one year of life gained); or the extra cost of an extra unit of effect; 
 utilities (e.g. QALY’s - years of life gained weighted for their quality or quality adjusted life 
years); and 
 monetary units (assuming that  one life year saved is worth e.g. $3,500). Many different types 
of benefit (e.g. avoided use of hospital services) can be added together or compared. This type 
of cost analysis is normally applied at national level (e.g. when choosing between defence vs. 
education vs. housing, etc). 
The type of units chosen defines the approach to economic analysis: natural units for cost-
effectiveness (CEA), utilities for cost-utility analysis (CUA), and monetary values for cost-benefit 
analysis (CBA) 
1
. 
2.13.3  Economic evaluation of renal replacement therapy and related disease management 
There have been a number of economic evaluations of renal replacement therapy, some going 
back to the late 1960s. For the purposes of this study they have been evaluated using ‘guidelines 
for authors and peer reviewers of economic submissions to the BMJ’181. Each relevant study 
should be scored under each of the evaluation criteria
182, 183
. On this basis only one study was been 
identified as a marginal cost-effectiveness analysis
184
. There are few cost-utility studies; and they 
have been concerned with secondary prevention of CKD, e.g. due to diabetes mellitus 
185
. In 
theory, economic evaluations should consider opportunity costs but there is only one study which 
achieved this 
186
.  
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Fig. 2.2 presents a general framework of costs adapted from Ehreth 
187
. 
The major weakness which most of these studies suffer from is the lack of good evidence on the 
relative effectiveness of the different modalities.  Also cost estimates change on a continuous basis 
and vary among countries, depending also on what is measured. However, the literature suggests 
consistently that the most cost-effective therapy is transplantation (living related followed by 
cadaver), followed by CAPD, and then hospital haemodialysis 
130
. Transplantation provides not 
only ‘best value for money’, but also best quality of life for the renal replacement therapy patient. 
Also, renal anaemia becomes significantly less of an issue under transplantation because the 
transplanted kidney secretes erythropoietin.  
Other forms of therapy, such as the newly introduced continuous-cyclic peritoneal dialysis 
(CCPD) and automated peritoneal dialysis (APD), or the combination of High Flux- and 
haemodialysis (HFHD), or haemodiafiltration and classical haemodialysis (HDF vs. HD) although 
appear effective treatment modality have yet to prove their cost-effectiveness. As with any “new” 
technology, there is not enough evidence and this will only become available once these therapies 
have been more widely established.  
Cameron refers to estimates of cost/QALY, but these appear to be based on costs from some 
studies and utilities from others. The UK values for cost/ QALY in the 1980s were: £4,710 for 
kidney transplant, £19,870 for CAPD and £21,970 for hospital HD 
6
. These values would be 
undoubtedly higher by 2010: a Greek study estimated values of: €60,353, €54,504 and €45,523 
per QALY for haemodialysis, peritoneal dialysis and 1
st
 year transplant 
188
. A more recent, 2010, 
Canadian cost-utility analysis showed that the introduction of erythropoiesis-stimulating agents 
(ESA) or hu-Recombinant erythropoietin or genetically recombined erythropoietin (hu-EPO) for 
the treatment of targeted renal anaemia levels has costs to the level of (Canadian) $ 96,270 per 
QALY for low target haemoglobin in CKD patients with or without dialysis. If they were not 
treated with ESA such costs escalate to $147,980 per QALY 
189
. The literature has not updated 
this indicator, RRT cost/QALY by modality for some time. 
When referring to the types of costs measured, the averted cost was mentioned only in those 
studies of secondary prevention of end-stage renal failure. Studies on tertiary care (i.e. HD, 
CAPD, etc) do not include such [averted] costs.  
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Figure 2.2 A programme cost input  
 
 
 
 
 
 
 
 
 
 
 
A more recent review by Ray surveyed the costs of major complications of diabetes (including 
end-stage renal disease) in 6 countries.  Compared with the costs of treating other complications, 
end-stage renal disease was most expensive, but varied between the six countries according to 
mode of renal replacement therapy and year of treatment (year 1 and year 2) as shown in Table 
2.21. These are not adjusted for quality of life 
190
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Table 2.21:   Costs of renal replacement therapy treatment in Europe (Italy and Spain), Canada 
and Australia (in €, inflated to 2003 – data on costs from 1998 to 2002) 
 Australia Canada France Germany Italy Spain 
HD year 1 17,188 58,159 56,487 58,116 43,075 31,233 
HD year 2 n/a 93,840 n/a n/a n/a n/a 
PD year 1 27,552 33,811 n/a 46,296 n/a 32,706 
PD year 2 n/a 47,447 n/a n/a n/a n/a 
Tx year 1
*
 16,246 60,903 24,608 68,175 56,717 28,370 
Tx year 2 791 19,986 6,866 10,904 11,582 8,336 
* does not specify type of transplant (living donor or cadaveric kidney); n/a= not available 
Table 2.21 suggests that:  
1)  the methodology applied must have differed between countries (Australia has by far the lowest 
costs); and that  
2)  both dialysis modalities are difficult to cost during the second year of treatment and beyond; 
these costs were not available in 5 of the 6 countries. This may reflect the need to target methods 
of measuring such costs if they are to inform decision makers for policy purposes.  From the 
Canadian figures, the costs of the second year of treatment are very different from the first, HD 
with a 61% increase, PD with a 40% increase and transplantation with more than a 300% decrease 
187;190
. 
Increasingly, measuring costs of CKD5 and complications is becoming difficult because of the 
complexity of both leading conditions and the care provided. Conditions leading to end-stage renal 
failure, such as diabetes mellitus and hypertension, incur costs from the moment of initial 
diagnosis. Costing a pre-end-stage renal failure stage is very difficult.  
Given the heterogeneity in approaches for cost estimation, the question asked was not whether 
costs were important for this study, but if they were, could they be reasonably measured in order 
to link this aspect to the treatment model? That is, after having established that, like other 
parameters for the epidemiological model, costs were also difficult to measure for this model, but 
worth attempting for the treatment model. 
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This research has considered accounting costs rather than opportunity costs. However, the dual 
elements of costing (data from sampled centres) and funding (national programme; reported 
average costs) were considered separately. There was some limited benchmarking in relation to 
average costs (reported and estimated by this research).  
2.14 Decision support: modelling for health planning and policy in renal replacement 
therapy 
Decision making in the area of renal replacement therapy for CKD5 involves a number of 
different ‘stakeholders’. The main ones are the providers (mainly nephrologists in tertiary care), 
third party payers (government and other agencies) and increasingly the end-user of the treatment, 
patients.  Nutritionists, psychologists, physiotherapists and other specialised nurses may be 
involved as well.  
Decisions are largely based on clinical grounds, despite the gaps in the evidence base. Since 2005, 
multi-disciplinary clinics (MDC-care) have had a place in the care of the end-stage renal failure 
patient, before they enter renal replacement therapy 
185
.  The value of early referral from general 
practitioners or family doctors (GPs) to specialists has also been explored in the UK through the 
new General Medical Service (GMS) contract, but this has raised further questions about the 
primary, secondary and tertiary interfaces 
24;154; 191,
 
192
.  
Decision analysis is a widely used technique for informing comparison of strategic options. It is 
also a useful tool in cost analysis 
193,
 
194
. 
Decision trees involve mapping out all the possible sequences of events that could occur after each 
decision ‘node’. Given the probabilities of each kind of event and the utilities associated with each 
end point, expected utilities can then be calculated for each decision option. Similar tree models 
can be used to estimate the flows down each branch 
195
. 
Examples are: 
 a seven-state mathematical model, based on a 26-state Markov chain, of an integrated 
haemodialysis and transplantation programme
196, 197
; 
 a model for predicting the future stock of patients on renal replacement therapy due to chronic 
renal failure in Denmark 
198
; etc. 
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These models have taken acceptance for renal replacement therapy as their starting point.  
The literature also describes other types of models, mostly used by management decision makers 
and third party payers. In the renal field examples, using both acceptance and stock, are: 
 static flow models (using stocks and flows) for predicting needs for treatment 3, 4; 
 a discrete-time, auto-incremented non-stationary Markov model 199   
 discrete-event simulations of renal replacement therapy 60, 200, 201, 202; 
 a system dynamics model used to predict the end-stage renal disease patient population in 
Japan 
203
; 
 a geographical information system mapping out renal replacement therapy need and provision 
204
. 
Most of these models use advanced programming 
60; 198, 199; 201;203; 205
, but some, such as those 
published on behalf of EDTA and most of those for renal disease service planning are based on 
spreadsheets 
3, 4
. 
All the models are, however, based on defined sets of states and transitions. The main states that 
are described are: the starting state - acceptance onto treatment; the starting dialysis state, e.g. 
haemodialysis and related, peritoneal dialysis and related, or a combination; and irreversible or 
‘absorbing’ states: transplantation and death. Transitions (transfer from one state to another) have 
probabilities (risks) attached to them.  These transition probabilities may depend on patients’ risk 
factors (e.g. age, diabetes, etc).   
Based on states and transitions, simulations (e.g. Monte Carlo with a 10
n
 size virtual cohort) are 
run.  Sensitivity analyses indicate the robustness of the model and help interpretation of the 
results.  
Validation of these models is an important issue, often involving comparing model results with 
historical pattern of change 
206
. 
Such models are vulnerable to errors in both logic and structure, or even: 
“...invalid syntax…the model conditions action on an unobservable disease state and fails to 
link variables; there is noted failure to apply constant biases, incorrect modelling of the results 
of a diagnostic test and incorrect modelling of a treatment...” 207. 
That is why calibration of the model in the first instance is important; followed by validation. 
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Nevertheless, using modelling in the area of health services research and resource allocation has 
advantages. They: 
“...condense reality, as they are trying to understand a complex reality...all analyses, including 
economic evaluations, involve simplification in order to infer something about the real 
world. The art of model building is to know where and when to simplify”194. 
Data from the literature show that with both discrete simulations and spreadsheet models, 
estimates of patients in stock can be made; for example in England, both models have been used 
since the mid 1980s and the latest model for chronic renal insufficiency stages 3-5 was used to 
predict the number of patients for England, given current stock and acceptance on treatment 
86; 196, 
197;
 
208
. 
In 1996 Berthoux used a spreadsheet model in a French centre; with the input parameters of 
acceptance and stock of 89 pmp and 453 pmp, the annual dialysis pool expansion rate was 
estimated at 5.3%, with dialysis patients reaching 55% of the end-stage renal failure pool whilst 
the remaining 45% which represented the transplant pool, had an expansion rate of 13.1%. This 
model did not make a distinction between the two dialysis modalities: HD and CAPD 
3
.  
2.15 Health care for renal disease in Romania 
Romania is one of the former ‘communist’ countries in Europe lying in the central south-eastern 
part of the continent. It covers an area of 237,500 km
2
, territorially the second largest country in 
Central Europe after Poland 
170;
 
209,
 
210,
 
211
 and has had a population of nearly 22 million in the last 
25-30 years.  
2.15.1  The economic and social environment 
Since the post-1990s events, governments have been democratically elected, but arguably, the first 
real political change took place with the 1996 elections.  
The 1996 government declared that progress in the fiscal and monetary policy was an essential 
precondition for sustainable improvement in the country’s microeconomic performance, which 
also would have an impact on the country’s services.  The short-term outlook for Romania 
remained uncertain through the mid-1990s, and constraints in public spending and a firm 
monetary policy were considered essential.  
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The ‘centrepiece’ of the 1996 government programme was the legislative package of over 100 
laws which was adopted in 1997.   
By 1998-1999 the government was becoming unpopular as a result of little or no progress in the 
economic reforms. Unemployment in men rose from 5.7% in 1996 to 8.5% in 1997 and in women 
from 7.5% to 9.1%. Unemployment in those aged 15-24 reached 19%.  
Table 2.22 summarises how Romania stands in comparison with some of its neighbours at similar 
stages of development, and some more developed countries.   
Table 2.22: Economic and Health Indicators for selected countries 1996-8 and 2007-9 
Indicator  UK 
F         M 
US 
F          M 
N Z 
F          M 
Hungary 
F         M 
Poland 
F         M 
Romania 
F         M 
Life expectancy 
at birth (years) 
1996-8 79 74 79 73 79 74 75 67 76 68 73 65 
2007-9 82 77 81 76 83 78 78 69 80 71 77 70 
Infant mortality 
rate (/ 1,000 live 
births) 
1996-8 6.1 7.8 7.4 10.6 12.3 22.3
1
 
2007-9 4.8 6.3 5.0 6.8 6.7 14.9 
GDP (US$ 
PPP) 
1996-8 21,740 29,326 17,272 4,461 3,509 3,975 
2007-9 34,619 46,381 26,708 18,567 18,072 11,917 
Unemployment 
(registered %) 
1996-8 8.2 5.3 6.1 9.9 12.2 7.6 
2007-9 7.9 9.7 6.0 11.1 9.0 8.1* 
1
 17 per thousand live births in 2005  
* April 2010 
212
; ^ IMF 2009 
Overall life expectancy has increased in all countries including Romania despite its still high 
infant mortality rate. GDP per capita (PPP) has improved significantly for Romania and two other 
former communist countries (Poland and Hungary) 
213.
 Life expectancy with and without CKD 
can be measured and is an increasingly important index for service planning as populations age. 
Life expectancy in non-dialysis CKD has been reported for the first time in a Canadian population 
and results are comparable for Western societies 
214
. 
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2.15.2  Organisation and funding of the health care system 
In 1998 the Romanian Health Service had a centralised, hierarchical structure, led from the 
Ministry of Public Health (MoPH) and its local structures, the Public Health Authorities. The 
system was 100% tax based until 1998, when a compulsory social health insurance system was 
introduced, the National Health Insurance Fund (NHIF) thus defining the new National Health 
Social Insurance System. It meant that healthcare funding has been ring fenced from this funding 
source as opposed to a share given from revenues obtained via general taxation 
12; 14
. There are a 
few alternative insurance schemes, but beneficiaries must work in specific domains or economic 
activities: defence, transport etc. Private care is based on a fee basis. RRT is delivered in public 
facilities. 
In the last budget before the insurance system came into existence in 1998 
  
the revenue was 9.74 
billion dollars US and expenditure was 12.75 billion, leaving a deficit balance of 3.01 billion.  A 
breakdown is given in Table 2.23 
163
: 
Table 2.23:  The state accounts for health in 1997, Ministry of Health, Romania  
Expenditure (million dollars US) % Source 
Total expenditure  
 
 
 
970.9 
137.7  
  36.1  
295.1  
114.1  
62.5% 
8.9% 
2.3% 
19% 
7.3% 
State budget* 
Special sickness fund 
“2%” 
Other sickness fund 
Local funds 
RRT**     17   Special funds for drugs 
* 66% was received from NHIF  (WHO, 2003)  ; ** reported figure (1996) 
Despite the changes in the health care system from NHS type to insurance type with ring-fenced 
funding, health care remains “free” for the end-user, with a small minority not contributing with 
premiums and accesses services paid by the social security.  
It was the main third party payer that was changed, from the government to a decentralised body, 
the National Health Insurance Fund (NHIF). There are now different compulsory contributions 
(insurance premiums) which are collected via NHIF and almost all of the population is covered by 
basic services. 
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Before 1998 an undisclosed variable but small part of general taxation, funded the health 
services. In 1998, and since, contributions or health premiums were set up as follows: an 
employers’ contribution of 7% before tax, and an employee contribution of another 7% from their 
individual monthly gross salary. Thus the total premium was 14% of pre-tax income.  
The revenue collections ensure an annual health insurance fund.  Most local health insurance 
funds also contribute to a national solidarity fund which allows a more equitable and equal 
distribution of funding at local level. The contribution to the health insurance fund has grown 
especially after new general taxation rate was established at a flat 16%; this has allowed 
improvement in revenue collection for health services 
215
.  
Whether any changes were attributable to the new layout of the third party payer system, or 
whether they were due to economic developments or both, remains undocumented and is also 
beyond the scope of this study.    
The flow in the financial system was restructured in 1998 and further structural changes to the 
health care system followed, similar to the ways in which payments are made to providers in 
countries where insurance systems operate in the health care sector. Some of the changes affected 
renal services and the national renal replacement therapy programme and annual contracts were 
put in place.  
 2.15.3  Other resources     
The proportion of health care funds devoted to specialist care varies, but historically has always 
been over 65%. Also, most of the money, over 75%, is used for salaries 
163
. 
Romania’s ageing population and the increase in diabetes, a leading cause of CKD, will continue 
to pose resource allocation issues amongst competing areas of healthcare, renal services included. 
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Table 2.24: Health care indicators: cross-country comparisons for 1997, 2002 and 2006 
9;11;216
 
 1997 Various 
years 
Indicator UK USA NZ Hungary Poland Romania 
% of GDP 
on health 
1997 6.9 13.6 7.3 6.7 5 2.8 (1997) 
2002* 7.7 14.6 8.5 7.8 6.1 6.3 
Practising 
Physicians / 
100,000 
population*
* 
1997 186 260 210 308 236 180 
2002 209 240 n/a 320 230 196 
2006 246 240 n/a 304 218 216 
Hospital 
beds per 
100, 000 
population 
1997 - - - 800 - 739 
2002 399 330 610 786 - 768 
2006 357 - - 792 645 675 
* 2003 (based on 2002 WHO data); ** 2010 (ECHI Indicators (Public Health/ DG SANCO) 
Table 2.24 shows that structurally, Romania reached similar levels in staffing and service use 
indicators to many other countries with the increase in share of GDP to around 6%. The number of 
beds per 100,000 population is similar to other central-eastern European countries and double that 
of the UK despite the similarity in numbers of practising physicians per 100,000 population 
(which was much higher in Hungary for example in 1997 only to become equal in 2006). By 
contrast this indicator increased between 1997 and 2006 in the UK 
9; 14
. 
Renal Replacement Therapy (RRT) is dependent on specialist nurses. An indicator could be the 
number of nurses per 100,000 population, yet this is poorly reported in the ECHI database: in 
1997 Hungary and Romania had 495 and 517 nurses per 100,000 population 
216
.  
2.15.4  Problems 
In 1999 the Ministry of Health identified a number of problems within the Romanian Health Care 
System, many of which are common elsewhere.  Some were still recorded as problems much later 
on, in 2010, e.g.: an aging population; health care becoming in general more expensive 
217
; 
“insufficient” funding;  low ‘morale’ for some professionals; inequalities in access to care, 
especially between regions; historical emphasis on specialist care; surplus of hospital beds and 
low occupancy rates; poor access to services in rural areas; unclear ownership of health care 
facilities, poor quality of care, migration of health professionals and loss of human resources, etc. 
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2.15.5  Reforms 
As with many other economic sectors, the health care system went through some changes during 
1990 to 1996, but the major changes came from 1996 onwards.  
The RRT was directly affected through the adoption of new legislation including that of the 
transplantation Law (Act) which was passed by parliament. However, the political turnover was 
most significant. Five ministers were appointed and replaced between 1996 and 2000, three of 
them in one year, 1998. Thus, changes happened mostly at administrative level: a) in the way the 
health care system operated: from an NHS type (Beveridge) to a Social Insurance type (Bismarck 
modified) system and b) down to various administrative policies at regional and local level.  
Other changes were: the formulation of National Health Programmes, defined around high priority 
areas, either from an epidemiological point of view (e.g. notifiable communicable diseases, 
immunisation, cardio-vascular, cancer) or from a financial point of view, such as renal 
replacement therapy. On the ground most changes occurred in the way things were working in 
primary care. After 1998 it became a legal requirement that each individual must register with a 
GP. Thus GPs became the system’s gatekeepers during 1998/1999. In the case of renal care, the 
GP registration never guaranteed an automatic early referral to a nephrologist. Future RRT 
requirements have continued to benefit from ad-hoc planning on a historical basis. 
2.15.6  The history of services for CKD5 
Romania started developing renal replacement therapy for end stage renal failure in the early 
1970s with an access protocol and guidance which lasted until 1998. Gradually local policies took 
over from national policy, the age threshold has been lifted and only defined co-morbidities 
exclude patients from entering treatment. However, inequalities persist since the more liberal 
criteria are selectively applied, particularly since the service started to be privatised in 2008 
218
.  
By the late 1990s there was a network of facilities covering most of the country. This type of 
service was usually provided in teaching and district hospitals. Continuous ambulatory peritoneal 
dialysis (CAPD) was only introduced in 1995 for patients with CKD5. However, the main 
modality of treatment remains hospital haemodialysis (HD). Kidney transplantation is legal in 
Romania and mainly performed with kidneys from living related donors (82%). However the law 
stipulates that transplantation can be also done with cadaver kidneys 
219
. Two centres perform 
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living related kidney transplantation (LTx): Cluj or Fundeni Bucharest. Cadaver kidney 
transplantation has been reported in one centre after the transplantation law passed through 
parliament (1998)
220
.  
Fig 2.3 shows the distribution of all renal replacement therapy centres as of 1997. Fig 2.4 shows 
catchment areas of the adult renal replacement therapy centres as of 1997. A more recent 
geographical distribution has not been available (2011). 
2.15.7  National Health Programmes after 1998 
 “National Health Programmes” are centrally led from the Ministry of Health and supported 
financially with NHIF funding.  
Keeping these programmes under direct political control allowed for minimum disruption in the 
delivery of care due to the changes that took place in the third party’s payer profile. In 1999 there 
were more than thirty national programmes on the Ministry of Health’s agenda.  
The budget for the RRT national programme has remained at about 0.5 to 1% of the public funds 
available for health care, despite an increase in the number of CKD5 patients receiving RRT. 
Providers remain reliant on sponsor donations. In 2008 when a third of the patient stock 
transferred into private RRT some £12.5 million worth of new equipment was purchased via one 
supplier who increased their Romanian market share by 80% compared with the previous year
, 9; 
10; 216
.  
Renal replacement therapy for end-stage renal failure is a high- technology, high cost medical 
speciality. Similar to other countries, Romania buys equipment and consumables such as 
computerised dialysis machines and equipment, specialised consumables, drugs, on the 
international open market. 
The increasingly demand on resources has put pressure on providers, and the third party payers 
(the government and health insurance fund) via the public health service.  
Romania has a need to further develop these services as they require careful planning, resource 
allocation and resource deployment, particularly when there are competing demands from other 
medical specialities for same resources.  
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As a high-technology, high-cost therapy RRT  requires strict budgeting controls and other 
financial regulatory mechanisms to keep spending under control, particularly if cost-effective 
pathways of care are not rigorously followed
 221
. 
Romania started developing renal replacement therapy (RRT) for end stage renal failure in a few 
centres in the 1970s. By the mid 1990s there was a network of facilities covering almost all of the 
country, mainly in teaching and district hospitals 
110; 122;177
. Continuous Ambulatory Peritoneal 
Dialysis (CAPD) for patients with CKD was introduced in 1995 but the main modality of 
replacement remains hospital haemodialysis (HD)
 222
.  
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Figure 2.3: Distribution of all Renal Replacement Therapy centres by district, Romania, 1997 
 
  
Figure 2.4: Catchment areas of adult renal replacement therapy centres, Romania, 1997 
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 By the mid-1990s two centres started carrying out living related kidney transplantation (LRTx).  
The number of patients receiving RRT increased from around 1,000 in 1990 to 3,200 at the 
beginning of 1998 
160;
 
223,
.  The primary and secondary health care systems have yet to develop 
care pathways for management of the precursors of kidney diseases, renal insufficiency or renal 
failure.  
Service contract negotiation is done annually with the NHIF which sets the budget together with 
the renal replacement therapy (RRT) national programme and then endorsed by the Ministry of 
Health. According to the NHIF, by 2009, the budget for the National Programme for CKD5 has 
increased about five times in real terms in 10 years, closely linked to the increase in the number of 
patients accepted for treatment. Much of the funding for the increase in the number of dialysis 
centres and dialysis stations has come from overseas donors.  
The Romanian renal replacement therapy market is shared by many known technology suppliers. 
National sources fund consumables, co-morbidity drugs, patient transport and most administrative 
services which include all human resources.  
Table 2.25 based on data from Cameron for the UK and the US, Ursea and the Ministry of Health 
for Romania gives preliminary crude comparative figures for ‘burden of illness’ and health care 
budgets for the three countries 
6;177; 218
. 
Table 2.25: Demographic data, morbidity and RRT 
Country Population 
(millions) 
SDR 
diseases of 
circulatory 
system/ 
100,000 
SDR 
malignant 
neoplasms/ 
100,000 
Annual  
CKD5 on RRT 
acceptance 
(pmp) 
Annual 
CKD5  
RRT stock 
(pmp) 
USA 1997 280  357.1  214.3 232.8 884.3 
USA 2008 298  n/a n/a 295.2 1,333.5 
UK 1996 55.6 449.6  269.8  125.9 449.6 
UK 2008 59.7  188.09 177.9 109^ 746^ 
Romania 1996 22.6   195.7  163.2 20.3  58.6 
Romania 2008 21.7  558.32 179.8 -  341.1** 
* SDR = standardised death rate; n/a = not available; **2007 (reported in absolute number of 
patients and a rate per million population or pmp was calculated); ^ these indicators are for 2007 
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Table 2.25 shows crude (1996) and standardised death rates (SDR, 2008) which should be 
interpreted with care. Countries such as the USA and the UK have seen increases in their 
populations of 6% and 7% during the eight year interval, while Romania’s population has changed 
little since the 1980s, the most recent estimate being 21.5 million (2008) which represents a small 
decline. It can be observed from these general indicators that Romania lags behind the UK and the 
USA in circulatory diseases and renal replacement therapy.  In 2008 the Romanian and UK rates 
for cancer were similar, but the UK rate had gone down by 51% since 1996 while Romania’s had 
increased by 10%. 
2; 9; 162; 216
. There was no recent information on SDRs for circulatory diseases 
and malignant neoplasms in the USA. 
2.16 Summary of the literature review 
2.16.1  Definitions of chronic kidney disease 
Clinical and epidemiological definitions are complementary. Section 2.3 gives the epidemiological 
definition of stage 5 chronic kidney disease (CKD) or just CKD5 used throughout this research. 
2.16.2  Risk factors and precursor conditions 
CKD5 develops over years or decades if an individual is exposed to a primary renal condition 
which becomes chronic.  The main primary renal conditions are diabetes and hypertension (raised 
blood pressure above 140/90 mm Hg).  These in turn are related to lifestyle factors, including 
obesity and smoking.  The associations between diabetes and hypertension and renal disease are 
summarised in Table 2.26. 
Table 2.26: Summary of risks associated with chronic kidney disease and CKD5: 
Factor or precursor disease OR: range for 
association with CKD 
OR: range for 
association withCKD5 
Diabetes mellitus 1.5 to 6.1 7.5 to 9.9 
Hypertension 1.1 to 3.1 1.5 to 5.7 
Overweight (via DM?) 1.2 to 3.1 1.2 to 1.3 
Obesity  3.0 
Smoking 1 to 1.6 1.4 to 2.6 
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- Further points include the following: overweight and obesity are strongly associated with 
diabetes, with ORs from 3.4 to 8.1. However  once on renal replacement therapy, being 
overweight may be a “protective” factor, giving rise to the term ‘reverse epidemiology”, 
phenomenon which is incompletely studied 
105,106;155;174; 224
; 
- obesity is strongly associated with a risk of developing high blood pressure (ORs from 2.80 to 
8.60); this points to interaction between risks. 
- there does appear to be a link between smoking and diabetes (OR from a meta-analysis of 14 
studies 1.44), between smoking and chronic kidney disease, particularly in males and in those 
aged >40 years, but any link with hypertension is a very weak one  (OR is one study 1.1, two 
studies not significant.)  
Other lifestyle or environmental factors may be related to chronic renal failure/ end-stage renal 
failure directly or, indirectly via diabetes and hypertension.  
2.16.3  Disease progression and prognostic factors 
The natural history of renal disease is complex since progression due to the underlying disease can 
very rarely be differentiated from progression due to adaptive factors. 
- Factors such as age, underlying condition and  presence of co-morbidity have been included in 
risk classifications of RRT patients, because they are predictive of mortality 
- Patients with diabetes and myeloma have an increased risk of death. However survival in 
patients with diabetic nephropathy is now much improved, firstly through better disease 
(diabetes) management which delays the development of the nephropathy, and secondly due to 
progress in transplantation with a simultaneous pancreatic-kidney transplant 
2.16.4  Treatment 
Renal replacement therapy has two main modalities: dialysis (haemodialyis, haemofiltration, 
peritoneal dialysis) and transplantation (living donor or cadaver donor). 
The literature describes various combinations of approaches to treatment, with some countries 
relying more on haemodialysis (e.g. USA, Romania, Greece etc) whilst others have shifted 
towards peritoneal dialysis (e.g. UK, Canada). 
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Technology has evolved and synthetic membranes plus the use of bicarbonate-buffered dialysate 
are evidence of best haemodialysis practice; and use of Y-set/ modified Y-set in CAPD represents 
best known practice for this modality. 
2.16.5  Need versus requirement for treatment 
Need is measured in different ways: normative need includes expressed need and reflects 
requirement for RRT; comparative need includes health economics and also elements of equitable 
distribution of resources. 
This research focuses on requirement versus a generic need for treatment or healthcare for CKD5 
patients. That is because of the many definitions of need. CKD is also complex, yet staging assists 
with timing at least some interventions through primary and secondary care at first. Treatment 
requirement for CKD5 falls into specialist care where planning is required. The assumption here is 
that once an individual patient reached stage 5 this individual needs a nephrology referral and after 
closer clinical monitoring (proteinuria and blood pressure) may require RRT. RRT requirement 
may be delayed through medical treatment. 
2.16.6  Outcomes   
If a patient is late diagnosed with CKD5 and is not monitored or does not start any treatment, 
conservative or RRT if needed, the risk of death becomes more imminent.  Thus survival is the 
main outcome studied in RRT. One-year probabilities are over 90% (excluding patients who may 
die within the first 3 months of treatment, who have a higher mortality; these patients are outside 
the scope of this study).  A 1-year fatality has been reported as around 18-20% overall in the USA 
35
, but increases with age 
92
, from 9% in patients aged 20 to 44 to 17% in those 46 to 64 and 24% 
in those aged 65 and older. Duration of survival is also a key outcome for planning purposes, 
because this is associated with the prevalence of the condition and thus the number of people 
requiring RRT. Individual risks and population risks provide different information: for clinicians 
and decision makers 
155; 174
. 
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There is some evidence for misclassification on the death certificates of patients undergoing 
RRT. Nonetheless a third to a half of deaths is attributed to cardio-vascular causes, a rate usually 
higher than in the general population and most likely a complication of the renal condition.  A 
further 12-19% is due to infections; and 10-12% is attributed to “unknown cause”.  Depression 
was independently associated with a higher risk of mortality among HD patients 
110
.  
Another outcome is quality of life. This has become an important intermediate treatment outcome 
and is related to its delivery and its quality. There is a vast range of measures, both generic and 
disease specific to allow measurement of health-related quality of life of patients undergoing renal 
replacement therapy. For some dimensions of health-related quality of life, transplantation gives 
similar values to those in the general population. For most dimensions of quality of life, patients 
on hospital HD or CAPD score lower than the general population or transplanted patients. 
2.16.7  Estimating population burden of chronic kidney disease (stages 1 to 5) 
There are epidemiological indicators which combine parameters: prevalence of precursors with 
incidence (acceptance on treatment) and prevalence (stock). The literature is scarce in their 
application in the case of CKD stages 1 to 5. They were used in this research. 
Indicators useful in measuring the burden of chronic kidney disease, described in Chapter 3, are: 
The population attributable fraction (proportion), sometimes called population attributable risk 
percent or PAR% or, the proportion by which the incidence rate of chronic kidney disease could 
be reduced in the population if a defined exposure were eliminated. The calculation of PAR% 
helps with benchmarking against the proportion of a precursor in the ESRF or CKD5 on RRT 
stock (%); and  
The impact fraction (IF) which helps with benchmarking against annual acceptance of CKD5 on 
RRT (incidence pmp) at t2, say after one year, when the prevalence of a precursor changes at t2 
(Chapter 3 shows the Methods and Results). Assumptions were made in this research that risk act 
individually on CKD as the multiplier effect measurement was out of the scope of this research. 
This is further discussed in the Conclusion. 
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2.16.8  Economic evaluation and cost-effectiveness studies  
Economic evaluations are difficult to carry out, especially for a complex condition such as end-
stage renal failure 
1
. It should involve the expertise of a multidisciplinary team (economists, 
physicians, statisticians, health services researchers, managers, etc).  
Different countries and settings may give different results. Research should be based on 
‘standardised’ methodologies (e.g. the use of Purchasing Power Parities) in costing methods used 
for cross-comparison studies or for benchmarking purposes 
1;186
. 
Studying costs in association with treatment outcomes can assist service planners in assessing the 
cost-effectiveness of renal replacement therapy when there is competition for resources. 
Transplantation is the most cost-effective renal replacement therapy method. 
2.16.9  Decision support modelling for policy and planning 
Models allow decision-makers to explore scenarios and policy options; e.g. CKD5 on renal 
replacement therapy: modifying the acceptance rate, providing and maintaining a constant 
transplant rate, the effect on stock of increasing patient survival, changing the numbers of 
facilities, capacity etc. 
60
. 
Modelling can become an important tool for main stakeholders (providers, consumers and third 
party payers). This can assist the treatment requirements with better evidence, clearer pathways 
and can improve efficiency. However, models that are too simple will often fail to capture 
important aspects of the real world, particularly when economic times are volatile 
224
.  
The complexity of models should only reach that level where health care professionals, policy 
makers, economists and, last but not least patients, can judge the validity of the reported results 
from a treatment model. It should not mislead users or patients, budget holders and further 
research. 
Decision-makers need be made aware of the possibility and implications of “uncertainty in key 
variables”. Sensitivity analyses can be important in providing clarification 1; 194;205;208.. 
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3  Epidemiological modelling of kidney disease in Romania 
3.1  Introduction and objectives 
The objectives of this chapter are: 
 to estimate the current burden of chronic kidney diseases in Romania;  
 to estimate the prevalence of, and trends in risk factors and precursors of chronic kidney 
disease and CKD5 in Romania; and on this basis; and  
 to estimate the future burden of CKD5 in Romania:  
- Specifically this will involve:  selecting plausible scenarios for the future prevalence of 
diabetes, hypertension and smoking in Romania as the precursors of chronic kidney disease, 
and of the odds ratios linking these precursors to kidney disease; and 
- On the basis of these scenarios, constructing plausible scenarios for the future burden of 
chronic kidney diseases in Romania.  
3.2  Methodology and Methods  
3.2.1  Definitions  
- Chronic renal insufficiency due to chronic kidney disease (CRI-CKD); the loss of kidney 
function which becomes clinically apparent by stages 3-5 and only detectable through 
screening in stages 1 and 2; an underlying chronic kidney disease (CKD) is established by 
stage 3, i.e. the likelihood of those in need of pre-dialysis nephrological care is clinically 
detectable; the evolution of the functionality of kidneys beyond stage 3 depends on the 
underlying CKD; 
- Chronic kidney disease (CKD): those who have reached stages of renal functioning 
insufficiency but who are not necessarily receiving any nephrological care. This may be either 
because their condition is still undetected, for which proxy measures are used (e.g. type 2 
diabetes and hypertension prevalence and risk of progression towards CKD5 or, because the 
treatment is not available or accessible (unmet need); and,  
- Chronic kidney disease stage 5 (CKD5) on RRT only: those who have reached the severe 
stage of chronic renal insufficiency, who require replacement therapy and receive it (in need), 
whether with dialysis or a kidney transplant 
48
.  The difficulty with this definition as a basis for 
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health care needs assessment and planning of RRT services is that it is partly dependent on 
existing levels of provision and service capacity, thus differentiating between normative and 
expressed need 
 21; 122;155;174;177
). 
The prevalence of chronic renal insufficiency (CRI) with chronic kidney disease (CKD) in stages 
1-5, both point and period, can be estimated using various sources of data 
49; 70; 73; 75
.  Most of the 
literature is concerned with stage 5 under treatment (which is also used in this research in the 
treatment model), but estimates for stages 3-5 can also be made, and were used here in the 
conceptual epidemiological model (Appendix 2) 
65; 96; 115; 225,226
.  
3.2.2  Sources of data on burden and precursors 
3.2.2.1  The Romanian National Health Survey  
The 1997 National Health Survey was used as a secondary source. This survey was based on 
interviews, clinical records, a standard clinical examination, and compulsory screening tests. The 
sample (n = 9,821) was designed to be representative of the national population aged 15 years or 
more, and used a stratified (five step) sampling method: region, district, locality, household, and 
individual 
163
. The original dataset for the 1997 survey was obtained. This provided for up to five 
diagnoses per patient, including a possibility of two primary renal diseases.  
Period: Data collection and processing took place during 1997. The 1997 results are presented 
along with earlier results (1983 and 1989) to show trends.  
Validity checks: Validity checks were performed at the source of data entry by staff who prepared 
the dataset.  
3.2.2.2  The Romanian National Renal Registry 
This registry provided data on end-stage renal failure and some very limited data on precursors 
60; 
152;  223
. The latest year for published estimates was 2004.  Consistency checks for these figures 
have been made by comparing them with earlier reported or published estimates 
103; 111; 122; 160;177
.  
The validity and accuracy of reporting may have improved somewhat between 1996 and 2004, but 
this is uncertain 
122; 177; 227
. 
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Period: The main sources of data are Registry reports available for the members of the Romanian 
Society of Nephrology from 1992 to 1996 
177
; data on later years, such as e.g. 2000, 2001 and 
2003, were available through published literature 
110,111; 122;227
. 
Validity checks: Checks were made at the point of data entry. Validity checks for any raw data 
from this source were not possible. Validity remains highly questionable, and has implications for 
the interpretation of outcomes, including the validity of the policy scenarios.  
3.2.2.3  Other sources of data  
In 2006 the MoPH Centre for Health Information, Informatics and Statistics, reporting for the 
National Health Insurance Fund (NHIF), published updated figures for hypertension and diabetes 
since the last national health survey in 1997. The most recent figures are for 2003-2005 
216 
. The 
figures reported were much lower than those in the 1997 survey and the prevalence was around 
6%. There was no other information, for example related to validity checks or the threshold 
definitions of hypertension; i.e. whether 140/ 90 mm Hg or 160/90 mm Hg was used in case 
inclusions. 
Neither source (National Renal Registry and National Health Insurance Fund Register) specifies 
the method of data collection for the conditions leading to chronic renal insufficiency. However, a 
published report which includes data from 1990s and 2003 show an increase in co-morbidities  
such as diabetes and hypertension in patients undergoing RRT from 2002 onwards 
122; 150;162;216
. 
One reason for this may be the health insurance default process whereby chronic conditions are 
now compulsorily monitored for policy and service planning purposes and have therefore become 
visible at the point of care. The ICD-10 was used for this period (2003- 2005). The rates reported 
are: prevalence per 100,000 population for hypertension and incident cases as absolute numbers 
for diabetes 
162
. 
Period: 2003 to 2005.  
Validity checks: There is no information available on validity checks and assumption is made that 
these data were all checked at the point of entry.  
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3.2.3  Analysis of data on burden and precursors: methods 
New variables were created such as body mass index.  Tables were produced for prevalence rates 
of disease and precursors.   
Age-specific rates from the 1997 Romanian National Health Survey were applied to data and 
estimates of local demography to give estimates of local point prevalence of precursor conditions: 
primary renal diseases, diabetes and hypertension.  The population estimates used were from 
Eurostat 
170
.  
A similar approach was used for estimation of prevalence of CKD, but without a breakdown by 
age.   
Reported point prevalence was estimated for a wider range of disease categories based on ICD-9 
coding. This coding was used with the national health survey data. In order to simplify data 
processing, conditions relevant to this study were re-coded into four major categories: primary 
renal diseases (all renal conditions), hypertension, diabetes mellitus and chronic renal 
insufficiency. Survey methods and the diagnostic criteria for each of 99 conditions and disabilities 
are listed in the main official Survey Report.  Definitions of primary renal diseases are given in 
Appendix 3. 
The results of new analyses were checked against the figures in the published reports 
122; 148
.   
Odds ratios (ORs) were computed to estimate the association of primary renal disease, diabetes 
mellitus and hypertension with chronic kidney disease in univariate analyses.  
The Population Attributable Risk percent PAR% (or PAF = population attributable fraction) was 
used to estimate the proportions of end-stage renal failure and diabetic nephropathy under renal 
replacement therapy attributable to e.g. diabetes (Section 2.9.2.2). The fraction of chronic kidney 
disease attributable to e.g. diabetes mellitus or hypertension is difficult to measure directly, but 
can be estimated indirectly from the ORs (or the Rate Ratios in case of prospective studies) using 
the Levin formula: 
PAR% = Pe (RR-1)/ 1+Pe (RR-1)  
This is the proportion or percentage by which the incidence rate in the population would be 
reduced if the defined exposure were eliminated (Pe= proportion exposed in the population and 
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OR = rate ratio of incidence of condition). In this case the incidence is for CKD5. Data are very 
sparse for CKD due to the low observed incidence. This formula assumes other causes have had 
equal effects on the exposed and unexposed groups and one other assumption that no multiplier 
effect for multiple hazards was considered 
228. 
  
For example, suppose that diabetes is the “exposure” factor of interest with a prevalence of 4% in 
the general population, and the incidence rate ratio for diabetic nephropathy in the literature is RR 
= 12 
56
.  Then the calculated PAR% with the two parameters, is interpreted as the proportion by 
which the incidence rate of end-stage renal failure due to diabetic nephropathy could be reduced if 
diabetes were to be eliminated as risk factor and in this example this is 30.5%. This was also 
benchmarked against the existing proportion of diabetic nephropathy on RRT 
122; 227
.  
Prevalence figures for diabetes, hypertension and smoking at baseline (1995), and ORs from the 
literature linking these precursors to chronic renal disease, were used to estimate PARs% for CKD 
in 1995. These PARs% were then combined with estimates of prevalence in 2005 and 2015 to 
provide estimates of the estimated PARs% of chronic kidney disease for these factors in 2005 and 
2015.  Then, assuming that the number of cases not attributable to each precursor remained 
constant over the period, the prevalence of chronic renal disease in 2005 and 2015 was estimated.  
This was done for a variety of scenarios for precursor prevalence and ORs (RR was available only 
for diabetes), and for combinations of precursors. 
The Impact fraction (IF) was also calculated in assisting scenarios for low and high acceptance 
(incidence) at t2 (future moment in time) on RRT 
229
. Summation is across the levels of exposure, 
however considered here dichotomously as: exposed and not exposed under the same assumption 
that there is no multiplier effect. 
The formula is: 
Impact Fraction = IF = 1- Σp2*RR/ Σp1*RR and this can be substituted in the formula below to 
establish low or high incidence rate ratios and proxies for future estimated acceptance on RRT: 
Incid 2 ESRF (or Acceptance on RRT) at t2 = Incid1 ESRF at t1 *(1-IF) 
In the impact fraction (IF) subscripts 1 and 2 refer to the higher and lower risk level or, the before 
and after a change (t1 and t2) in the prevalence of precursors. RRs can be replaced with ORs 
229
.   
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Both PAR% and the IF help with benchmarking against: 1) proportion in stock (% precursor 
which led to CKD5, such as in the case of diabetes) and 2) acceptance (incidence of CKD5 at 
entry point on RRT when prevalence of precursors change from t1 to t2) 
The low and high levels of prevalence of precursors and ORs or RRs were used in establishing 
PAR% as well as the IF. A summary of results is given below in Table 3.12.  
Data were analysed with Excel. 
3.3  Reanalysis of data from the 1997 National Health Survey 
3.3.1  Sample representativeness 
The age distribution of the National Health Survey sample was checked for representativeness 
against the age distribution in the Eurostat population estimates for Romania in 1997.  The results 
are shown in Table 3.1.  The 15-24 year-old age- group appears slightly under-represented (16% 
in the survey vs 19% in the population) while the 55 – 64 and 65- 74 age groups appear somewhat 
over-represented (32% vs 26%).  Forty-six percent (46%) of the sample were male compared to 
49% in the population. It was not possible to check whether the urban/rural split in the sample was 
representative.  
Table 3.1: The Romanian population by age group in 1997: national* and survey sample 
Age group Number Proportion (%) 
Population Survey Population Survey 
<15 n/a n/a n/a n/a 
15-24 3,804,979 1,525 22.0 15.5 
25-34 3,246,987 1,555 18.8 15.8 
35-44 3,188,645 1,699 18.4 17.3 
45-54 2,597,509 1,534 15.0 15.6 
55-64 2,511,831 1,877 14.5 19.1 
65-74 1,932,691 1,301 11.2 13.2 
≥ 75 n/a 360 n/a 3.7 
All 15+ 17,282,642 9,821 100% 100% 
* Eurostat reference population.   
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3.3.2  Prevalence of chronic renal insufficiency  
The survey only reported twelve cases of chronic kidney disease. On this limited basis the crude 
prevalence of chronic renal insufficiency (MDRD with e-GFR <60) was 1,222.5 pmp (per million 
population) with a very wide 95% confidence interval (631.4 to 2,134.4 pmp).  In 10 of the 12 
cases at least one criterion cast as “associated precursor condition” was recorded.  Five had 
primary renal disease, 3 had hypertension and one had diabetes mellitus. One had both 
hypertension and diabetes. Age specific rates are highly unreliable, but are given in Table 3.2.  
3.3.3  Prevalence of primary renal disease 
A total of 298 diagnoses of primary renal diseases were recorded in 283 individuals, giving a 
prevalence of 2.9% (95% CI: 2.6 to 3.2%). The official Survey Report gives an overall rate of 2.5%, 
in broad agreement with the reanalysis.  
A primary renal disease was recorded as co-morbidity in only 5 of the 12 cases of chronic renal 
insufficiency. Of these, there were 3 interstitial nephropathies, 1 nephrotic syndrome and 1 prostatic 
hypertrophy. The 278 individuals who did not have a recorded diagnosis of chronic renal 
insufficiency had 294 primary renal diseases diagnoses, some individuals again having more than 
one. Of these diagnoses, 53% were kidney or uretheral lithisasis, 23% prostatic hypertrophy, 19% 
chronic interstitial nephropathy, 2.3% chronic glomerulopathy, 1.7% nephritic syndrome and 1% 
autosomal polycystic kidney disease (ADPKD). No more recent data were available except the 
proportionate distribution of CKD5 on RRT for 2003 by Mircescu et al 
122
. These proportions differ 
from those from the national health survey as they represent individuals on RRT. 
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Table 3.2:    Distribution by age group of chronic renal insufficiency and main underlying 
conditions: percentage prevalence rates (Romania, 1997) 
162
 
Condition Sex 
No. of 
cases 
15-24 25-34 35-44 45-54 55-64 65-74 75+ 
Overall 
rate 
Chronic 
renal  
insufficiency 
m 5   0.14 0.00 0.15 0.50 0.00 0.11 
f 7   0.11 0.23 0.09 0.29 0.50 0.13 
Primary 
Renal 
Disease 
m 141 0.4 1.4 1.1 3.4 5.2 7.3 11.3 3.3 
f 142 0.2 1.3 3.7 4.1 2.4 4.0 2.7 2.7 
Diabetes 
m 128 0.3 0.0 0.5 2.9 6.1 7.1 5.7 2.8 
f 135 0.2 0.2 0.7 3.2 5.2 5.6 2.0 2.5 
Hypertension 
m 653 1.1 8.2 10.8 13.9 27.2 22.6 15.5 14.5 
f 796 0.1 3.2 7.7 14.6 31.7 22.9 14.7 14.9 
Diabetes & 
hypertension 
m 26    0.6 1.0 1.5 0.7 0.58 
f 34    0.3 1.7 1.2 0.6 0.63 
Respondents 
m 4492 724 378 715 794 702 761 413  
f 5329 801 462 794 907 978 897 490  
3.3.4  Prevalence of diabetes mellitus 
The reanalysis of the survey data gave 263 individuals coded as having diabetes, a prevalence rate 
of 2.7% (95% CI 2.4 to 3.0%).  The published report quotes 3.2% as the point prevalence for 
diabetes mellitus in adults aged 15 or more.  
Cross-checking against cases with glycaemia >= 120 mg% and other diagnostic criteria for 
diabetes proved difficult. However, 19 people in the dataset were not coded as having diabetes 
even though they had an impaired fasting glucose test of ≥ 120mg/dL.  Adding these to the coded 
diabetics increased the rate to 2.9%.    
The prevalence rate for 2009 in the EuroDiab study was reported as 4% 
161
. 
3.3.5  Prevalence of hypertension 
In the National Health Survey data, hypertension was far the most common of the precursors of 
kidney disease. The overall prevalence was 14.6% (95% CI of 14.4 to 14.9%). However there was 
considerable variation in crude specific rates between the 41 Romanian counties, ranging from 
2.4% to 17.5%.  
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Again, cross-checking cases coded as hypertension against their blood pressures proved difficult. 
A cut-off point of 140/90 mm Hg was chosen for the new analysis in line with the international 
standard definition of JNC-VIth revision also used by NHANES 
53; 78
 and HSE 
85
, which is 
different from the threshold chosen by the survey methodology in line with WHO MONICA 
(1997) which uses 160/90 mmHg. The figure in the official Survey Report was 16.7%, a 
difference of 2.1% that could be explained by different cut off thresholds.  
However, in 2006 the National Health Insurance Fund provided overall prevalence figures for 
hypertension in the region of 6%, making the different estimates of the prevalence of hypertension 
highly variable 
216
. However, these could be registered patients who are in treatment. 
 3.3.6  Prevalence of diabetes and hypertension together  
Data on the prevalence of diabetes and hypertension together are given in Table 3.2. If the 
prevalence of diabetes and hypertension together is estimated as the product of the prevalence of 
diabetes (with or without hypertension) and the prevalence of hypertension (with or without 
diabetes) the total estimated number of cases in the survey come to 32 for males and 34 for 
females, compared to actual figures in the survey of 26 and 34.  This suggests that estimation of 
the numbers with hypertension and diabetes combined on the basis that the two conditions are 
uncorrelated could be an acceptable approach.   
There are no comparative figures in the national report for 1997, or for 2007.  
3.3.7  Trends in prevalence 
Results from the last three national health surveys (in 1983, 1989 and 1997), which used identical 
methods, are summarised in Table 3.3, by year of survey, condition, sex and residence. The 
official reports suggest that the three surveys were representative to similar extents.  Comparing 
the 1997 results with the two previous surveys (1989 and 1983), the 1997 Survey Report 
concluded that: 
“The prevalence of primary renal diseases as defined in Chapter 2 (PRD) has almost doubled in 
1997 compared with the 1989 estimate with an increase of 83%, and trebled if compared with the 
1983 estimate; there was an increase of 56% from 1983 to 1989; in urban areas the increase from 
1989 to 1997 was only of 66% whilst in the rural areas the increase was more than double.” 34; 179. 
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Table 3.3: Trends in prevalence of CKD, hypertension and diabetes, Romania, National Health 
Survey for 1983, 1989 and 1997 
 Year 
Prevalence rate (per 100 population surveyed age 15+) 
Total Increase Male Increase Female Increase Urban Rural 
Primary 
Renal 
Disease 
1983 0.88  -  -  - - 
1989 1.38 56.8% 1.09  1.61  1.84 0.88 
1997 2.53 83.3% 2.07 89.9% 2.93 82.0% 3.06 1.97 
Diabetes 
b
 
1989 2.69  2.44  2.88  3.55 1.83 
1997 3.18 18.2% 3.41 39.8% 2.98 3.5% 3.81 2.48 
Hyper-
tension 
a
 
1989 15.6  14.2  16.7  15.2 15.9 
1997 16.7 7.1% 14.8 4.2% 18.4 10.2% 17.2 16.1 
Source: MoH, Romania
 179
 
There are no data from 2007/08 suitable for inclusion in this table.  
The prevalence of diabetes mellitus increased by 18% between 1989 and 1997. It increased by 
40% in males but only 5% in females.  Also it increased significantly more in rural areas, by 36% 
compared to 7% in urban areas. There was a further increase from 2.9% to 4% (37%) between 
1997 and 2007, but there was no available breakdown by age or gender.  
3.3.8  Association between different risk factors and kidney disease in the survey data 
Table 3.4 shows the strength of the associations found in the National Survey data between 
different risk factors and chronic renal insufficiency, in terms of odds ratios (ORs). Two cut-off 
points were chosen: BMI=25 for overweight and BMI= 30 for obesity.  
It can be seen that the ORs linking overweight and obesity to CRI are low. There is some evidence 
from the literature that while BMI is a risk factor for the development of end-stage renal failure, 
once renal disease has developed, overweight appears to be protective (‘reverse epidemiology’ 
131,132
), which may account for this lack of association. Nonetheless a variety of studies have 
shown that high body mass index is predictive of the development of kidney disease.  
Table 3.4 shows the links between overweight/obesity, and other risk factors for chronic kidney 
disease.  
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Table 3.4  Strength of association between hypertension, diabetes, overweight and obesity data 
from the national health survey, Romania, 1997 for precursors of diabetes and/ or 
hypertension
1
: Obesity
2
 data 
Overweight/ obese: 
BMI ≥ 25 
Number of cases 
BMI<25       BMI≥25 
 
      OR           95% CI 
 
p>chi
2
 
Age ≥ 45          No 
                         Yes 
2,055            310 
3,763         3,693 
    0.15         0.14 to 0.18 0.000 
Age ≥ 50          No 
                         Yes 
3,906         1,674 
1,912         2,329 
    2.84          2.62 to 3.09 
 
0.000 
Hypertension   No 
                        Yes 
5,192         3,180 
   626            823 
    2.15          1.92 to 2.40 0.000 
Diabetes          No 
                        Yes 
5,713         3,845 
   105            158 
    2.24         1.74 to   2.87 0.000 
Hypertension   No 
and diabetes    Yes 
5,778         3,928 
      40             75 
   2.76        1.88 to 4.06 0.000 
Obese: BMI ≥ 30 
Number of cases 
BMI<30       BMI≥30 
  
    OR           95% CI 
 
p>chi
2
 
Age ≥ 45          No 
                         Yes 
2,322            43 
6,502          954 
  7.92          5.82 to  10.79 0.000 
Age ≥ 50          No 
                         Yes 
5,265          315 
3,559          682 
   3.20         2.78 to 3.69 0.000 
Hypertension   No 
                        Yes 
7,626          746 
1,198          251 
   2.14        1.83 to 2.50   0.000 
Diabetes          No 
                        Yes 
8,618         940 
   206           57 
   2.54         1.88 to  3.43 0.000 
Hypertension   No 
and diabetes    Yes 
8,741        965 
      83          32 
   3.49         2.31 to 5.28 0.000 
Note for table 3.4: 1 HT defined as 140/90 mm Hg 
2
 Obesity is defined in the national health survey as “excess of weight” and compared with tabulated values 
calculated with the formula: G=T-100-(T-150/4) where G= weight; T= height; 20% or more in G (weight) compared 
with the theoretical value qualified the person as obese; according to this formula, prevalence was 7.3% in the 15 
years and above sample;  
Given that height and weight were recorded in the dataset, BMI was calculated according to the formula weight/ 
height
2
 (Quetelet index) and the threshold of 30 was used to define obesity; prevalence was 10.2% in 15 years and 
above for sample n=9,821; weight and height measurements did not indicate whether self-reported or actually 
measured or whether scales for weight measurement were similarly calibrated etc. (validity) 
  
  
 
 
106 
3.4  Data on precursors from the National Renal Registry 
The Registry does not record information on co-morbidity for conditions leading to chronic 
kidney disease and end-stage renal failure. Moreover the proportion of patients with underlying 
co-morbidity showed that in 1991 nearly all end-stage renal failure patients under renal 
replacement therapy had a primary renal disease. In the 1996 report only 2% were reported as 
diabetics, and none had hypertension. By 2003 the Registry reported that the proportion of 
diabetic cases had increased to 10% of all patients on renal replacement therapy from 1% before 
1996. The Registry did not provide data by age-group for either 1996 or 2003. 
3.5  Estimating the future population burden of chronic kidney disease 
3.5.1  Projected changes in population size and structure 
The future burden of chronic kidney disease will clearly be affected by the size of the population 
and its structure.  Tables 3.5 and 3.6 show that according to the mid-projections, the population is 
expected to decline by about 10% for men and 14% for women by 2020.  However the proportion 
of people aged 65 or more will increase by almost 50% (men) and 42% (women) and of those 
aged 75 or more by over 70% (men) and 56% (women).  
Eurostat also provides upper and lower variants on these estimates.  For example, according to the 
upper estimate the population will have declined by 8% instead of 11.5%; according to the lower 
estimate it will have declined by 15%.  
The age-specific prevalence rates of chronic kidney disease and its precursors can be applied to 
these figures to give projected prevalence rates on the very conservative assumption that the age-
specific rates will remain unchanged. The results of doing this are shown in Table 3.7.  It can be 
seen that in spite of a decline in population of more than 10%, primary renal disease would be 
projected to increase by 18% for men and 9% for women, diabetes by 14% and 8%, and 
hypertension by 16% and 11%. 
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Table 3.5: Population estimates for men: Romania, 1995 to 2020 (000s)
170
 
Age 1995 2000 2005 2100 2015 Change  
0-14 2273 1992 1649 1554 1467 -39.4% 
15-24 1855 1732 1617 1397 1094 -44.4% 
25-34 1560 1744 1737 1642 1541 -14.2% 
35-44 1636 1414 1473 1674 1678 -2.6% 
45-54 1277 1477 1556 1352 1421 27.2% 
55-64 1370 1225 1179 1379 1462 -6.8% 
65-74 1061 1117 1147 1036 1019 13.7% 
75+ 523 623 731 835 926 72.7% 
Total 11555 11324 11089 10869 10608 -10.4% 
15+ 9282 9332 9440 9315 9141 -3.3% 
% 0-24 35.7% 32.9% 29.5% 27.2% 24.1% -34.9% 
% 25-44 27.7% 27.9% 28.9% 30.5% 30.3% 2.4% 
% 45-64 22.9% 23.9% 24.7% 25.1% 27.2% 22.3% 
% 65+ 13.7% 15.4% 16.9% 17.2% 18.3% 48.6% 
 
Table 3.6: Population estimates for women: Romania, 1995 to 2020 (000s) 
170
 
Age 1995 2000 2005 2010 2015 Change 
0-14 2373 2086 1740 1642 1553 -38.5% 
15-24 1929 1808 1684 1459 1153 -43.5% 
25-34 1606 1797 1801 1709 1600 -13.1% 
35-44 1635 1412 1489 1698 1719 0.5% 
45-54 1231 1411 1479 1292 1388 29.9% 
55-64 1216 1060 1030 1206 1280 -6.9% 
65-74 823 868 866 767 768 11.4% 
75+ 313 373 450 503 528 56.2% 
Total 11126 10815 10539 10276 9989 -12.6% 
15+ 8753 8729 8799 8634 8436 -5.6% 
% 0-24 38.7% 36.0% 32.5% 30.2% 27.1% -32.2% 
% 25-44 29.1% 29.7% 31.2% 33.2% 33.2% 7.3% 
% 45-64 22.0% 22.8% 23.8% 24.3% 26.7% 27.7% 
% 65+ 10.2% 11.5% 12.5% 12.4% 13.0% 41.6% 
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Table 3.7: Projected change in prevalence with constant age/sex prevalence rates, Romania, 
1995 to 2020 (000s) 
  Primary Renal Disease Diabetes Hypertension 
Men 1995 298,466  239,490  285,681  
 2000 312,756 4.8% 244,642 2.2% 1,325,504 3.1% 
 2005 327,535 9.7% 252,363 5.4% 1,383,920 7.6% 
 2010 334,649 12.1% 257,039 7.3% 1,420,742 10.5% 
 2015 347,771 16.5% 267,194 11.6% 1,475,720 14.8% 
Women 1995 206,257  173,487  1,044,746  
 2000 207,303 0.5% 173,434 0.0% 1,049,242 0.4% 
 2005 214,023 3.8% 175,777 1.3% 1,083,133 3.7% 
 2010 214,138 3.8% 175,290 1.0% 1,108,487 6.1% 
 2015 219,313 6.3% 182,083 5.0% 1,153,452 10.4% 
 
3.5.2  Projected changes in prevalence rates 
In the previous section it was assumed that while the demographic structure was expected to 
change, the age/sex-specific prevalence rates would remain constant. However there is good 
evidence from other countries (Chapter 2), and some evidence from Romania, that the prevalence 
of some risk factors is changing. In England, age-specific prevalence rates for diabetes 
approximately doubled between 1994 and 2006, but are still below rates from the US. 
Hypertension has been increasing slowly in the US but decreasing in England. Smoking has been 
gradually declining in both the US and England, but in both cases the declines have flattened out.  
Obesity and overweight have been increasing strongly and are still increasing in the UK, although 
they do seem to have peaked in the US.  
The second approach to estimating the future prevalence of kidney disease in Romania is based on 
estimating the impact on the prevalence of chronic renal disease of possible changes in the 
prevalence of risk factors and precursors.   
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The precursors considered up to this point include diabetes, hypertension, smoking and obesity.  
There is some controversy over whether there is a direct link between obesity and kidney disease. 
However, the link between obesity and diabetes is relatively clear. Thus, including both obesity 
and diabetes as independent factors in this estimation procedure, risks would double count.  For 
this exercise only the effects of diabetes, hypertension and smoking will be considered.   
The next step is to define plausible scenarios for risk factor or precursor prevalence for CKD5 in 
Romania for the period up to 2016. From Table 2.14 and Table 3.2 it can be seen that prevalence 
rates for diabetes for England in 1994 and Romania in 1997 were reasonably similar for both men 
at around 2.5-3% and women at 2-2.5%. The English rate for 2003 (about 4%) was similar to the 
EuroDiab Romanian rate reported in 2009 in the adult population aged 15 years and above. 
However US rates rose from about 5% in 1990 to over 6% in 2002 and rose above 7% by 2009. 
On this basis the proposed scenarios for the prevalence of diabetes in Romania are 2.5% 
(unchanged) and 4% in 2005, and 2.5%, 4% and 6% in 2015 (Table 3.8). 
Estimates of the prevalence of hypertension in Romania vary widely. The MONICA study 
reported a prevalence of about 4.7% for 1997, and the Romanian Ministry of Public Health 
reported a value of 6.5% for 2006 (section 2.12.2). However the analysis of the Romanian Health 
Survey for the same year gave values of around 14.5% (section 3.2.5), and this is closer to figures 
from western countries such as the US and UK, which are around 30%. The differences in figures 
could be explained by misclassification of cases. On this basis the proposed scenarios will be 5% 
and 14.5% as baselines in 1995; 5%, 14.5% and 27% in 2005; and 5% 14.5% and 27% in 2015.  
The prevalence of smoking has been high in Romanian men (around 41%) compared with data 
from the UK and the USA but lower in women (around 25%; Table 2.19).  Although the rates are 
very different in men and women, for the purposes of this analysis an overall baseline figure of 
33% will be assumed. The proposed scenarios for Romania will be 33% (unchanged) and 23.5% 
in 2005; and 33% and 23.5% in 2015.  
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Table 3.8: Scenarios for projected levels of risk factors in Romania in 2005 and 2015  
Prevalence 
scenarios Scenario Source  1995 2005 2015 
Diabetes Static Romania 1997 2.5% 2.5% 2.5% 
  Mid England 2003   4.0% 4.0% 
  Upper US 2002    6.0% 
Hypertension static 1 Romania 1997a 5.0% 5.0% 5.0% 
  static 2 Romania 1997b 14.5% 14.5% 14.5% 
  Upper England  2003   27.0% 27.0% 
Smoking Static Romania 2003 33.0% 33.0% 33.0% 
  Lower England 2004   23.5% 23.5% 
3.5.3  Impact of trends in precursors on burden of end-stage renal failure  
The task here is to estimate the impact on the prevalence of chronic renal disease in 2006 and 
2016 of the risk factors/precursors scenarios set out in Table 3.9.  As set out in the Methods above, 
the approach is to estimate PARs% for diabetes, hypertension and smoking for 1995, 2005 and 
2015 using RR and ORs from the literature and the different prevalence scenarios, low, medium 
and high, in Table 3.8. Then, assuming that the number of cases not attributable to each precursor 
remained constant over the period, the prevalence of chronic renal disease in 2006 and 2016 can 
be estimated.   
The literature (Chapter 2) and the analysis of the Romanian Health Survey (Table 3.4) report a 
range of values for the ORs so a set of scenarios with a plausible range for each OR was set up.  
These ORs are: for diabetes 7, 9 and 12 as the lower, mid and high variants respectively; for 
hypertension: 1, 2 and 3; and for smoking: 1, 1.5 and 2.  
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Table 3.9:   Population attributable fractions derived from prevalence of precursors of chronic 
kidney disease and OR scenarios (Levin’s formula) 
Year  1995 2005 2015 
  PAR PAR PAR 
  estimate of OR estimate of OR estimate of OR 
prevalence Low mid high low Mid high low mid high 
Diabetes static 13% 17% 22% 13% 17% 22% 13% 17% 22% 
 mid      19% 24% 31% 19% 24% 31% 
 upper           26% 32% 40% 
Hypertension static 0% 5% 9% 0% 5% 9% 0% 5% 9% 
 static      0% 13% 22% 0% 13% 22% 
  upper            0% 21% 35% 
Smoking static 0% 14% 25% 0% 14% 25% 0% 14% 25% 
  lower       0% 11% 19% 0% 11% 19% 
 
Table 3.10:  Impact of changes in risk factors (precursor conditions) on prevalence of CKD 
  2005 2015 
  Impact on prevalence Impact on prevalence 
  Estimate of OR Estimate of OR 
  Low mid high low Mid high 
Diabetes (D) Static 100% 100% 100% 100% 100% 100% 
 Mid 108% 110% 113% 108% 110% 113% 
 Upper     118% 123% 130% 
Hypertension (H) static 1 100% 100% 100% 100% 100% 100% 
 static 2 100% 109% 117% 100% 109% 117% 
  Upper       100% 121% 140% 
Smoking (S) Static 100% 100% 100% 100% 100% 100% 
  Lower 100% 96% 93% 100% 96% 93% 
D + H both static 100% 100% 100% 100% 100% 100% 
 both mid 108% 120% 132% 108% 120% 132% 
 both upper       118% 149% 182% 
D + H + S all static 100% 100% 100% 100% 100% 100% 
 D & H mid, S lower 108% 115% 123% 108% 115% 123% 
 D & H upper, S lower       118% 143% 169% 
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Table 3.10 suggests the following: 
 The different estimates of the increase in the prevalence of diabetes could mean increases in the 
prevalence ratios of chronic kidney disease (CKD) of between 0% and 30% (from 100% to 
maximum 130%) 
 The different estimates of the increase in the prevalence of hypertension could mean increases 
in the prevalence of chronic kidney disease of between 0% and 40% (from 100% to 140%). 
 The different estimates of the decrease in the prevalence of smoking could mean decreases in 
the prevalence of chronic kidney disease of between 0% and 7% (from 100% to 93%). 
 The combined increases in the prevalence of diabetes and hypertension could mean increases in 
the prevalence of chronic kidney disease of  between 0% and 82% if the changes in smoking 
are zero or can be are ignored 
 The combined changes in the prevalence of diabetes, hypertension and smoking could mean 
increases in the prevalence of chronic kidney disease of between 0% and 70%. 
  
 
 
113 
Table 3.11: Impact Fraction: impact of changing risk factors (precursor conditions) on 
acceptance rates (stage 5 CKD with ESRF and Acceptance at t2)  
 
Prevalence of risk factor 
at t2 (t1) 
Acceptance 
on RRT 30-44 45-64 
Diabetes 6% low 10.5 30 
  (from 4%) high 54 105 
      
  4% low 11.2 32 
  (from 2.5%) high 57.6 112 
      
  6% low 16.8 48 
  (from 2.5%) high 86.4 168 
      
Hypertension 27% low 140.4 513 
 (from 5%) high 286.2 982.8 
      
  14.50% low 75.4 275.5 
  (from 5%) high 153.7 527.8 
      
  27% low 48.36 176.7 
  (from14.5%) high 98.58 338.52 
      
Smoking 23.5% low 7.54 27.55 
  (from 33%) high 15.37 52.78 
     
Table 3.11 suggests the following: the incidence of CKD5 can vary not only with a given 
prevalence of a risk factor, but also with the level of that change, for example in the case of 
diabetes when prevalence takes values from 2.5% to 4% or to 6% or from 4% to 6%. As an 
example, the low and high Acceptance rates at t1 were taken from this study, as reported from 16 
RRT centres: 20 (lowest) and 80 (highest) pmp. In case of diabetic nephropathy, its Acceptance at 
t2 can take a range of values between 10.5 and 54 pmp in 30 to 44 year olds and 30 pmp to 105 
pmp  in the 45-64 year olds when 20 and 80 pmp are used for Acceptance at t1. Because of 
assumptions made, such as: 1. the prevalence of the risk factor (diabetes) is highest at 6% at t2 in 
the overall population; and 2. the differences in the occurrence according to age can explain the 
different levels of Acceptance at t2; it means that Acceptance rates at t2 can take as many values 
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as: the type of precursor condition, its prevalence in the age group, assuming further that no 
interaction (multiplier effect) exists between precursors in this example 
228
. 
In the case of hypertension highest value could be 983 pmp and in the case of smoking acceptance 
can reach 28 pmp from 53 pmp if the prevalence of smoking decreases from 33% to 23.5%. A 
value of 983 pmp in a maximum 1,940 pmp projected stock could reflect a 50% proportion of 
RRT due to hypertension, in a given year, assuming all other parameters are kept at values 
described in the treatment model (Chapter 8). 
These incidence (acceptance) rates were used as guidance in the treatment scenarios where 
acceptance is increased by up to 50% in 10 years, with or without changes in the ratio diabetic/ 
non-diabetic CKD5 (Chapter 4 and Chapter 8 Tables 8.1, 8.2 and 8.3). The baseline acceptance 
is between 11 (low) and 85 (high) pmp and has local variations (Chapter 4).  
3.6  Strengths and limitations 
The strengths of the results obtained in this Chapter for specific objective 1 of this research are: 
- Availability of local, national data and information with some precision and accuracy  
- Sufficient demographic detail: place of residence, gender, age 
- Representativeness of sample at national level 
- Comparative trend with two previous cross-sectional point estimates  
- Major condition precursors included as well as PRD (primary renal disease) diagnoses 
However, limitations are as follows: 
- Information or data from a follow-up design are not available; 
- It was impossible to validate the data (no random sample with record checks); 
- Prevalence estimates (rates) for hypertension were calculated from the National Health Survey 
1997 dataset using 140 and 90 mmHg as the threshold.  The resulting prevalence (16.5%) was 
very different from the prevalence given in the published report (4.5%. One possible 
explanation is that different thresholds were used, such as 160 and 90 mmHg, or that the 
published report relied on clinical diagnoses with unspecified criteria;   
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- Overall quality of data could not be established with precision and accuracy (same example 
as above); 
- Many assumptions had to be made in order to estimate PAR%.  
3.7  Summary 
 Estimates of the point prevalence of chronic renal insufficiency and other major leading 
causes of chronic renal insufficiency are important starting points for service planning and 
resource allocation 
60,61;88,89
 
 The 1997 Romanian national health survey estimates for underlying conditions of chronic 
kidney disease and chronic renal insufficiency were: main primary renal diseases 2.7% and 
3.1%, diabetes 2.5% and 2.9% and hypertension 16.7% and 14.7% with little or no difference 
between genders, although with substantial apparent geographical variation;  
 Not all primary renal diseases contribute to progression to chronic kidney disease and/or 
chronic renal insufficiency. However, the proportion of patients on treatment with a primary 
renal disease and other non-diabetic conditions remains high in Romania: 90% as suggested 
by 2003 data
122
.  
 The survey showed an age gradient for these conditions: the prevalence of primary renal 
diseases doubled from the age of 40 years in women and was highest in the over 70 year age-
group in men. Diabetes peaks in both men and women after the age of 50 years, with nearly a 
fourfold increase.  
 This study has found that a combination of hypertension and diabetes may increase the odds 
of developing chronic renal insufficiency development by almost 8 times (OR = 7.74, CI95% 
from 0.99 to 60.38, Table 5.3).  This is in line with the wider literature which has identified an 
association even for single conditions such as diabetes, with an RR of 12 in a longitudinal 
study 
82
. The caveats here are the cross sectional nature of these data and the small sample.  
 The chronic renal insufficiency national estimate of all stages, 1-5, may lie in the region of 
1,222.5 pmp in 1997. However, this figure is unreliable due to the very small number of 
individuals in the survey.  The 95% CI, from 600 to 2000 pmp, is very wide. Given this rate, 
the country as a whole would have expected a total number of affected individuals in stages 
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1-5 of CRI in the range of n=21,000 (95% CI of 11,000 to 37,000). As around 3,200 patients 
were receiving RRT at the time this represented an age 15+ specific stock rate of 186 pmp. 
One reported figure at the time (1997) was 78 pmp and this research found stock rates of up 
to 230 pmp for the same year 
160;177.
 This is further discussed in Chapter 9.  
 The PAR% for chronic kidney disease entities can be indirectly estimated for various 
precursors in order to compare the proportion of patients on renal replacement therapy 
recorded for those with defined co-morbidity where the co-morbidity constitutes an associated 
“risk” factor; e.g. the diabetes prevalence and the rate ratio of presence over absence of 
diabetic nephropathy may indicate that if diabetes were eliminated as precursor condition, so 
would the theoretical proportion of 30.5% of diabetic nephropathy on RRT. The last (2003) 
renal replacement therapy reported proportion for Romania is about 10%. This difference, 
between the theoretical proportion, which is a value closer to proportions of diabetic 
nephropathies in Western societies and the reported proportion could be explained by a series 
of facts: that not all diabetic cases require RRT as they may be in various stages from 1 to 5, 
that not all diabetic nephropathy cases in stages 4 and 5 come to the attention of the 
nephrologist or, that they come to RRT too late, with further consequences in the 
administrative data, such as, deaths under 90-days on RRT. Patients entering dialysis and not 
surviving 90 days on treatment are excluded from CKD5 data.  
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4  Provision of services for CKD5 
4.1  Objectives 
- to describe the existing provision of services for CKD5 
- to assist with the conception of the treatment model: CKD5 under RRT; 
- to place and discuss results in relation to the treatment model in international context  
4.2  Methodology and Methods 
To describe the existing provision of services for CKD5 
4.2.1  Sources of data on provision 
4.2.1.1 The ERA-EDTA database 
The Registry of the EDTA/ERA was contacted in 1997 and the electronic dataset on Romania was 
re-analysed for acceptance and stock (Appendix 3).  
4.2.1.2 A questionnaire for each RRT centre  
A Centre Questionnaire was designed to obtain operational and administrative data from all 
Romanian centres offering treatment for CKD5 (Appendix 4).  This questionnaire was sent to all 
30 adult renal replacement therapy centres identified through the National Renal Registry. 
Paediatric units were excluded. The main items in the questionnaire were: 
 Year in which the centre was set up 
For acceptance and stock: 
 Acceptance (new patients) and stock (old and new) per year for 1995 to 1997 
 1997 stock : patients distribution by 5-year age bands 
 1997 stock : patients distribution by renal replacement therapy modality 
For resources matching existing provision with renal replacement therapy: 
 HD stations : total number and percentage functional; type of station 
 HD- types of membrane used 
 HD dialysate buffer used 
 CAPD activity 
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 Human resources: full-time dedicated and shared - physicians, nurses, ancillary, others. 
 Centre’s catchment area 
 1997 financial year Budget 
 1997 financial year Expenditure (Actual Budget) 
 Membership of the European Renal Association and year of membership (for cross-check with 
EDTA 1997 data) 
The questionnaire (in Romanian) was sent by post. After receipt of the first three replies, the 
remaining units were reminded first by telephone and then again by e-mail. In total 16 centres 
replied out of 30. 
Data from 13 centres were usable; these centres replied to the questionnaire in full. Two of the 16 
were excluded partly because they opened during 1997, but mainly because there was a problem 
with misclassification of their patients (i.e. stock patients who moved back to the catchment area 
as a result of the centre’s opening were defined as ‘accepted’ patients in newly opened centre).  A 
third centre was excluded because it had no defined catchment area and treated diabetic 
nephropathy only. 
Centres have defined catchment areas.  Cross boundary flows were considered but turned out to be 
negligible.  
4.2.1.3 The National Registry Report  
This secondary source of data was used to cross check the information obtained from the EDTA 
and the Centre Questionnaire, particularly on acceptance and stock. The validity and accuracy of 
this source may have improved somewhat between 1996 and 2004, but this is uncertain 
122; 227
. 
4.1.1 Analysis of data on provision 
4.3.1.1  The capture-recapture method for estimating ‘stock’ levels 
Where data are known to be incomplete but there are independent sources, capture-recapture is a 
method of improving estimates can be combining data from the different sources.   The 
independent data sources in this case were the ERA-EDTA data for 1997, and the Centre 
Questionnaire described above. The total number of cases was estimated by the reverse of the 
process for computing an expected value in the contingency table (Table 4.1) below 
229
: 
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Table 4.1 Capture-recapture method 
 
 
 
 
 
a is the number identified by both sources and b and c are the numbers identified by one of the 
independent sources not by the other.  This gives: 
Maximum Likelihood Estimate (MLE): (a+b)(a+c)/a 
Nearly Unbiased Estimate (NUE): [(a+b+1)(a+c+1)/(a+1)]-1 
A 95% confidence interval can be calculated from 
Var (NUE) = (a+b+1)(a+c+1)(b)(c)/(a+1)
2
 (a+2).  
The proportions of identified numbers are (percentage): 
Source A = (a+b)/NUE* 100 
Source B = (a+c)/NUE* 100 
Sources A, B = (b+c)/NUE* 100  
The two sources of data were consulted independently. The independence of the sources could not 
be fully checked. Assuming that the same responsible data management individual would have 
reported data to both ERA-EDTA and the CQ was taken into account. The time sequence for the 
1997 data was: January 1999 for the CQ returns and June 1999 for ERA-EDTA information 
returns. Data validation was performed in 3 sampled units starting from the CQ information 
(Chapter 5). 
 Source B 
Source A Detected Not detected 
Detected A B 
Not detected C  
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4.4  Results 
4.4.1  Responses to the EDTA survey and the Centre Questionnaire  
There were 34 RRT Romanian centres registered with the EDTA-ERA in 1997: 30 adult units, 
three paediatric units and one providing treatment for acute renal failure (ARF). Of these, 24 
(71%) responded to the EDTA survey centres); these were 20 out of the 30 adult centres.  
For the Centre Questionnaire, 16 of the 30 adult centres replied. However, only 13 provided usable 
patient data.  Of these, two were set up in 1990 and the remaining 11 in 1994. Neither early 
established centre (i.e. before 1994) replied to the Centre Questionnaire. 
Six centres reported both to the EDTA Register and returned a centre questionnaire. These were 
six of the more established centres: Iasi, Craiova, Fundeni Bucuresti (Nephrology), Brasov, 
Oradea and Hunedoara. (Two of these centres, Iasi and Brasov, were among the three units 
sampled to provide data on patients outcomes): one centre (Iasi) which responded to both EDTA 
survey and Centre Questionnaire had in 1998 the largest catchment area (six counties with a 
population of over 3 million).  
4.4.2  Data from the EDTA and the Centre Questionnaire  
From the six centres with data from both sources, the modal distribution was: 82% on HD, 13% 
on CAPD and 5% transplants. This confirms that HD as the dominant modality, with CAPD 
second and [living related] transplantation third.   Table 4.1 gives further information from these 
two sources and the non-respondent estimates are the result of the identification of non-respondent 
centres, plus the total number of patients treated in 1997 as reported by the National Registry. The 
non-respondent estimates are unreliable and the imbalance patients in these centres could be 
explained by the very small numbers of patients treated in these centres.  
The two sources provided independent figures for 1997, which made the capture-recapture method 
(CRM) possible. 
4.4.3  Data from the National Registry 
Estimates from the Centre Questionnaire and EDTA-ERA were compared with the national 
registry reported stock estimate for 1998 for triangulation. One reported 1997 figure was that of 
3,189 patients (185 pmp), of which 912 were newly accepted during the same year 
160
. For 
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comparison, for 1994 the reported stock rate was 55 pmp 
177
 and in 2003, the reported stock was 
7,026 (250 pmp) of which 2,790 were newly accepted during the same year 
122
. 
Subtracting the 912 (acceptance), from 3,189 (stock), the result became 2,277. The national figure 
reported in the National Registry Annual Report for 1997 and preceding the 2000 publication was 
2,474 patients. Part of this difference, between 2,277 and 2,474 may be attributable to paediatric 
patients (<15 years of age) and also other reasons, such as double counting, or simply by having 
newly accepted patients included in stock. However, the difference is small 
160; 227 
.  
4.4.4  The stock of patients  
The importance of classification of conditions and modalities of treatments was explored and 
discussed in Chapter 2. Because the reported figures are unreliable or incomplete, the stock was 
estimated with using the capture-recapture method (CRM) (Section 4.4.6) 
229
. 
4.4.5  Acceptance for RRT 
The Registry records only patients with CKD5 on RRT. This secondary source of data provided 
information on acceptance, reporting it as the “incidence benchmark” of CKD5 (that of treatment 
requirement). In 1995 the reported estimate was 127 new cases per million population (pmp) and 
in 2004, despite a major expansion of services, it remained at a reported 128 pmp. The basis for 
these estimates is, however, obscure despite the fact that they were both reported as national 
figures. The 2003 figure may have been the caseload from 71 centres reported for Romania, but it 
was not possible to confirm this 
122
.  
A similar acceptance rate of 128 pmp was found for Austria in 1999. At the time, the explanation 
was that the 1995 Romanian estimate was a result of the expansion of treatment facilities (from 12 
in 1991 to 30 in 1997) and with a reportedly sudden increase in acceptance of new patients 
122
. 
If the 1995 acceptance rate was applied to the population aged 15+ years the expected number of 
new patients on RRT would have been 2,196 of ESRF patients newly accepted on RRT for the 
year. Proportionately this would have been 69% of the 1997 stock (2,196/3,198*100). According 
to the data from the National Registry Report “acceptance varies very little in consecutive years; 
exception makes when an expansion of services has been significant”223.  
  
 
 
122 
Given the various national acceptance and stock rates, in 1997, Romania could have expected 
between 11,000 and 37,000 individuals who were affected by CKD, in various stages of the 
condition or CKD states 1 to 5. A NHIF information report for 2006 gave a figure for CKD of 
10,382 patients of whom 6,600 were on RRT 
215
. However this could not be cross-checked against 
any other source, such as the MoH information for the same period, for size or CKD staging 
150
. 
This represents almost 70% of patients with CKD stages 1 to 5. 
Current epidemiological information systems monitoring (2008) does not allow valid assessment 
and ascertainment of numbers.  Ten years on from when first data were collected through this 
research, very little progress has been made in relation with the quality of data collected or the 
information governance. For example,  if the unmet need target was set at 10,000 individuals for 
2008, given the reported figures of 6,600 for 2006 and 7,400 for 2007 and an expected CKD stock 
could be up to 37,000 individuals, then by 2008 around 67% may still represent unmet need. The 
upper limit of 37,000 is high and this is due to a very large confidence interval or explained by a 
small sample which gave a large confidence interval to the estimate obtained from the 1997 health 
survey 
150;160;215; 227. 
4.4.6  Capture-recapture method to calculate the stock estimate 
The two sources of information used were EDTA Registry (Section 4.1) and the Centre 
Questionnaire (Section 4.2). EDTA provided a list of centres which provided the data and this was 
independently cross-checked with the answer in the Centre Questionnaire to the question: “is the 
centre member of the EDTA-ERA?”  
Table 4.2: CRM results: calculations for MLE and NUE 
 Centre 
Questionnaire 
 
 
EDTA 
 
Yes 
Yes No  
616 989 1605 
No 534   
 1150   
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(Maximum Likelihood Estimate) MLE = 2,996 
(Nearly Unbiased Estimate) NUE = 2,995 
95% CI for NUE of 2,995 patients was estimated from 2,869 to 3,121 patients in stock (at national 
level) 
This range compares with a value of 3,170 stock of adult patients for 1998; 3,189 included 
paediatric patients 
160
:- 
The EDTA captured 54% of the 1997 stock (70% response rate) while the Centre Questionnaire 
only captured 38% (53% response rate). Both sources together identified 71% of the 1997 stock of 
patients (2,995 with a 95% CI from 2,869 to 3,121). A reported figure of 3,170 from the National 
Registry was just outside the upper 95% CI limit of 3,121 
227
; the calculated CRM estimate of 
2,995 was used as starting point for the treatment model (Chapter 8). 
After the CRM was applied, the national stock rate was estimated at 161.2 to 175.3 pmp in the 
population aged 15+ years. The reported national RRT stock rate for 1998 was 139 pmp; for 2003 
this was 250 pmp, these values could not be checked for validity 
122; 160;227
. The 1996 figure was 
also given in another source as 57 pmp which implies a nearly fivefold increase of stock in 10 
years 
122; 177
. The National Registry itself had less than 100% response in data collection in 2004. 
The reported figures therefore appear unreliable. The values obtained by this study are very 
different from any published figures.  
In another example, in one of the 13 centres which responded to the CQ the highest value in this 
research was 222 pmp in 1997, in a centre from Transilvania. The lowest was 31 pmp. These 
variations may show inequalities in provision. 
In 1998 there were 175 patient transplants throughout the country. No information was available 
on these individuals as the two transplantation units did not responded to the Centre Questionnaire 
and no details were given through the EDTA-ERA report.  
Kidney transplantation is a legally regulated activity and mainly performed with kidneys from 
living related donors (82%). The law stipulates that transplantation can use cadaver kidneys, but 
Romania is faced with limited availability of organs, as in other western countries.  
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Because there was little information on transplant patients the final scenarios were based on 
transplantation data from the literature and the EDTA questionnaire (i.e. mortality, new 
transplants). The only available information on the existing transplant patients from the three units 
surveyed was that they all received living related transplants (LTx).   
4.4.7  Resources 
To summarise data from the Centre Questionnaire: 
 there were 43 full time equivalent nephrology physicians, or 1 per 259,336 population aged 
15-74 years. By 2003 an increase of 450% of nephrologists was reported compared with 
information from 1993 
177
; 
 there were 468 full-time equivalent nurses or one nurse per 36,848 adult population;  
 there were 69 health care assistants and 58 other staff including: technical support and 
psychologists in the 16 centres. The ratio of physician to support staff was 1 to 3; 
 haemodialysis equipment was, on average, 4 years old;  
 the number of stations had doubled since 1995 in the Centre Questionnaire 16 centres: from 83 
to 169 functional stations in 1997; furthermore there were 780 recorded in 2003, in line with 
the increase in stock of patients. The 2003 figure represents a 700% increase from 1991 (114 
stations) to 2003 
122; 160
; 
 25%  of the functional stations were new (either purchased or obtained through charitable 
donations) in 1995; as many as 66% of the total were old or outdated and would have been 
replaced by 2003. For 1997 equipment figures the National Registry reported that “38% was 
new equipment, which was purchased and was not obtained through charitable donations”. 
Information on the age of equipment was difficult to ascertain. The 2003 figures may include a 
100% replacement of stations over 1997 numbers, but this could not be checked 
122
;  
 of the 16 units covered by the Centre Questionnaire only 2 centres had 5- year and 8- year old 
equipment in use; 17% of the stations were non-functional. For the same year the Registry 
reported 31% non-functional stations, but there may have been different centres from the 16 
centres which reported to the Registry. The equipment information was not available from the 
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Registry or the 16 centres. It was however apparent from unpublished documents that as 
many as 13 multi-national companies were sharing the renal Romanian market at the time;  
 14 on-line haemo-dia-filtration (HDF) stations (n=14) were purchased in 1997; this HD 
modality was recorded as available in 10 centres in 2003. However, the number of stations or 
patients attending such sessions was not given; 
 artificial kidneys: 69% used cellulose membranes, 19% used both cellulose and non-cellulose 
and a small proportion (12%) used only non-cellulose membranes. The figures for 2003 data 
show an increase to 63% in the use of the latter type, which is described as more “bio-
compatible”, in a review by MacLeod from 1998 125 and thus shows an uptake of the latest 
technology; this should assist in an indirect evaluation of quality of care and translated into 
‘better’ outcomes (survival) on HD; 
 HD dialysate buffer: 14 centres (88%) reported the use of acetate, one centre reported using 
both types (acetate and bicarbonate) and one using only bicarbonate. The literature shows the 
benefits of the use of bicarbonate over the acetate, by reporting that both cost the same, but the 
bicarbonate is better tolerated, thus improving treatment outcomes (survival). By 2003 nearly all 
HD centres (95%) reported the use of bicarbonate buffer; and for CAPD, only eight centres 
reported this form of RRT and six of them reported it after 1997; a Y connection was used with 
catheters connected to double bags identified as the standard delivery of this mode of therapy. 
4.4.8  Provision of RRT in the three sampled units: stock and acceptance 
The Centre Questionnaire results from the sampled units are shown in Table 4.4. 
- Centre 1: Sf. Ioan, Bucharest.  A teaching unit with a catchment area of just over 1 million 
population. The stock of patients was n= 322 during the 3-year period 1995-1997; of the 322 a 
sub-sample of 136 patients (42%) were newly accepted during this period. 
- Centre 2: Iasi, A teaching unit with catchment area of 3.6 million population. The centre stock 
was 400 patients during 1995-1997; of the 400 a total of 158 (40%) were newly accepted in 
this period. 
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- Centre 3: “Sarah” Brasov, A district unit with catchment area of about 0.5 million population. 
The centre stock was n= 229 patients during 1995-1997 of which 83 (36%) were newly 
accepted in this period.  
In each centre the majority of patients were treated with haemodialysis, the proportions varying 
from 78% to 95% (Table 4.4). CAPD had just been introduced in 1995. Although centre 2 was one 
of the country’s pioneering centres for peritoneal dialysis, only three patients were treated there 
that year on CAPD, although reported numbers varied, 21 patients compared with 34 patients, 
according to the Centre’s Register and as reported by the manager at interviews. The reported 
CAPD patients could not be validated against the number of patients for whom notes were 
available from the archive. Thirteen could not be found. The proportions of 14% to 19% were 
those of patients treated with CAPD in Centres 1 and 2 in 1997, and they were newly accepted on 
this form of treatment during that year.  
Transplant patients, in proportions of 1%, 3% and 3% were recorded under this modality under 
each of the Centers’ registers. Transplantation was actually performed in other reference centres, 
but once the surgical and peri-operative care have been completed follow-up care is carried out in 
the centre of their catchment area. 
Ten patients had a transplant in 1997: one in Centre 1 (here shown as a proportion); 6 patients 
from Centre 2 (proportion of 3%) and 3 patients in Centre 3 (proportion of 3%) as shown in Table 
4.3. 
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Table 4.3: Operational RRT activity from the three sampled centres (1997) 
 Centre 1 
Bucharest 
Centre 2 
Iasi 
Centre 3 
Brasov 
Year in which centre was set up 1994 1990 1994 
Catchment population 
(15+ years) 
1,069,824 3,811,673 505,575 
Acceptance*      1995 (% of stock) 
                           1996 (% of stock) 
                           1997 (% of stock) 
rate pmp             1997 
62 (70) 
61 (55) 
48 (27)  
44.9 
66 (47) 
65 (44) 
52 (28) 
13.6 
30 (64) 
32 (53) 
34 (30) 
67.3 
Stock**                          1995 
                                       1996 
                                       1997 
Rate RRT pmp              1997 
Rate HD pmp                1997 
89 
111 
175  
164 
138 
141 
149 
186  
49 
38 
47 
60 
112  
222 
210 
Doctors (f/t) 
Patients/doctor 
8.5 
21 
7 
27.5 
3 
37 
Nurses (f/t) 
Patients/nurse 
60 
3 
36 
5 
25 
4 
RRT proportion on (1997): 
HD% 
CAPD% 
Tx% 
 
85 
14 
1 
 
78 
19 
3 
 
95 
2 
3 
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The stock and stock rate by age group from the three sampled centres in 1997 are shown in Table 
4.4: 
Table 4.4 Stock on HD in the three sampled centres, 1997, by age group (15+ years) 
Centre 1 
(20 stations) 
<15 15-24 25-29 30-39 40-49 50-59 60-69 70+ All 
Stock no. 
(%) 
n/a 5 
3 
9 
6 
25 
17 
41 
28 
38 
26 
30 
20 
- 148 
100 
Stock (rate 
pmp) 
n/a 25 76 161 211 273 203 - 138 
 
Centre 2  
(32 stations) 
<15 15-24 25-29 30-39 40-49 50-59 60-69 70+ All 
Stock no. 
(%) 
n/a 6 
4 
14 
10 
47 
32 
45 
31 
31 
21 
3 
2 
- 146 
100 
Stock (rate 
pmp) 
n/a 7 33 84 71 66 6 - 38 
 
Centre 3 
(14 stations) 
<15 15-24 25-29 30-39 40-49 50-59 60-69 70+ All 
Stock no. 
(%) 
n/a 6 
6 
8 
8 
16 
15 
23 
22 
31 
29 
22 
21 
- 106 
100 
Stock (rate 
pmp) 
n/a 54 145 188 226 517 410  210 
 
The variation in stock rates between the three centres is partly attributable to the different sizes of 
their catchment areas. Stock rates go up with age as expected in all three centres, but as table 4.4 
shows, there is substantial variation in the age distributions of their patients.  This is partially 
explained by the demographic profiles of the regions they belong to but this needs further 
investigation.  
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4.5  Strengths and limitations of this element of the study 
Amongst strengths are:  
- The reported service use was available for the requested period for this research and was 
reported as cross-sectional information allowing for the description of a baseline year  
- Some demographic detail was also available, especially from the 3 sampled units 
- Staffing levels were reported 
- Financial resources were available 
- Due to the availability of data from two sources, further analytical methods allowed the 
estimation of a baseline stock level (rate per million population) 
Limitations were also identified: 
- The centre response rate was poor  
- No precursor condition record for any of the patients, newly accepted or in stock, was 
available either at individual level (sampled units) or in aggregate format, at centre level 
- Transplantation information was little to absent thus hampering the inclusion of local 
transplantation data in the treatment model 
- Validation of information was not possible and neither were checks for precision or accuracy 
of reported estimates 
4.6  Summary 
Service use for CKD under RRT has established a baseline level for acceptance and stock for the 
year of 1997 after the use of quantitative and qualitative methods. Although the reliability of the 
estimates is low, the acceptance and stock rates can be used as parameters for the treatment model 
in scenarios applicable to local context. 
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5  Clinical outcomes 
5.1  Objectives 
The general objective in this chapter is to assist with the estimation of parameters for the treatment 
model. 
It has the following more specific objectives: 
- to measure observed outcomes (survival) for individual patients in three sampled units in 
Romania; 
- to place the results in an international context and discuss them in relation to the treatment 
model. 
5.2  Methodology and Methods 
To assess clinical outcomes based on a sample of units. 
5.2.1  Data on outcomes 
Data were sought on three cohorts of new patients, entering renal replacement therapy in 1995, 
1996 and 1997.  
Table 5.1 summarises the data collected. 
Table 5.1: Data collection points 
Cohort Baseline data 
1 year 
follow-up 
2 year 
follow-up 
3 year 
follow-up 
1995 1995 end 95-96 end 96-97 end 97-98 
1996 1996 end 96-97 end 97-98  
1997 1997 end 97-98   
Appendix 5 contains the form used for data collection. It consists of baseline data and additional 
data sheets data for each year of follow-up. The baselines were from 1 January 1995, 1996 and 
1997. The data collection period ended on 31 December 1998.  
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5.2.2  Inclusion criteria  
All patients who were enrolled on a dialysis programme, or who had had a kidney transplant, were 
initially included, irrespective of the duration of treatment (see definition at the beginning of this 
Chapter and Chapter 2). Chronic renal replacement therapy patients became ‘cases’ after 90 days 
or more of RRT 
60
.  
5.2.3  The units sampled  
The initial design involved sampling six units. However it was discovered that one satellite unit 
was no longer treating chronic RRT patients. In two other centres there were problems in 
obtaining access to their patient database and register. Eventually only three centres were 
recruited: two teaching centres and a district unit.  
The three centres were sampled according to their level of occupancy (patients/station) in 1997 
with cluster analysis (SPSS 9.0).  These centres are representative of three of the seven historical 
regions (Muntenia, Moldova and Transylvania) as described in the national health survey, in terms 
of both size of population and geographical location 
163
.  
Consent was sought from the Ministry of Health from the National Commission for renal 
replacement therapy, which co-ordinates the RRT National Programme. Members of the 
Commission are clinicians but some of them combine clinical and managerial roles.   
Consent was also sought at the Dialysis Centre/Unit level for access to individual patient records 
from the centre’s manager or the chief medical officer of the centre/nephrology department. 
Consent letters were sent out to the three centre managers (Appendix 5) for patient data collection 
in 3 cohorts: 1995, 1996 and 1997 (Patient Form in Appendix 6).  
The three units were as follows:  
5.2.3.1 Sf. Ioan Teaching Hospital, Bucharest  
This centre is located in the capital city of Romania, Bucharest, in district 4 (Bucharest has 6 
districts). It is a teaching unit, attached to a general teaching hospital. Established in 1994, it is the 
second biggest and oldest centre in Bucharest. The catchment area for this RRT centre and the 
other renal services it provides comprises approximately 1,012,129 population (1998). 
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The letter of consent was sent to the dialysis centre manager to obtain access to the centre’s 
database, registers and to the nephrology department archive. A two-person team ensured the data 
collection from this centre. Data were validated while researchers were on the premises. 
5.2.3.2  C I Parhon Teaching Hospital, Iasi 
This centre is in the north-east of Romania, and is the capital of Iasi county. It is an academic 
centre within a teaching hospital, providing health services for the city, county and the north-
eastern region of Romania, Moldova, which has borders with Republic of Moldova and Ukraine. 
Established in 1990, it is one of the oldest centres in the country. The catchment area for this 
centre and the other renal services it provides comprises approximately 3,635,150 population in 
eight counties (1998). Since 2006 each of the eight counties has established its own centre. 
The letter of consent was taken to the dialysis centre manager to obtain access to the centre 
database, registers and nephrology department archive. A second two-person team ensured the 
data collection from this centre and overlapped with data collection in the other two centres. Data 
were validated while researchers were present on the premise. 
5.2.3.3 Sarah District Hospital, Brasov 
The third centre is in Brasov, the capital city of Brasov county. This is one of the Transylvanian 
counties in the central part of Romania. The centre is attached to the district hospital of Brasov. In 
1997 it provided health services for the city and surrounding county and partially for the region, 
i.e. counties which border with Brasov: Covasna and Prahova. This was the case in 1997. In 1998 
the catchment population for this RRT centre and other services it provided was 486,183. 
However, by 2006, it was reported that each of these three counties had set up its own dialysis 
centre. Set up in 1994, it belongs to a ‘second generation’ of RRT centres.  
The letter of consent was sent to the dialysis centre manager to obtain access to the centre’s 
database, registers and the district hospital’s nephrology archive. A third two-person team ensured 
the data collection from this centre. Data were validated by the lead researcher electronically after 
the team completed data extraction. 
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5.2.4  Data collection timetable and analysis  
Each Centre’s Register provided a list of all patients who entered renal replacement therapy, i.e. 
haemodialysis or peritoneal dialysis between 01 January 1995 and 31 December 1997.  
Baseline socio-demographic and medical data were taken from the Centre’s Register.  
Follow-up data were collected on subsequent co-morbidity, biological markers, complications, 
hospitalisation and other key events (transfer, loss to follow-up or death).  The Centre’s sources 
for follow-up data were: the Biological Tests Register, the RRT Register and individual clinical 
notes from the Centre’s Archive. Data collection teams were trained by the lead researcher (during 
an induction day) to collect items according to a standard protocol across all three centres.   
Total numbers of new and old patients were validated against the reported figures obtained from 
the CQ for these two centres. Eleven patients were the mismatch between the clinical records and 
the sum of patients from the 3 CQs (Figure 5.1).  
5.2.5  Methods of survival analysis  
The descriptive analysis of the sample from the three centres is shown in Appendix 7.  
Patients who had been on treatment for less than 90 days were excluded. Survivor probabilities for 
1, 2 and 3 years were computed by type of therapy for 1) aggregated cohorts (hospital HD, CAPD, 
transplantation), 2) by centre, irrespective of treatment modality and 3) by aggregated cohort and 
year of starting the RRT: e.g. 1-year survival for the 1995 cohort, 1996 cohort, etc. Patient 
survival probabilities, standard errors and 95% CI were estimated using both life tables and the 
product limit method (Kaplan and Meier). The Software used was SPSS 9.0. Five-year survival 
probabilities and survival by age-groups were taken from the literature 
122; 180; 230
. 
Cox regression was used to identify prognostic factors associated with survival: first, variables 
were dropped if they had high values of correlation coefficients 
231
. Same Software was used for 
this analysis. 
Then logistic regression was run with a limited number of variables detected as clinically 
important: e.g. presence of diabetes and malignancies. These were systematically checked for 
statistical significance. The logistic regression was run with these variables as well as 
demographic ones using binary coding for presence or absence of: age equal or above 60 years, 
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gender, cancer, diabetes, hypertension, with cut-off points for time on treatment at 12 months and 
24 months. Data from one centre met the 36-month time criterion; however, the number of 
patients became too small and data on co-morbidity (cancer) were absent, making the 3-year 
probability unreliable.  
Model 1 included age ≥60 years, presence of: diabetes, and cancer as co-morbidity at baseline;  
Model 2 included age ≥60 years, presence of: diabetes, cancer as co-morbidity at baseline and 
presence of complications during follow-up at 12-, 24- or 36- months. 
A relatively low threshold of 60 years was chosen because of the relatively lower life expectancy 
at birth in the Romanian population. Survivor probabilities were subsequently used for guidance in 
the treatment model and hypotheses were made in the final chapter (Chapter 8) given the treatment 
capacity of the country.  
5.2.6  Numbers of subjects   
Clinical outcomes data were obtained from 3 of the sampled units. 
For the three centres the total sample of newly accepted patients for 1995, 1996 and 1997 was 
N= 450 (Fig 7.1).  Of these, 377 (84%) were eligible for descriptive analysis, as they had spent 
more than 90 days on RRT as per eligibility and so met the inclusion criteria; of these, only 236 
(63%) had records usable for outcome measurement.   
For patients with less than 90 days on treatment: 30 patients died; that is 7% mortality in the 
first three months. Twenty-seven (27) patients were lost to follow-up after initiation of treatment 
(6% of the original cohort of 450), of whom 12 patients had an initial assessment record and 
treatment plan but no other notes, and the remaining 15 had an assessment record and notes 
which showed they moved to another catchment area. Five (5) patients recovered their kidney 
function (1%) giving a total of 62 patients who were ineligible for data analysis and who were 
excluded. 
For patients in treatment for longer than 90 days:  11 patients were excluded due to poor 
records (e.g. no date of birth, no date of entry on treatment, recorded death, but with no month 
and/or year of death, etc.). Of these 11, 8 patients were from Centre 3. Centre 3 has the smallest 
  
 
 
135 
sample and therefore the survivor probability results for this centre as well as the LYG (life 
years gained) may be affected and they need cautious interpretation.  
Figure 5.1 shows the sample and exclusions. 
Baseline data were analysed for the aggregate cohort (N=377) as well as for each centre (n1 =136, 
n2 =158, n3 =83). Table 5.3 shows the eligible number of patients in each centre, by cohort and 
those considered for the aggregate analysis of the survival at 1- year, 2- year and 3- years. 
Fig 5.1 shows the total number of patients in the Centres’ Registers. Data from newly accepted 
patients in 1997 (n=120) were sought on complications and hospitalization. However, these data 
were highly unreliable and the information was not used.  
Figure 5.1  Sample size by centre 
 
     Exclusions (n=73) 
(16.0%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
All patients 
N=450 
Centre 1 
N1= 171 
Centre 2 
N2= 183 
Centre 3 
N3= 96 
N1= 136 N2= 158 N3= 83 
All eligible 
N=377 
<90 days 
(not eligible) 
n= 62  
>90 days 
(incomplete records) 
n=11  
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Table 5.2: Sample size of newly accepted patients, centre and type of RRT 
 
Cohort 
1995* 1996 1997 1995-1997 
HD CAPD HD CAPD HD CAPD Total (%) 
Bucharest 42 - 43 6 34 11 136 (36.1) 
Iasi 53 3 48 12 32 10 158 (41.9) 
Brasov 23 - 27 - 33 - 83 (22.0) 
Total 118 3 118 18 99 21 377 
Total for 
adjusted 
survival**  
53 3 48 12 99 21 236 
* Tx patients are not included anywhere (insufficient data) 
** Cox regression was carried out on aggregated cohorts of new patients: centres 1 and 3 for 
1997; centre 2 for all new patients: 1995, 1996 and 1997 (in Bold). 
Table 5.1 shows that the uptake of new patients was fairly constant over the three years.  Centre 1 
had 42 new patients in 1995, 49 in 1996 and 45 in 1997. There is a slight decrease in those 
entering HD in 1997 when the uptake on CAPD increased over 1996 in Centre 1 and Centre 2 but 
not in Centre 3 where between 1995 and 1997 the increase was 43% with acceptance only on HD.  
The underlying ESRF diagnosis was similar in all three centres, also similar to reports in the 
published literature 
103; 122
.  
There were no data available for any socio-demographic analysis e.g. on education, occupation (at 
baseline and follow-up), marital status or residency. There were data on the means of 
transportation to and from the RRT centre. All patients used the centres’ ambulances (none used 
urban or inter-urban public transport or private cars). A descriptive analysis of the sample is 
shown in Appendix 7. 
5.3  Treatment outcomes: survival 
5.3.1  Unadjusted survival 
Romanian patients on RRT tend to be younger when accepted on treatment than their peers in 
other western societies: age was: mean 42 years; median 43 years and modal value 45 years.  
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There were 30 to 50% more male patients than female patients overall (228 males/ 149 females), 
a pattern seen in all three centres (Appendix 7). 
The unadjusted survival probabilities at 1- , 2- , and 3- years were: 84% (79 to 87%), 73% (69 to 
78%) and 68% (62 to 74%); 1- year survival is significantly higher; 2- and 3- year probabilities do 
not differ statistically.   They can be compared with 86% (1-year), 78% (2- year) and 71% (3-year) 
for the 1997 English cohort 
232
. By treatment modality these were HD: 83%, 73% and 67% with 
differences noted not to be statistically significant; CAPD: 1- and 2- year only: 90% and 81%. 
Survival by RRT modality did not differ at 1- and 2 years; CAPD had only n=36 new patients; 
confidence intervals (95% CI) were very large. 
No differences were observed in the survivor probability at 1 year by cohort (“vintage”): 82%, 
87% and 82% for 1995, 1996 and 1997 newly accepted patients; this again compares with 86% in 
the 1997 English patients. At 2- year the 1995 and 1996 patients showed a small, but not 
significant difference: 70% and 77% respectively. The observed 3- year probability for the 1995 
cohort was 65%. The 1997 English cohort had a 71% probability 
232
. 
Results for survival fell in the expected range as reported in the literature 
122
.  Any differences 
could be also explained by factors such as: age at entry on treatment, cause of CKD5 (primary 
renal disease predominant in Romanian patients), presence and type of co-morbidity, number of 
complications developed during the next 12 months of RRT, etc., or age and co-morbidity 
combined. The extreme age groups in Khan index refer to a < or ≥ 70 years old. However, with no 
patient in this study being this old, this index proved to be of no use for the Romanian data 
5
.   
Estimation of survival by modality was very difficult with the information held on clinical file. At 
the introduction of CAPD in 1995-1997, most patients did not die on this modality. One 
explanation was that they may have been allowed to switch therapies: e.g. if a CAPD patient 
developed an irreversible complication on this mode or “showed no improvement in clinical status 
and general well-being” i.e. including a lowered serum creatinine level, or changes for the better 
in other biological markers (e.g. parathyroid activity levels etc.), the quick solution was to switch 
them on to HD. These were most frequent explanations in the two centres which offered CAPD as 
an RRT modality and from the answers recorded at local interviews. This was also given as 
possible reason as to why CAPD notes were not found on the CAPD Register. 
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However in this analysis CAPD patients were considered to have stayed on CAPD for one year 
even if they switched modality before the year elapsed.  This is similar to analyses in other studies 
60
.  To clarify, if the switch to another form of RRT took place after 60 days from entry on RRT, 
on top of the 90 days already on RRT for the purpose of data analysis, the patient would be kept 
for the year on the original form of treatment and would be changed only after 31 December (i.e. 
December 1998 in this study).  
As a new therapy, CAPD being only introduced since 1995 in a few centres, one cannot conclude 
whether this modality was an alternative to haemodialysis or whether it was good practice in 
offering a new alternative of treatment in Romania. This marked the introduction of the ‘safety 
valve’ of RRT in Romania which allowed the extension of life for ESRF patients who otherwise 
would have died in a much shorter period of time. It is also unlikely that the analysis of data on 
the total of 36 patients brings significant information at this point, but it was thought to be worth 
exploring this sub-sample as the treatment model includes this form of therapy.  
5.3.2  Cox regression 
This statistical method allows adjustment for variables which may have an influence on the 
survivor probabilities or time. The unadjusted Cox regression analysis used data from all 377 
patients. Age (equal or above 60 years), diabetes, cancer and the presence of complications in the 
first year of treatment were considered in the Cox regression with survival time considered at one, 
two and three years. The one-year survival probability was significantly influenced by the 
presence of cancer or a combination of age ≥ 60 years and co-morbidity: diabetes and cancer. A 
Poisson distribution model was used. Two models were used: one with gender included; a second 
with this variable excluded. Table 5.2 presents the results from the second model (gender was not 
statistically significant). 
After running the 12, 24- and 36- month period for two models non significant variables were 
dropped until scenarios showed age and co-morbidity associated with the 12-, 24- and 36 month 
survival.   
The 2- year probability was significantly influenced by: a combination of age ≥ 60 years, diabetes, 
cancer and the presence of complications (binary variable) in the first year of treatment;  
The 3- year probability was significantly influenced by the presence of diabetes.  
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A summary of the statistically significant unadjusted coefficients are shown in table 5.3: 
Table 5.3:  Unadjusted coefficients from Model 2, Cox regression (n=377) 
 B coefficient 
(unadjusted) 
SE 
(standard error) 
P value Notes 
Age 
Diabetes 
Cancer 
1.23 
1.14 
3.03 
0.39 
0.55 
0.59 
0.001 
0.038 
0.000 
1-year survival 
Age 
Diabetes 
Cancer 
Complications 
1.96 
1.32 
2.66 
1.65 
0.68 
0.58 
1.09 
0.59 
0.004 
0.023 
0.015 
0.005 
2-year survival 
Diabetes 2.15 0.92 0.020 3-year survival 
 
Survival appears to be significantly influenced by a combination of age and specific co-morbidity 
here defined as the presence of diabetes and cancer; this is despite the fact that Romanian patients 
tend to be younger than western patients. It also appears to confirm results from the literature such 
as the North Thames Dialysis Study (NTDS) in which gender was not shown significantly related 
to survivor probabilities, despite the greater proportion of men on RRT 
232
. Also, the NTDS had an 
older age profile. 
The observed 3-year survivor probability is smaller than those observed in Western societies (e.g. 
England has 60% and 50% at 5 and 8 years; results are taken from a study initiated in 1997, same 
year as this study took its survival data from) 
230 
. 
Precursor condition morbidity, such as PRD at baseline and gender did not show any influence on 
any of the three survivor probabilities (excluded from Table 5.3); moreover, when the presence of 
“complications” was dropped from the regression model, a change occurred in the 2- year survivor 
probability: cancer, now had an unadjusted B coefficient of 2.40 (p= 0.000; SE= 0.53) and 
remained statistically significant, whereas diabetes, with an unadjusted B coefficient of 0.80 
(p=0.09; SE= 0.47) became a statistically non-significant variable. Table 5.3 also shows that 
diabetes has an increased hazard (risk of death) from 1.14 in the first year to 2.15 in the third. 
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5.4  Strengths and limitations 
Strengths: 
- The results in this Chapter have further added to reported information through first hand 
analyses of 1- to 3- year survivor probabilities from 3 local sampled units 
- The annual survivor probability and annual mortality was used as parameter in the treatment 
model (dialysis only) 
- Because of the availability of individual data, it was possible to exclude deaths which 
occurred in the first 90 days of RRT, increasing the validity of comparative survivor estimates 
The limitations are numerous: 
- Samples were too small to adjust and present for age, gender or treatment modality 
- Diabetes was a ‘rare’ condition (< 5 cases/ the 377 sample of patients); very wide confidence 
intervals showed no statistical significance for hazard ratios (B coefficients) and makes the 
interpretation of the increase from 1.14 to 2.15 inconclusive 
- Co-morbidity was insufficiently registered and thus not possible to be better described an 
analysed 
- Transplantation patient data were not available, therefore survival from this modality was not 
measured from local data; Tx information on this parameter had to be taken from the literature 
- Despite the individual data from 3 centres, the information may not be representative for all 
adult centres (30 centres) across the country 
- A 5-year observed survivor probability was not calculated; only 3-year data were available  
5.5  Summary 
 Over three years a total of 450 patients entered RRT in the three centres.  A total of 377 were 
eligible for descriptive analysis; 236 patients had usable data for clinical outcomes (survival 
analyses). 
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 90% of patients were on HD.  Almost all the rest were on CAPD. The number of patients 
having transplants was very small. 
 The demographic data show that the Romanian RRT patient is most likely to be a middle-aged 
male patient (modal age in sample 45 years and 30-50% more male patients); 
 Survival for HD was: 83% at 1 year, 73% at 2 years and 67% at 3 years. For CAPD it was 
91% at 1 year and 81% at 2 years. These figures for CAPD need to be interpreted cautiously 
due to the small number of patients (n=36), but they are consistent with the literature from 
elsewhere. 
 In the Cox regression the main factors related to survival were age and co-morbidity (diabetes 
and cancer); gender was not a significant factor in this small dataset. The role of obesity could 
not be assessed because physical measurements of weight and height were not available.  
 The literature suggests that age in isolation does not influence survival. Cardiac and social 
causes are most quoted as possible predictors for mortality, but these could not be assessed 
from the data available.  
 Late referral, as a predictor of early death on treatment, may also vary very widely across 
countries, depending on the definition of ‘late’ which is or is not preceded by nephrological 
care. This remains a possible explanation for the variation in early case fatality on RRT which 
in turn influences survival, as outcome, on treatment. However, time to referral, as a covariate, 
was also not included in the original research protocol.  
 There was no evidence that co-morbidity (PRD) at baseline (excluding DM and cancer) 
influenced survivor probabilities in the Cox regression. When the presence of complications in 
the first year of treatment was excluded as a variable in a second Cox regression model, all 
parameters remained unchanged with the exception of diabetes which became a statistically a 
non-significant factor for survival of up to two years on RRT. 
 The half-life (median survivor probability or time at which 50% of the initial cohort is still on 
treatment) of the Romanian RRT cohorts was between three and four years 
29
.  Regarding co-
morbidity and survival, the diabetes literature suggests that type 2 diabetes patients have a 
worse prognostic on treatment outcomes (survival) than type 1 diabetes ones (ref) and this is in 
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contradiction with the “inverse epidemiology” regarding obesity on RRT, knowing that 
obesity is strongly associated with type 2 diabetes. 
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6  Treatment cost estimates in sampled units 
6.1  Objectives 
The general objective is to look at the economics of treatment of CKD5 in Romania: how much 
does it costs and, how does it compare with other countries when accounting for effectiveness. 
This Chapter has the following specific objectives: 
- to measure the cost of illness (CKD5) in three sampled units; 
- to estimate the average cost per patient by alternative therapy: HD and CAPD; and 
maintenance cost for a Tx patient; 
- to estimate the cost-effectiveness ratio for i) no treatment versus any dialysis alternative and ii) 
HD versus CAPD. 
6.2  Methodology and Methods 
6.2. 1  Data on inputs and costs 
Data on costs were gathered during interviews with the local key persons, financial managers and 
clinical nephrologists, using specially designed forms (Appendix 8 and 9).  
Data on human resources were taken from each Centre’s Personnel Department. Data on 
biological tests and their costs were obtained from each Centre’s Head of Pathology Department 
attached to the district or teaching hospital. 
The costing framework and the purpose cost form were adapted from the literature and translated 
into Romanian 
1; 186
.  
Accounting data were gathered during interviews with key financial personnel for volume of 
activities, overhead costs, etc., with clinical specialists or head nurses for consumables by type of 
RRT and from heads of Personnel Departments on numbers of employees, salaries, etc. Staff costs 
were estimated from activity sheets. Overhead (semi-fixed) costs were also collected. The 
interview form is shown in Appendix 10. 
Each item identified as a main cost component was further sub-listed for each type of treatment: 
HD, CAPD, LRTx.  Costs on transplantation were taken from the literature as local costs were 
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difficult to document, difficult to validate where they were available and also considered 
unreliable.  
The steps in estimating total programme operating costs were: 
1. Estimate costs of outputs: 
- Haemodialysis session and haemodialysis/ year of treatment 
- Continuous Ambulatory Peritoneal Dialysis training session and subsequent yearly treatment 
- Transplants costs (taken from literature and the NHIF, 2007  233. 
2.  Calculate annual average cost of HD treatment from the number of dialysis sessions per 
patient-year in the three centres. 
3. Calculate annual average cost of CAPD based on the initiation session and the variable 
component of this cost (i.e. treatment at home, ambulatory).  
4. Estimate Transplant costs based on the maintenance medication documented in all centres as 
well as from the National Register.  
6.2.3  Overhead costs 
Shared costs (overheads) were considered, although in a short-run cost analysis they would not 
change much 
1
. The direct allocation method was adapted from Churchill et al 
186
: 
- For centres 2 and 3:  building maintenance (cleaning, disinfection, porters/receptionists, 
administration, heating, telephone lines, laundry, kitchen and cafeteria); administration of 
wards, pharmacy, supplies, X-ray department, laboratories, changing rooms, common areas 
and all rooms where renal replacement therapy linked activities are identifiable  
- For centre 1: hospital overheads (all of those listed above, but related to the hospital building 
or inpatient wards, plus teaching and research) 
This study excluded non-market items (e.g. volunteer and carer time, patient/family leisure time, 
etc.). It did not consider ‘price’ adjustments if, for example, a centre had a local monopoly and 
where “access charges” may have deviated from costs. This is because this economic study was 
not purely undertaken from the viewpoint of a third party payer (i.e. for whom charges may be 
more relevant than the costs).  
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This study considered included two types of patients’ payments (or cost-shifting): travel costs (if 
patient covered the costs from her/his own pocket) and medication by prescription (the out-of -
pocket component).  However out-of-pocket prescription costs were excluded because no data 
were available. 
An attempt was also made to measure opportunity costs, particularly for capital revenues (land and 
buildings) but this was abandoned as too unreliable. Guidance from Churchill and Torrance was 
applied.  
6.2.4  Cost- effectiveness analysis 
For Centres 1 and 2 the cost/life-year gained was computed by type of therapy. Centre 3 treats 
patients with HD only. A weighted average RRT cost per centre and therapy was computed. 
Transplantation could not be included in this analysis due to lack of sufficient information.  
Life-years gained (LYG) were computed as the sum of months alive on a therapy in a year for all 
new patients treated in that centre, for the given year, 1997.   
Costs for the first year of treatment (1997) were distinguished from the expected costs in the later 
years on treatment to allow discounting. The cost-effectiveness (C-E) baseline ratio was calculated 
for the first year of life gained on RRT, for the 1997 cohort.  
The final cost/ LYG was given by the total cost of treatment for new patients (proportionate 
centre’s total cost) divided by total LYG 1. 
6.3 Budgeting, expenditure & costing at national level: National Registry report 
According to the Ministry of Health, in 1995 the “Programme for development of Nephrology and 
Renal Replacement Therapy” spent the whole of its budget of US$ 171 million for the reported 
1,325 patients in stock (Ministry of Health, 1996) 
177
.  According to the Romanian Society of 
Nephrology Annual Report the budget for the previous year, 1995, was US$ 15.8
1
 million for 
1,301 patients in stock (Tables in Appendix 8) 
177
.  Regardless of the source used, the sum 
accounted for approximately 1.7-1.9% of the health care budget and, on average, the annual cost 
per patient was estimated at US$ 12,145- 12,831. These are high costs per patient in Romania, and 
RRT is considered to be a therapy with an economic impact on the health care budget as a whole. 
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However, there were no reported figures on expenditures and on how much the Programme 
overspent. The Programme was reportedly overspent in 1997 but information came from the 
limited numbers of centres which responded to the Centre Questionnaire (Chapter 4).  
In the financial section of the Centre Questionnaire most centres who answered to this question 
revealed a negative balance at the end of fiscal year with a median deficit of 21% (Chapter4). 
Inflation and other macroeconomic aspects may have had an impact on this tertiary service as any 
of the other budgetary sectors since 1997. Ten years later, inflation had stabilised at 6-7% (2007), 
yet at 2010 level budget was again under threat. Over a third of centres were privatised since 2008 
and as a new practice the economics of these centres was not assessed 
234
 
According to interviews with National Key Persons, “the Programme’s budget is set in accordance 
with the patient’s average cost on each mode of RRT.” This historical principle ruled the annual 
budget of the RRT National Programme; it was still the case in 2007.  
The share of money from the health budget is highly competitive.  Each health care area has to 
negotiate their own budgets and, it is often the Health Minister that decides “who” gets “how 
much” making RRT a top political decision; negotiations can often take as long as half year and 
this was the case in 1998. By 2003 RRT had become an established tertiary health care area, 
distinguished from Nephrology which had become a branch of internal medicine.  
Table 6.1 summarises from secondary sources the annual costs of the RRT patients. 
Table 6.1: Total annual programme estimated cost of RRT, Romania, 1995 and 1997 (USD)  
Year HD 
 
CAPD 
 
Tx 
 
Total Programme Cost 
(US$) 
(weighted ∑ according to 
proportion of patients on 
each type of RRT) 
Cost/patient % 
patients 
Cost/patient % 
patients 
Cost/patient % 
patients 
1995 12, 796.8 - 15, 686.4 - 7, 759.2 - 15, 824, 613.6
1
 
1997 14, 946.4 82 16, 595.9 11 7, 588.8 7 35, 171, 448.8 
 
In 1995 and 1997 around 82% of patients were on HD, the rest had either a transplant or were on 
CAPD. The figures for this estimated Total Programme Cost are rough. The Total Cost should be 
interpreted with caution. This is because the RRT Programme’s budgets and expenditure for these 
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years were not obtainable from any of the Reports of the National Renal Registry or the 
Nephrology Commission in the Ministry of Health. The reported figure of US$ 17.1 million for 
1995, which this study estimated at US$ 15.82 million was an exception. It seems that, although 
under major constraints, by 1997 the health care system could afford to more than double the 
proportion of budget allocated to this type of care.  
According to the responses to the Centre Questionnaire, eleven centres reported a total budget of 
US$ 7.9 million, and a total expenditure of US$ 9.1 million, with a balance of US$ –1.2 million or 
a -22% deficit.  
Financial resources: eleven centres of the 16 asked answered this question.  With the exception of 
two centres which reported expenditure matching the budget, all respondents were “overspent” at 
the end of fiscal year. One local key interviewee explained that “…the programme is under-
funded…”; and “due to the fact that trends in overspending “are customary” and centres know that 
their future budgets are drawn on a historical basis, with no adjustment for need whatsoever, 
overspending is not a problem” (local interviews). 
On average, the reporting centres were overspent by 22.3% (median: 21.3%); there have been 
other financial and accountancy explanations, too, but information was limited and time was 
insufficient to explore this further. 2007 data showed that the RRT network matched 98.1% of the 
allocated budget in expenditure.  
No further breakdown of financial information was available. 
6.4  Cost of illness  
6.4.1  Annual cost of haemodialysis 
For 1995 and 1997 the National Registry reported the average cost of a dialysed patient as follows 
(Table 2 in Appendix 8):  
‘the cost of HD treatment in Romania is low [US$ 87for a HD session]...operating costs 
represent almost all of it [US$ 81] and consist mainly of consumables and drugs ’ (1995); 
we add the fact that, if a treatment is provided three times a week, the reported monthly 
average cost is US$ 1,066.4/ patient and the annual sum would be US$ 12, 796.8; ‘as of 
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1997, the reported annual cost of an HD patient (allowing for an average number of 3 
sessions/week) is US$ 14, 946.4; the figures give a US$ 95.81 per HD session.’  
These figures were included in the National Registry Report, 1995: US$ 95.81/ HD session. The 
report used this figure which was then multiplied by the reported average of 154-158 sessions/year 
to obtain an average cost per HD patient 
27
.  
On this basis, to treat a haemodialysis patient would have cost US$ 14,754.74 to 15,137.98 per 
year based on cost per session x 156 sessions (3 times a week is the average). This reported cost 
was higher than expected given the estimated values obtained from the sampled units in this study 
(Section 6.4; Table 6.6).  
6.4.2  Annual cost of CAPD   
Table 3 in Appendix 8 shows the reported accounting costs for this modality of treatment: 
‘the monthly average cost of a patient on CAPD is US$ 1,307.2’ [an annual total of USD 
15,686.4.] 
‘…as of 1997, a CAPD patient would bring us to a total cost of $US 16,569.4 and USD 
5,725.3 (or 35%) would cover only the initiation of treatment [28 days on average]’  
It was also commented that CAPD was ‘more costly’ in Romania, ‘as compared with the 
cost of this modality in other countries’. 
6.4.3  Annual cost of a kidney transplant  
Table 4 in Appendix 8 shows the reported accounting costs: 
‘it is the least costly method of RRT and on a monthly basis such patients cost USD 646.6, 
(an annual cost of USD 7,759.2’  in 1995).  
Note that the cost components did not include e.g. HLA tests, organ ‘prelevation’, surgery 
and immediate and long term postoperative care (e.g. testing the immune response). 
In 1997, a kidney transplant patient would cost US$ 632.4 a month, of which 93% 
represents the cost of drugs, thus giving an annual total cost of US$ 7,588.8; it remains the 
‘cheapest’ type of RRT’.  
  
 
 
149 
All costs in Appendices 8 and 9 were reported as accounting costs.  
6.4.4  Results from sampled centres (volume of activities and total costs) 
This Section presents the results from costs in the three sampled units which provided additional 
local details on the costing of their RRT. Cost data obtained from interviews with the finance 
managers were analysed and results are summarised in Table 6.2 (Tables are in Appendix 8). 
From figures in Table 6.2: 
 Overhead costs account for 6.7 to 7.6%. This is well below the reported national range of 
22 to 28% in all three centres. However, when accountants recommended the inclusion of 
salaries in the overhead costs, the proportion increased to 20%. Including salaries as 
suggested could explain the observed difference between 7% and 20%. At interviews, 
accountants reported that all salaried personnel were employed on “permanent” basis and 
therefore these moneys are included in “fixed direct costs”; 
 Three main categories of staff were considered: doctors, nurses and health care assistants. 
However, for example, registered nurses who represented the largest proportion of staff 
working in RRT care could be employed in similar specialties if for example there were 
major fluctuations in RRT provision, such as centre closures. Also, it was not very clear, 
what was the basis for the calculation of the reported national figure of the overhead cost 
(22 to 28%)? From this study’s perspective these costs were equally and directly allocated 
to RRT patients, regardless of the RRT modality in the first instance. 
Variable costs account for the greatest proportion 80%. There was no national reported figure to 
validate against this kind of costs which represents the significant cost component and which 
could present variations. It was assumed that since reported fixed costs accounted for 22 to 28%, 
the variable component was implicitly set at 72 to 78% and this is sufficiently close to the 80% 
estimated value.  
The average annual costs of treating a patient on RRT in these three centres are summarised in 
Table 6.3. 
The average costs for a RRT patient with exclusion of salaries from the overhead (fixed) costs are 
presented in Table 6.2 (related to the Cost Form in Appendix 9).  
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Table 6.2 Total costs in the three sampled centres, FY 1997 
Cost item Sf Ioan Iasi Brasov Romania 
Building     
 
N/A 
 
Year of built/ opening 1982 1996 1938 
Area (m
2
) 660 788 430 
US$/m
2
 75^ 20 35 
Total building (at 1997 
opportunity costs)* 
49,500 15,760 15,050 
Overhead costs     
Water 15,192 14,797  
 
 
 
 
 
72,534 
 
Electricity 23,856 19,343  
Gas 8,900 7,979  
Heating 47,960 11,318  
Lift N/A 2,176  
Waste 2,265 2,454  
Inventory of assets* 24,420 21,518  
Cleaning 2,901 2,507  
Laundry 5,620 5,507  
Phone 1,939 2,902 1,088  
Ambulance 11,001 23,694 12,814  
TOTAL (%) 144,053  (6.7) 114,195 (7.4) 86,436 (7.6) (22 – 28) 
Salaries     
MD (f/t) 10,992 (4) 30,789 (7) 13,195 (3)  
Nurses 253,627 145,451 108,680  
Health care assistant 11,534 6,519 10,432  
Other 4,576 6,258 1,877  
TOTAL Salaries 280,730 (13.2) 189,018 (12.1)  134,184 (11.8)  
TOTAL Salaries including OC 
(%) 
424,783 (19.9) 303,213 (19.5) 220,620 (19.4)  
Variable cost     
Consumables dialysis 1,061,533 1,078,377 710,397  
Drugs (co-morbidity ) 641,647 159,776 196,091  
Pathology (routine) 16,453 13,941 8,117  
Food 4,292 786 1,992  
TOTAL (%) 1,723,925 (80.1) 1,252,880 
(80.5) 
916,597 (80.6)  
TOTAL COST /YEAR 2,148,707 1,556,093 1,137,217  
* building opportunity costs and “inventory of assets” comprising of assets such as ward furniture, etc ; these costs 
have become obsolete under 2008 economic circumstances and hence may have become a significant component of 
the 2008 RRT cost, well above the 6% discounting levels since 1997 (^e.g. one m
2
 land in Bucharest stood at Euro 
1,500 to 2,000 in 2008) 
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The adjustment in the overhead costs reflects costs included by type of treatment. CAPD patients 
are not provided with meals, except in the first month when they start treatment as inpatients. 
Transplanted patients are not provided with meals and do not use dialysis consumables, etc. 
Nurses as the largest proportion of the human resources employed by RRT units are mainly 
dialysis trained specialist nurses; they work in shifts at the centre, therefore HD patients would 
mostly benefit of their care.    
An international comparison shows that Romania’s annual observed/ measured cost per CKD5 
HD patient differs from UK costs and other countries’ costs and may only be comparable to 
Australia; these costs were measured for patients under RRT mainly for their first year under 
treatment;. It was difficult to distinguish the “new” transplant patient from the transplant patient 
“in stock” and the assumption was made that these results can be used for a “new” transplant 235. 
Table 6.3 Annual average cost in sampled units, 1997 (US$) 
Cost item Sf Ioan Iasi Brasov 
Total cost RRT programme (US$) of which: 2,148,707 1,556,093 1,137,217 
Overhead costs (salaries incl.) 424,782 303,213 220,621 
Variable costs –dialysis related 1,065,825 1,079,163 712,389 
Variable costs – drugs and pathology   658,100    173,717  204,207 
Total variable cost 1,723,925 1,252,980 916,597 
No. of patients on RRT 175 186 112 
No. of patients on HD (%) 148 (85) 146 (78) 106 (95) 
No. of patients on CAPD (%) 25 (14) 34 (18) 3 (2.5) 
No. of Tx patients (%) 1(1) 6 (3) 3 (2.5) 
Average cost /RRT patient/year  12,278.3 8,366.1 10,153.7 
Average cost/HD patient/year* 12,333.3 8,536.1 10,327.0 
Average cost /CAPD patient/year** 12,008.7 8,551.2 10,664.2 
Average cost /Tx patient/year*** 10,828.8 3,179.5 3,540.2 
*proportion of (overhead costs +consumables + food + drugs and pathology)/ HD patients; **proportion of (overhead 
costs + consumables + drugs and pathology)/ CAPD patients; ***proportion of (overhead costs + drugs and 
pathology)/ Tx patients  
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6.6  Cost effectiveness analysis from the sampled units 
6.6.1  Cost of a life-year gained (LYG) on RRT by type of therapy in the three centres (CEA) 
Table 6.4 shows the cost/ unadjusted LYG: 
Table 6.4:  Cost/ unadjusted LYG
§
 for RRT patients in sampled units (1997) 
Cost (USD) and LYG Bucharest Iasi Brasov 
Total cost dialysis (weighted HD + 
CAPD patients) 
2,148,707 
(HD=149; CAPD=25) 
1,556,093 
(HD=146; CAPD=34) 
1,137,217 
(HD=106) 
Total cost dialysis (new HD patients)  419,862.3 
(HD=34) 
276,638.8 
(HD=32) 
353,700.23 
(HD=33) 
LYG on HD 29 27 31 
Cost/ LYG HD 14,478.0 10,245.9 11,409.7 
Total cost dialysis (new CAPD 
patients) 
135,837.8 86,449.6 N/A 
LYG on CAPD 10.4 9.7 N/A 
Cost/ LYG CAPD  13,061.3 8,912.3 N/A 
Total dialysis patients 1997 (new HD 
+ new CAPD)  
555,700.1 
(HD=34; CAPD=11) 
363 088.4 
(HD=32; CAPD=10) 
353 700.23 
(HD=33) 
LYG/ centre 39.4 36.7 31 
Cost/ LYG RRT 14,104.1 9,893.4 11,409.7 
§ total life year gained with no adjustment for age, sex, presence of co-morbidity, etc. 
 
Three CER (cost-effectiveness ratios) were calculated and results described are: 
i) cost of HD per life-year gained over no RRT: 
Centre 2 and 3 appear to be more cost effective than Centre 1: US$ 10,245.9/ LYG (Iasi), US$ 
11,409.7/ LYG (Brasov) compared with US$ 14,478.0 (Bucharest).  If Centre 2 (Iasi) is taken as 
reference then cost/ LYG on HD in Centre 3 exceeds this reference by 11% and in Centre 1 by 
41%.  However, centre 2 has a younger population of patients in treatment and most likely less 
other co-morbidity. Costs are not adjusted (Table 6.2). 
ii) cost of CAPD per life year gained over no RRT: 
Centre 2 also appears to be cost-effective compared with Centre 1 for CAPD (Centre 3 does not 
provide CAPD). If Centre 2 is taken as reference then cost/ LYG on CAPD in Centre 1 exceeds by 
47%. However, the number of new CAPD patients was small in both centres in 1997 (eleven in 
  
 
 
153 
Centre 1 and ten in Centre 2) and the difference, although apparently significant, could be 
explained by other unidentified factors. These ratios are also unadjusted. 
iii) cost of HD/ 1LYG over the cost of CAPD/ 1 LYG (HD/CAPD ratios): 
- Centre 1: CE ratio HD/CAPD = 14, 478.0/ 13,061.3 = 1.11; 
- Centre 2 : CE ratio HD/CAPD = 10,245.9/ 8,912.3 = 1.15. 
The above is interpreted as:  one life year gained costs 11% more in Centre 1 and 15% more in 
Centre 2 to treat a patient with haemodialysis over a patient treated with CAPD. Both are teaching 
centres. The 4% difference is not statistically significant. These ratios are not adjusted in any way.  
6.7  Strengths and limitations 
The economic analysis shows limited strengths defined as: 
- Availability of reported national and local costs by treatment modality  
- Ability to calculate life-years gained from individual data from the baseline cohort of new 
patients who entered RRT in 1997; 
- The size o financial resources were identified at 0.5% to 1% in the annual 1997 healthcare 
budget (figures in the literature give a proportion of 1-2%), thus allowing the benchmarking 
for financial resource allocation in Romania. 
Again there were many limitations with the secondary information or the analysed data: 
- The CEA could not include: observed costs of transplantation from either of the 3 centres 
which provided local costs for the other two treatment modalities; and could not include 
calculated LYG for Tx;  
- setting assumptions such as the costs of transplantation surgeons was extremely unreliable 
and results would have been most likely invalid;  
- limiting the Tx treatment to “maintenance” with immune suppressive drugs is insufficient, but 
no information was available for transplantation; 
- the CEA is limited without ICER (incremental cost-effectiveness) information; 
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- the limited availability of utilities, which could not be validated, did not allow a calculation 
of QALY per RRT patient in Romania; or the cost/ QALY; the CUA would have given 
further insight in the economics of this clinical area; 
- it was not possible to apply discounting to costs due to the economic uncertainties and high 
inflation which were marking the 1997/1998 period; and 
- for the same reason, opportunity costs could not be estimated. 
6.8  Summary  
 RRT is an expensive high technology health care activity with significant life saving for renal 
patients. 
 When benchmarking against the centre with the lowest cost/life year gained (Centre 2), the 
other two centres vary by 11% and 41% excess; this may have implications when 
recommending cost-effectiveness to be taken into account in resource allocation and related 
RRT policy. 
 CAPD appears to be between 11% and 15% more expensive/life year gained than HD; 
however, this information is unreliable due to the very small numbers of cases on which it is 
based. 
 Romanian costs appear to be similar to Australian costs (HD, first year), yet the two countries 
have very different purchasing power parities for the %GDP on health.  Given that the costs 
were estimated from three centres only, more accurate cost measurements are needed. A more 
health economic approach based on ICERs (incremental cost-effectiveness ratios) would 
provide better support for budget planning.  
 Planning, including budgeting is made on a historical basis; there have been “incentives” to 
become over-spend in both systems: 1) During the Semashko system “one patient’s costs was 
another patient’s benefit” (money was taken from other healthcare to cover for financial gaps; 
2) During the NHIF system the RRT network has become reliant on the solidarity fund; 3) 
either system, with deficiencies in GDP% spent on healthcare, relies on unregistered “out-of-
pocket” money; these aspects were beyond the scope of this study, but are further discussed in 
Chapter 9. 
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7  Policies, protocols, guidelines and existing provision 
7.1  Objectives 
The objectives of this chapter are: 
- -     to improve on the national and local quantitative information with qualitative 
information related to national RRT policy and its local applications; to cross-check 
information obtained at interviews with that available from secondary data sources such as 
official reports and papers from the grey literature.  
7.2  Methodology and Methods 
The methodology for this part of the study was qualitative. Semi-structured interviews of national 
and local “key persons” informants were used, the agenda being to identify current policies and 
protocols; and to assess local adherence to them.  
7.2.1  Data sources 
7.2.1.1  National key person interviews.  
Five individuals at national level were interviewed: 
 A lecturer in Nephrology (teaching unit), who worked part time for the National Registry of 
Dialysis and Transplantation (I1) 
 A consultant in Public Health, who worked part time for the National College of Physicians; 
since 2005 Professor in Public Health Medicine (I2) 
 A consultant nephrologist, president of the National Committee of RRT, MoH (I3) 
 A consultant nephrologist, Reader, Secretary of State, National Health Programmes, MoH (I4) 
 A consultant nephrologist, Professor and manager of the National Registry of Dialysis and 
Transplantation (I5) 
These interviews took place at the subjects’ workplaces. The form used is in Appendix 10. The time 
taken ranged from 15 minutes (I4) to 4 hrs (I2). The interview dates were within three days of each 
other.  
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7.2.2  Local key persons interviews in sampled centres (Appendix 10) 
The same three centres were used as for the outcomes data from the centre questionnaire (Section 
5.2).   
The local key interviewees were: 
- The manager of the RRT Centre or the Clinical Director of the RRT Centre or Department 
(consultant nephrologist) ( all three centres)  
- The financial manager or (hospital) accountant (all three centres) 
- The head nurse of the haemodialysis and of CAPD units (two centres; one did not have CAPD 
patients) 
7.2.3  Analysis of interviews on policy protocols 
The results include a summary of the information regarding the application of the National Access 
to Treatment Protocol (policy) in sampled units, and compliance at unit level with the Protocol.  
All semi-structured interviews attempted to find answers to the following questions: 
1.  How does the [RRT] Programme receive its budget: nationally/ locally? (Budget flow)  
2.  What is the resource allocation policy and is there a defined geographical equity?  
3.  Was future expansion of the RRT network considered a priority among services and if so, 
how would the expansion support itself and is sustainability feasible? 
7.3  Results from National Key Persons Interviews 
The main aim of the interviews was to gather independent expert opinions on the national RRT 
programme, its resource allocation policy and whether it employed equitable means. Below are 
three quotes, all relating to financial resources: 
“…The scope beyond calculating the average cost of the RRT patient is that it allows estimation 
of the next year’s budget. If each centre allows for this, the final figures are to be presented by the 
director of the centre, along with other documentation, to the Ministry of Health having therefore a 
justification for obtaining their individual budget. Then, a national figure can be drawn for the 
entire Programme; money is the most important resource”. [I3] 
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“…The centres basically, do not receive individual budgets from a National Programme. While 
most centres provide these services along with those provided by teaching or district hospitals they 
will receive their annual budget accordingly, along with the historically set hospital’s budgets…” 
[I4] 
“..While freestanding centres will receive their budgets independently (being registered as legal 
entities), units having had to provide inpatient care, will receive their budgets along with the 
Nephrology or Internal Medicine Department of the hospital they belong to; therefore it is a mixed 
budgeting…” [I5] 
Most interviewees did not answer the question on “equity” (“what is the distribution of resources, 
particularly budgets by centre?” and “what was the resource allocation policy and was there a 
defined geographical equity?”).  One interviewee answered in relation to the Social Health 
Insurance Law recently passed through the Romanian Parliament: 
“…as long as 7% of the National Health Insurance Fund is deployed to districts in order to 
balance equity in access to services, one assumes that ‘wealthier’ districts are willing to employ 
the same process within the ministry’s annual health budget; however, it is more difficult to 
achieve this knowing that the health budget is small; the ‘attitude’ of these ‘wealthier’ districts 
will probably be to hold on to their budgets in order to improve services or to only maintain them 
at a certain quality, therefore allowing Renal units other options in order to improve their 
funding… …there were also some proposals regarding the ‘channelling’ of some financial 
resources from the health insurance fund towards the health budget of the Ministry of Health, 
namely a crude figure of  6-7 million USD for the RRT haemodialysis component [the term 
consumables was even specified what this money was to be used for]…” (as of April 1999 this 
non evidence based enforcement was still under debate at ministerial level). [I5] 
The RRT Programme receives a proportion of the health budget on an annual basis. The money to 
treat the RRT patients has been [historically] allocated to the Programme, regardless of the overall 
health budget situation; this had not changed by 2004. By 2007 the Programme appeared to be 
within spending parameters, but no one suitable was available to discuss this further. 
Expansion of the RRT programme has always been a critical issue. This implies an increase in 
expenditure and while the budget is historically fixed, the Programme would have to look for this 
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type of resource elsewhere. However, the understanding remains that money was always required 
in accordance with the numbers of patients who were in stock in the previous financial year and 
multiplied by an estimated average cost. This was explored through the cost of illness Section in 
Chapter 6.   
For the third question (Section 7.2.2) most interviewees addressed the structural changes needed 
for the renal services network. However financial issues were again highlighted:    
“…as long as patients’ transportation costs represent a ‘good’ proportion of their treatment cost, 
more smaller units have to be set up within a distance of no more than a 100 km distance from 
patients’ homes, given the road infrastructure, etc”. So far, “the difficulties encountered converge 
towards one single issue: the lack of financial resources”. [I2]  
Other points interviewees made include the following: 
Teaching centres have deployed some of their resources to neighbouring district hospitals within 
their catchment area. The idea behind this was that both patients and the other major stakeholders, 
providers and third party payer, received an efficient resource allocation. However, some of the 
issues under concern were beyond the aim of this research: e.g. national key persons were very 
unforthcoming with expert opinion as to what should happen in the Romanian RRT. Almost all 
interviewees referred to written documents such as the old access to treatment policies with 
comments such as “all the needed information is there…”. 
Nonetheless, all interviewees encouraged future research and changes in ways of decision making 
and priority setting.  The clinical guidelines were dated 1991 and they were undergoing a radical 
review at the time the fieldwork was taking place.  For example in the old guidance a capped age 
limit of 60 years old was set for acceptance on treatment and this was due to be changed to 70 
years. The result of this change in policy has been a significant increase in the proportion of 
patients entering RRT above the age of 55 years, from 20% in 1996 to 32% in 2003, a 60% 
increase 
122
.  
All three centre managers confirmed that the RRT policy has clearly taken up CAPD as the main 
safety valve in meeting treatment need and demand in Romania. Uptake on CAPD has been 
increasing after the first year since its introduction in 1995.   Hospital HD remained the main form 
of RRT, but the proportion of those on hospital HD declined from 82% (1997) to 78%  (2003) 
122
. 
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Financial resources appeared scarce in 1997, inequitably distributed, i.e. with no link to needs. 
For example, the network expanded very markedly since 1995, but the issue of transportation and 
distance from centre was still high on the agenda in 2003. This was despite reported outcomes on 
treatment apparently having improved, with survival above European reported figures. A 
mismatch in the efficiency of resource allocation raised further research questions, such as why 
has the network expanded to 71 adult centres and why only a fifth reported back on activity in 
2003, similar to the number of centres which were providing RRT in 1997 
122; 215;217
.   
7.3 Secondary sources related to the national RRT policy & access to treatment 
Access was granted to two key secondary sources of information in relation to the RRT policy at 
national level: the 1998 Annual Report of the Romanian Society of Nephrology, a national Charity 
and the National Access to Treatment Protocol 
177;218
. 
The annual report contains achievements in relation to policy related outcomes, for example 
whether the acceptance or stock targets have been met and if so, by how much; however, in 
practice it was unclear from the report whether targets were achieved or not.   
The National Access to Treatment Protocol was a dated national clinical guideline. Experts 
pointed out highlighted that a new one was being developed.  By 2003 this was still not available 
for consultation, but a check with the second interviewee at the time suggested that the change 
made was that the age limit of 55 was lifted and no other age limit was set. 
7.4  National clinical guidance and protocol for access to RRT 
 “…this is a rather an old guideline, but is the only one in use; we [the Dialysis and 
Transplantation National Committee] are currently working on a second, updated, edition, 
which should be soon released, albeit for internal use” [I3]  
The 1991 National Guideline Document contains: general policy background for RRT; patient 
selection criteria for acceptance onto treatment; HD and access on this mode of treatment; CAPD 
and access on this mode of treatment; inclusion criteria (biological markers). 
The general policy contains a Section entitled “Rights and entitlements” which lists social care 
issues associated with the renal patient. This guideline was not applied in practice, and the extent 
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of the implementation of these rights was not fully documented. No documentation of the pre-
1989 clinical guideline and protocol was available in order to make comparisons.  
7.5  Local interviews: local protocols on access to treatment  
All local centre managers were medically qualified. The position allowed them to perform clinical 
and managerial tasks within one job role.  
However, financial management was the job of an accountant. This was known as the Economic 
Director or Deputy Director, always deputising for the clinical or managing director on 
organisational matters. The clinical job attributes were usually delegated to either a consultant 
and/or the chief nurse.  
Operational management was carried out by the chief nurse or nurse manager or Head nurse. Each 
treatment modality had one head nurse each. For the provision of hospital HD, each shift agreed 
upon someone responsible for operational management therefore the role of head nurse was 
delegated for that particular shift. These were usually the afternoon and night shifts. 
A summary of the main points from local levels shows: 
The national protocol on access to treatment served as a rough guideline; local rules and 
regulations were applied and most likely prevailed. Two of the local key persons were members of 
the National Dialysis and Transplantation Committee and both were aware of and working on the 
revised protocol; the third key person was not aware of the revision but did not seem surprised 
when they learned that it was in progress. 
There were no written local protocols on access to RRT, whether pre-RRT care was included or 
even an early referral to a nephrologist when a CKD1 to CKD3 stage may have been detected, 
diabetes or hypertension diagnosed. The national Service Development Programme allowed 
centres or units to develop their own guidelines, flexibly around the national guidelines and the 
RRT policy. However, if access to RRT was not a critical issue, maintaining a patient on treatment 
could become a sensitive issue when provision with consumables which took over three quarters 
of the centre’s budget, became critical.  This might be the result of insufficient budgeting or 
changes in market prices or a bit of both; or, as and when at times the centre had a full capacity 
allowing a waiting list to develop with little flexibility of accessing treatment unless the patient 
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moved catchment area. Delay in start of treatment was not documented, nor were deaths due to 
such circumstances.  
None of the local interviewees were aware of any budgeting decisions which took into account 
geographical (in)equities or other resource allocation criteria:  
“…budgets are approved as such and we make sure we get the supplies for some months 
while this money lasts; sponsors come along sometimes, they always did. The exchange rate 
of the LEI to the USD is another issue.  Sometimes, the only difficulty that arises in money 
matters is the “additional” financial support which arrives from the government late in the 
year [second half of December]; it basically means that we cannot spend that money and it 
has to go back to the public budget…Then, this is counted as a non-spent fund. The paradox 
lies there; by the time the next year’s public budget is debated the government decides: “we 
shall not increase the health care budget as they made returns at the end of last year”. 
Basically each national programme encounters this difficulty and since the national health 
insurance law was passed matters have become even more complicated…the mass media 
have a major role in spreading such news, and inaccurate information leads to more 
confusion…” 
At local level the national protocol is regarded as detailed and useful, but the sampled units use 
“local” variations of the national clinical guideline, for example: 
- serum creatinine was interpreted as greater than 7 mg% and not greater than 8-10 mg%, which 
meant a lower threshold; 
- while connective tissue disease (e.g. lupus nephritis) and diabetic nephropathy were excluded 
from the national protocol list of underlying causes of CKD, all three centres were accepting 
these patients locally, albeit not in big numbers; 
- whereas a strict 5-6 HD initiation number of sessions/week was given by the national protocol, 
local centres had a more flexible RRT initiation policy and adapted initiation of treatment 
according to local casemix; 
- it was difficult to document how the protocol was applied in relation to the real age-based 
inclusion and exclusion criteria for RRT;  
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- the definition of certain medical conditions had different interpretations at the at local level 
despite what the national protocol defined as exclusion criteria e.g. “psychotic symptoms”; 
locally this was interpreted as “psychoses” taken from psychiatric terminology and when 
patients were excluded from entry onto RRT; 
- biological testing departed widely from the national guideline; particularly in the frequency 
with which they were carried out; local protocols often demonstrated that “there was no reason 
to perform a particular test as often as the national clinical guideline stated it (e.g. monthly, 
every 6 months, etc.);  
7.6  Summary 
The treatment policy was old and the new one was not available for consultation during the time 
the research was carried out. ERA-EDTA guidance was gaining more interest amongst an 
increasing number of centres and the National Renal Registry. 
Local input into a national policy gathered momentum after 2000 and the age threshold is 
completely lifted.  
By 2008, the administration of the RRT network laid the privatisation basis for 30% of centres. 
By 2011, the entire RRT network operated under 100% private administration (similar to 
pharmacies). 
Although out of scope, the public or private management of the renal network was not included in 
any of the discussions with policy makers. Inequity in resource allocation could inevitably be still 
recorded regardless of the network’s ownership.  
A hypothesis could be formulated, in the sense that: the health care system’s “immaturity” (less 
than 15 years under current social insurance model), being under constant reforms and with an 
increased visibility of a political pressure for privatisation beyond RRT, leaves essential 
components such as universal access to good quality care behind. Policy issues were considered 
contextual in this research, but future recommendations include a greater emphasis on this aspect 
due to the high technology involved and due to the complexity surrounding acceptance on RRT, 
survival and quality of life at various points when under treatment.  
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8  The treatment model  
8.1  Objectives  
The broad objective of this chapter is to develop a treatment model for CKD5 under RRT and use 
it to help formulate policy recommendations for resource allocation in the context of estimated 
future needs for RRT.  
The more specific objectives are:  
- to calibrate the treatment model by fitting it to estimates of the stock of patients on RRT in 
Romania from the period 1996 to 2006; and  
- to use it to estimate future stocks of RRT patients over the period 2007-2016.  
8.2  Methodology and Methods 
8.2.1  The structure of the treatment model for RRT 
A patient’s experience of RRT can be modelled as a number of changes of state.  Some of these 
changes involve states of health (e.g. well, primary renal disease, end-stage renal failure, dead) 
and some involve the kind of care received (none, dialysis, transplant). In this model there are 4 
states: RRT-HD, RRT-CAPD, RRT-functioning transplant and dead. 
Over a given period of time, patients who start the period in some given state have certain 
probabilities of remaining in that state, or of transferring to some other state. A state transition 
model involves i) a set of ‘initial conditions’ (the numbers in each state at time zero) and ii) 
estimates of the probabilities of making the transition from each state to each other state in a given 
period. The set of these transition probabilities defines the transition matrix. Starting at the initial 
conditions, the transition matrix is applied repeatedly in a sequence of discrete time periods, and 
in this way the future behaviour of the system is simulated. 
In this model new patients are ‘accepted’ into the patient pool and become prevalent patients (in 
stock) at the end of their first year of treatment. Patients accepted for treatment are initially put on 
either HD or CAPD.  Subsequently they may switch between these modalities or receive a 
transplant at rates determined by the transition matrix. After a successful transplant a patient 
transfers to the functioning transplant state.  After a failed transplant the patient can transfer to 
HD, CAPD or death.  Each year, numbers of patients flow from state to state until they enter the 
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‘absorbing’ state of death 193;195.  Flows between states and events are indicated by arrows in 
Figure 8.1.The main model output is the distribution of patients across states at the end of each 
year.  
In the calibration phase the model takes as data the annual number of new patients requiring HD 
and CAPD at the beginning of the period.  Different values are then tried for subsequent 
acceptances and in the transition matrix to see how well the projected numbers in each state at the 
end of the period correspond to the observed values.  In the projection phase, estimates of the 
numbers of acceptances each year are used and the model provides the projected numbers in each 
state in each future year.   
Figure 8.1: Treatment model adapted for the illustration of the Romanian RRT 
 
 
 
 
 
The model is adapted from Roderick et al and is implemented in Excel 
60
.  
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8.2.2  Data for the model   
Initial conditions: The calculations begin with a total number of patients aged 15+ years across all 
types of RRT in 1997.  This is based on data from all the centres which replied to both the EDTA 
and the Centre Questionnaire (Appendices 2 and 3) and the capture-recapture method (CRM) 
229
.  
The proportions allocated to each treatment modality HD, CAPD and Tx are then either estimated 
from study data (Section 5.3, Objective 3 and Chapter 6, Section 6.2) or, for transplants, taken 
from the literature. 
Transition probabilities:   Initial estimates were based on study data or, for transplants, taken from 
the literature 
60; 224
.  The number of transplant patients at baseline was very small. Also the 
indications for transplantation (i.e. criteria for suitability) were not explicitly or publicly stated, 
and when these few patients had had their transplants could not be determined. However, as of 
2006, the policy target was to achieve 250 transplants per year. This target matched the total 
number of patients alive with a transplant in 2003. It was not clear whether this target has been 
met since, but if it has, there would be a cumulative 500 patients by the end of 2004 and 750 by 
the end of  2005.  
The treatment model allows for transitions between treatment modes, but these were not used in 
the analysis presented here; the necessary data on switching between HD and CAPD were not 
available, and switching from dialysis to a transplant was a rare and undocumented event in 
Romania 
60
.  
8.2.3  The scenarios considered 
Baseline acceptance scenario:  This was set at 80 new patients per million and combined with 3 
variants of mortality: a) a baseline value; b) a 50% increase and c) a 25% decrease.  
Acceptance scenario 1 and variants: acceptance increases by 10% in ten years (an increase in the 
baseline of a cumulative 1% year on year) , combined with 3 variants of mortality: a) baseline 
value unchanged; b) a 50% increase and c) a 25% decrease.  
Acceptance scenario 2 and variants: acceptance increases by 30% in ten years: combined with 3 
variants of mortality: a) baseline value; b) a 50% increase and c) a 25% decrease. 
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Acceptance scenario 3 and variants: acceptance increases by 50% in ten years: combined with 3 
variants of mortality: a) baseline value; b) a 50% increase and c) a 25% decrease. 
Thus a total of 12 scenario variants were modelled, and these are summarised in Table 8.1.  
Some of the reasons for considering changes in acceptance rate are that the prevalence of CKD 
may increase with improved detection of the syndrome itself, with ageing of the population and/or 
with an increased diagnosis of PRD and systemic conditions leading to it, most notably diabetes 
and hypertension.  
One reason for considering variations in mortality was that the proportion of diabetic cases was 
not taken into account explicitly. However on the basis that diabetic patients would have a higher 
mortality rate, the high mortality rate scenarios were intended to represent situations with high 
percentages of diabetics. Thus the assumption made here was that scenarios with “high” mortality 
were consistent with an increase in the proportion of diabetic patients under RRT from the current 
10% up to 30% (a third of stock).   On the other hand mortality could decrease if quality of care 
improved, or if for some reason acceptances had less severe disease and/or fewer co-morbidities. 
Table 8.1: Scenarios used in the treatment model. 
Modelled 
stock/Assumptions 
Acceptance Mortality 
Scenario 1a 
(baseline) 
Baseline 80 pmp Baseline 13% per year 
Scenario 1b  Increased by 50% (19.5%) 
Scenario 1c  Decreased by 25% (9.5%) 
Scenario 2a Increase of 10% in 10 years  Baseline 13% per year 
Scenario 2b  Increased by 50% (19.5%) 
Scenario 2c  Decreased by 25% (9.5%) 
Scenario 3a Increase of 30% in 10 years Baseline 13% per year 
Scenario 3b  Increased by 50% (19.5%) 
Scenario 3c  Decreased by 25% (9.5%) 
Scenario 4a Increase of 50% in 10 years Baseline 13% per year 
Scenario 4b  Increased by 50% (19.5%) 
Scenario 4c  Decreased by 25% (9.5%) 
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8.3  Model calibration (1997-2006) 
Acceptance rates, both estimated and reported
122
 from the same year by main type of iterative 
RRT, along with mortality estimates, were used as parameters to model ESRF for 10 years. For 
example acceptance rates in the 16 adult centres ranged from 11 to 85 pmp.  Stock rates ranged 
from 119 to 169 pm, with one outlier at 222 pmp. Survivor probabilities from the three sampled 
units varied from 68% at 1 year to 84% at 3 years. Mortality rates after one year were 13% for 
HD, 5% for CAPD and 4% for transplant. (Transplant mortality was taken from the literature.)  
In the baseline scenario, the 1997 starting stock was 78 pmp, and the acceptance rate 25 pmp.   
On this basis the model suggests that total of 6,698 patients would have been in treatment by the 
end of the year 2006 (95% CI 6,602 to 6,887). The age-specific 15+ stock rate is 389 pmp (Table 
8.2).  
The figure for 2006 reported by the National Health Insurance Fund (NHIF) was 7,071, which is 
just outside the upper limit of the 95% CI for this baseline estimate.  
In fact the best fit is given by the baseline scenario, with an estimate for 2006 of 6,698 patients in 
stock (95% CI from 6,602 to 6,887).  The second closest result was scenario 4 (mortality 
unchanged and acceptance increased by 10%) with a figure of 6,978 (95% CI from 6,880 to 
7,171).  
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Table 8.2: Results for 1997 to 2006: calibration and validation of the model – Baseline and 3 Scenarios (4x3 =12 combinations) 
  Acceptance unchanged Acceptance increased by10% Acceptance increased by 30% Acceptance increased by 50% 
  Mortality: 
 
1 
Baseline 2 3 4 5 6 7 8 9 10 11 12 
Stock 
Un-
changed 
Increased 
by 50% 
Decreased 
by 25% 
Un-
changed 
Increased 
by 50% 
Decreased 
by 25% 
Un-
changed 
Increased 
by 50% 
Decreased 
by 25% 
Un-
changed 
Increased 
by 50% 
Decreased 
by 25% 
1997 2,995 2,995 2,995 2,995 2,995 2,995 2,995 2,995 2,995 2,995 2,995 2,995 
1998 3,645 3,311 3,819 3,645 3,311 3,819 3,645 3,311 3,819 3,645 3,311 3,819 
1999 4,215 3,543 4,588 4,224 3,553 4,599 4,265 3,591 4,640 4,304 3,628 4,684 
2000 4,715 3,715 5,310 4,743 3,744 5,339 4,859 3,843 5,465 4,981 3,948 5,592 
2001 5,156 3,841 5,986 5,210 3,891 6,044 5,437 4,080 6,292 5,678 4,277 6,554 
2002 5,545 3,932 6,617 5,633 4.011 6,710 6,003 4,303 7,129 6,405 4,623 7,577 
2003 5,888 3,997 7,208 6,016 4,104 7,348 6,559 4,523 7,973 7,167 4,990 8,666 
2004 6,191 4,043 7,760 6,365 4,185 7,949 7,114 4,742 8,828 7,973 5,384 9,826 
2005 6,460 4,074 8,274 6,684 4,251 8,525 7,668 4,962 9.701 8,828 5,806 11,071 
2006 6,698 4,097 8,755 6,978 4,310 9,070 8,226 5,187 10,589 9,742 6,263 12,407 
2006 rate pmp 389 238 509 406 251 527 478 336 616 566 364 721 
2006 reported 6,600 6,600 6,600 6,600 6,600 6,600 6,600 6,600 6,600 6,600 6,600 6,600 
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8.4  Model projection: 2007-2016 
Having calibrated the first 10-year cycle against the 2006 reported stock, a further 10-year cycle 
(up to 2016) was projected under each scenario. The estimates are summarised in Table 8.3, with 
details in Appendix 11. The model projection scenario 4 for 2007 (6,978) was quite close to the 
reported figure for 2007 of 7,400 patients, implying that the 2007 figure is consistent with only a 
slight increase in capacity and little or no change in mortality 
215
. 
Furthermore, from the point of view of the patient, the most optimistic scenario (scenario 12) 
suggests the following: if an increase in acceptance by 50% and a decrease of mortality by 25% 
are achieved then a stock rate of 721 pmp would have been recorded for 2006 and the projection 
for 2016 would have become 1,940 pmp.   
The most pessimistic scenario (scenario 2) assumes that the acceptance rate remains unchanged, 
and that mortality increases by 50%.  This gives a stock rate of 238 pmp for 2006 and an almost 
unchanged figure of 239 pmp for 2016. This scenario could arise if the stock of patients were to 
consist of an increasing proportion of the patients accepted having diabetic nephropathy and/or 
multiple co-morbidities (for example because they are older than current patients). 
Under most scenarios, with current service provision, a total of up to 9,000 or 10,000 patients 
would be in treatment by 2016. This would be an increase of 40 to 45% in stock over the 2006 
figure, reaching the rate of 526 pmp. If HD capacity cannot be increased beyond 2011 levels (70 
centres), and the volume of transplantation remains limited, such an increase could only be 
achieved by substantial increases in the numbers of patients on CAPD.  
The value of 526 pmp is close to the 1998 UK stock of 529 pmp (Table 2.3, literature review). 
This would also match the upper range of the reported European median stock rate of 579 pmp in 
1992 
9
. Furthermore, in absolute terms the reported figure for stock in 2008 of 10,000 patients is 
closest to scenarios 3 and 6 (Table 8.3, year 2008).   
Scenario 12 implies an increase in stock with estimated values of over 33,000 patients and a stock 
rate of 1,940 pmp. This rate is likely to be an over-estimate, as Japan and the USA have stock rate 
values around 1,000 pmp and health care in these countries appears to have met 100% of the 
CKD5 need on RRT. 
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8.5 Strengths and limitations 
The treatment model has a number of strengths:  
- it is the first model of this kind for Romanian CKD5 patients on RRT, and it is based 
primarily on Romanian data; 
- at the heart of the model is the basic and well-known epidemiological equation:  
  stock = acceptance x duration on treatment (prevalence= incidence survival); 
- the plausibility of parameter values can be tested further with sensitivity analyses; and 
- use of an Excel spreadsheet allows other scenarios to be easily investigated once the model is 
validated. 
However it also has a number of limitations: 
- survival in the model was not related to age.  This is consistent with the literature 230. Also 
there were insufficient Romanian data to estimate age specific rates. Overall 3-year survival 
was estimated at 68% (1995 cohort from the 3 centres), which compares with 60% survival in 
England (1997 cohort from UK Renal Registry reported in 2007 
230
).  For context, life 
expectancy at birth is lower in Romania than in England, but the mean age at entry on RRT 
was much lower (modal age in Romania: 45 years, modal age in England > 60 years). 
- likewise, no explicit allowance was made for effects of gender, or precursor conditions such 
as diabetes, or stage (CKD1 to CKD4) due to lack or unreliability of data.   
- there were no Romanian data on transplants; and 
- this simple model does not provide a platform for cost-effectiveness analysis. 
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Table 8.3:  Results for 2007 to 2016: the projection period of the Model – Baseline and 3 Scenarios (4x3 =12 combinations) 
  acceptance unchanged acceptance increased by10% acceptance increased by 30% acceptance increased by 50% 
  mortality: 
 
 Baseline 2 3 4 5 6 7 8 9 10 11 12 
Year and stock 
Unchange
d 
increased 
by 50% 
decreased 
by 25% unchanged 
increased 
by 50% 
decrease
d by 25% 
unchange
d 
increased 
by 50% 
decreased 
by 25% 
Unchange
d 
increased by 
50% 
decreased 
by 25% 
2007 reported 7,400 7,400 7,400 7,400 7,400 7,400 7,400 7,400 7,400 7,400 7,400 7,400 
2007 6,910 4,108 9,205 7,250 4,362 9,591 8,791 5,420 11,495 10,717 6,760 13,844 
2008 7,097 4,117 9,624 7,501 4,410 10,087 9,366 5,664 12,424 11,770 7,301 15,391 
2009 7,265 4,123 10,014 7,735 4,455 10,563 9,954 5,915 13,380 12,903 7,890 17,062 
2010 7,414 4,124 10,377 7,954 4,501 11,016 10,556 6,181 14,365 14,126 8,533 18,867 
2011 7,548 4,124 10,717 8,160 4,542 11,450 11,178 6,460 15,374 15,448 9,232 20,822 
2012 7,667 4,123 11,034 8,354 4,584 11,868 11,819 6,751 16,420 16,881 9,999 22,937 
2013 7,775 4,119 11,330 8,538 4,626 12,270 12,486 7,060 17,504 18,440 10,836 25,238 
2014 7,870 4,119 11,603 8,715 4,668 12,654 13,170 7,383 18,620 20,126 11,748 27,727 
2015 7,957 4,115 11,856 8,884 4,711 13,027 13,887 7,725 19,783 21,963 12,746 30,429 
2016 8,037 4,111 12,094 9,046 4,752 13,380 14,633 8,082 20,986 23,956 13,836 33,370 
2016 rate 467 239 703 526 276 778 851 470 1,220 1,393 804 1,940 
Table 8.4 Summary of scenarios in the two periods: 1997 -2006 and 2007- 2016 
  acceptance unchanged acceptance increased by10% acceptance increased by 30% acceptance increased by 50% 
  
mortality: 
Year and 
stock unchanged 
increased 
by 50% 
decreased 
by 25% unchanged 
increased 
by 50% 
decreased 
by 25% unchanged 
increased 
by 50% 
decreased 
by 25% unchanged 
increased by 
50% 
decreased 
by 25% 
2006 6,698 4,097 8,755 6,978      4,310 9,070 8,226 5,787 10,589 9,742 6,263 12,407 
2016 8,037 4,111 12,094 9,046 4,752 13,380 14,633 8,082 20,986 23,956 13,836 33,370 
2006 rate 389 238 509 406 251 527 478 336 616 566 364 721 
2016 rate 467 239 703 526 276 778 851 470 1220 1393 804 1940 
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Although the effects of case-mix on survival were not included in the model explicitly, some 
indication of their likely implications is given by the use of variant scenarios, expressed as higher and 
lower mortality rates and higher and lower acceptance rates.  In future modelling, the impact of 
changing risk factors on levels of disease should be incorporated more explicitly, with epidemiological 
and treatment models linked.    
As well as population demographics (aging) and patient risk factors including leading conditions or 
precursors, local requirements for RRT will also depend on factors such as changes to catchment areas, 
and changes in policy on access to treatment perhaps reflecting changes in socio-economic variables 
and demand for care etc.   
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9  Discussion, conclusions and recommendations 
9.1  Introduction 
In this chapter results from each of the earlier chapters will be summarised and discussed, including: 
- the burden of CKD and the prevalence of the main precursor conditions, in Romania and 
elsewhere;  
- factors affecting need for RRT; 
- the Romanian network of RRT services and its development;  
- outcomes of RRT in Romania;  
- data on costs of different forms of RRT in Romania;  and 
- the structure and validity of the decision-support treatment model.  
Conclusions will be drawn, and suggestions made about possible lines for future research. 
9.2  Epidemiology 
9.2.1  Chronic Kidney Disease and its precursors 
Chronic kidney disease is a complex syndrome.  If left untreated, and kidney function deteriorates below 
a certain level (CKD5), it can lead to complications, accelerated progress of co-morbid conditions, and 
earlier than expected death.     
There are many risk factors or precursor conditions for CKD, including primary renal diseases (PRD), 
diabetes mellitus (DM), hypertension (HT), lifestyle factors such as smoking, and also acquired and 
congenital immune-related conditions, or congenital and genetic disorders such as ADPKD (autosomal 
dominant polycystic kidney disease). 
The limited data available on the prevalence of CKD5 (or stock for RRT) suggest that it is an uncommon 
condition in Romania. At least it was in 1997, when the estimated CKD5 rate in the national health 
survey was 1,222 pmp 
163
. An earlier report of the Romanian Renal Registry gave a "prevalence rate of 
renal diseases" as 1,232.5 pmp with an annual "incidence" of 125 to 160 pmp 
177
. There are no more 
recent Romanian data and only one English paper reports on a 1,700 pmp 
151
. No other European country 
reports on this; neither has the National Health Insurance Fund nor the Ministry of Health through the 
Renal Committee, nor the Romanian Renal Registry have reported estimates for CKD by stages 1 to 5 in 
more recent years. However, some of the precursor conditions are highly prevalent in the general 
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population: hypertension for example, reaches a prevalence of 20 to 50% after the age of 50 years.  
Diabetes, predominantly type 2, reaches 4-8% in the adult population.    
Also this is against a background of a Romanian population that has generally high mortality by 
European standards. According to WHO data, infant mortality and life expectancy in Romania have 
slightly improved between 1990 and 2006 
236
.  (These indicators have the advantage of being regularly 
updated via Eurostat 
170
.)  Nonetheless in 2006 life expectancy at birth was 73 years, which is still 
substantially less than, for example, France (81 years) or the United Kingdom (80 years). 
237
.  
9.2.2   Rates of Primary Renal Disease (PRD) in Romania 
The published PRD rate was 2.5% but the rate calculated for this study from the same dataset was 2.9%.  
This difference may be attributable to the use of different denominators; the denominator used in the 
reanalysis was the population aged 15 years and older, but it is unclear what denominator was used in 
the published rate. Another calculation, based on the number of PRD diagnoses/ population aged 15+, 
gave 3.03%, which is slightly higher as there were 298 PRD diagnoses in 283 individuals. These 
differences are small in the context of this study, but as a general rule the same inclusion and exclusion 
criteria should be used for both numerators and denominators.  
In the reanalysis of the National Survey data 
163
, PRD was reported as the cause in 5 out of the 12 cases 
of CKD5 receiving RRT in Romania. This made PRD the most commonly reported cause, but the 
numbers involved are very small. More specifically, the 5 individuals with ICD-9 defined PRD and also 
CKD5 had the following: interstitial nephropathies, nephritic syndrome and prostrate hypertrophy which 
are also amongst the most frequently recorded PRDs in terms of percentage of population. Note though 
that while some PRD diagnoses are ‘irreversible’, (e.g. prostate hypertrophy complicated with interstitial 
nephropathy if the hypertrophy is not treated), some may recover, and then may or may not recur.. 
Perhaps a more important concern is that while in the developed or western societies the rate of PRD as 
an aetiological factor in CKD5 has dropped since the 1990s, possibly as a result of better treatment of 
streptococcal infection, this seems not to have happened yet in Romania 
122
. This is despite a reported 
decrease in some form of glomerular disease, the MPGN 
148
.    
9.2.3  Rates of hypertension in Romania 
Hypertension is the most common of the precursors for CKD in the general Romanian population, but it 
does not necessarily affect the kidneys until late in life, typically after 50 years of age.  
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The substantial difference between the officially reported rates of hypertension in the National Health 
Insurance Fund data (6%) as against those in the National Survey Report (16.7%), and in the reanalysis 
of the e-dataset (14.7%) could be a result of poor case ascertainment in the insurance data due to 
inadequate description of the inclusion and exclusion criteria. Alternatively the figures based on the 
survey data may be over-estimates. The survey methodology included clinical measurements as well as 
self-reporting and if the coding guidelines are unclear, the results can be inconsistent.  It is striking that 
the number of cases coded as hypertension in the survey dataset is greater than the number with recorded 
blood pressure measurements of ≥140/90 mm Hg. On one hand there may be over-reporting due to 
misclassified blood pressure readings, or un-validated self-reported hypertension.  On the other hand it 
may be that effective management has brought high blood pressure down to within normal ranges.  
Reported values from different parts of the country from other sources of data (National Health 
Insurance Fund and Ministry of Public Health) also vary widely, from under 3% to over 17%.  However 
these prevalence rates are not age- or gender standardised in the smaller counties, and at least part of the 
observed variation may be attributable to differences in demographics, with higher prevalence in older 
populations. This could also be affected by variations in the amount of unmet need for treatment in older 
groups.   
9.2.4  Rates of diabetes in Romania 
Health data systems in Romania are weak, and this study sought to cross-reference estimates from 
different sources.  
i)  The National Survey, 1997.  
The reported prevalence of diabetes in the National Survey was 3% 
163
.  However there were a further 12 
cases in the dataset reported as having raised glycaemia levels but not coded as diabetes. They were 
possible impaired fasting glucose (IFG) tests, at a rate of 0.12%. These could have been “newly” 
detected (incident) DM cases, or possibly DM diagnosed but poorly treated, or non-compliant with 
treatment. These survey data give higher rates in older groups, but later (1998 to 2007) survey reports 
did not give age-specific rates. 
ii)  The Ministry of Public Health and National Health Insurance Fund (NHIF) 
This source reported figures of 2.1% and 2.2% for 2004 and 2005 respectively, based on whole-
population denominators.  However, if a population denominator of people aged 15 years and above is 
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used, the 2.2% rate becomes 2.9%, which is closer to the 3% value measured in the 1997 National 
Health Survey.  
iii)  European Commission Report on major chronic diseases (EuroDiab Study
161
). 
A slightly higher prevalence of diabetes of 4% was reported for Romania in 2007. 
The estimates from sources i) and iii) were based on empirical data collection and nationally 
representative samples. The reported MoH and NHIF figures were estimates based on historical data for 
numerators (diabetes cases) and inter-censal population estimates for denominators.  
The literature suggests that 25% of all diabetic individuals may develop chronic kidney disease within 
10 years of diagnosis. (In one prospective Canadian study 
56
, all diabetic nephropathy cases eventually 
developed an impairment of the kidney function.)  
One potentially important result from this study is the odds ratio of the diagnosis of chronic renal 
insufficiency in the presence of hypertension and diabetes together. In a calculation using data from the 
National Survey, an individual was almost eight times more likely to have chronic renal insufficiency 
when both diabetes and hypertension co-morbidities were present (OR =7.73).  The numbers are small 
and the confidence interval very wide indeed (95% CI from 0.99 to 60.38), but this result is consistent 
with the literature.  
9.2.5  Factors affecting the future requirement for RRT in Romania 
One determinant of the numbers needing RRT is the prevalence of precursors and risk factors, and trends 
in these will affect future need. There have been increases in the prevalence of precursors or risk factors 
for CKD in Romania, be mainly in diabetes and hypertension, and these are expected to continue, in 
some scenarios by up to 82% (Table 3.10); indeed, Romania’s diabetes prevalence may well grow to 
match that of western societies. Such increases in rates could be offset, but only to a limited extent, by 
the expected decrease in the country’s total population (Tables 3.5 and 3.6), a decrease in smoking, and 
potentially a decrease in the prevalence of PRD.   
A second determinant of the numbers needing RRT is duration of survival while on treatment. If survival 
improves, then the need for treatment capacity will increase even if acceptance rate is unchanged.  
However data on current survival (Section 9.1.4) are difficult to interpret. Three-year survival on RRT 
appears to be better in Romania than in England (68% vs. 60%), but age at acceptance for RRT is much 
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younger in Romania.  One factor in this may be the lower expectation of life in Romania, and another 
may be past policies which excluded older patients from acceptance on RRT. With the expected 
increases in acceptance rates for older individuals, and the changing pattern of disease precursors (e.g. 
fewer smokers, more obesity and diabetes), current survival rates are an unreliable guide to what the 
rates might be in the future.   
Early diagnosis of CKD may improve prognosis, and prevent or postpone the need for RRT.  This may 
involve screening with e-GFR, with progression to later stages followed up with clinical check-ups. As 
of 2009, two surrogate markers are used to determine progress of CKD: proteinuria (the presence of 
proteins in urine, a highly sensitive marker of evolution towards diabetic nephropathy) and blood 
pressure. 
Finally better management of precursor conditions will help contain population need for RRT. Effective 
treatment of high blood pressure and DM delays the onset of CKD 3 to 5.  Good data on the prevalence 
of, and trends in, obesity, HT and DM will help in the prioritisation and targeting of the ‘upstream’ 
interventions essential to controlling the high and increasing prevalence of these conditions.  
 9.2.6  Evidence for unmet need for care for CKD 
Unfortunately there were no direct data on levels of unmet need of CKD in Romania. For example in the 
National Survey there was no information as to whether any of the twelve individuals with chronic renal 
insufficiency were receiving renal replacement therapy, i.e. whether they represented a met or unmet 
need in terms of replacement therapy. They could have been on a waiting list for renal replacement 
therapy, but neither this nor their staging (1 to 5) was recorded in the dataset or the survey report.  Thus 
for indications of levels of unmet need it was necessary to rely on indirect indicators.  These are 
discussed in more detail in Section 9.3.5. 
9.3  Services and utilisation 
 9.3.1  The economic context 
In about ten years, from 1992/93 to 2002/03, the share of GDP spent on health care in Romania 
increased from 2.5% to 6%.  This WHO-reported value should be treated with caution however given 
that it includes an increase of 100% in 5 years.  This compares with a 10% average for the EU27 with 
further increases to come, and almost 20% for the USA (2010) at the time 
236
.  
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By 2000 the government was forecasting good long-term economic prospects and since 2002/03 the 
economy has been growing at a faster pace. By 2006 Romania was experiencing one of the highest rates 
of economic development in the Central European region, and unemployment dropped to 6% (4.5% in 
Bucharest). By 2010 unemployment had recovered to 1997 levels.  
However over this period there were signs of emigration and depletion among skilled employees (in e.g. 
the building industry as well as among medical and nursing professionals) which only by 2008 had 
started to reverse.  
9.3.2  The health care system: funding, legislation and the broader picture 
The healthcare system is predominantly publicly funded and based on social insurance. New legislation 
would be required to allow new approaches to assessing quality of care alongside health technology and 
health economic assessments. However the legislative process is complex and in recent experience it 
takes time to draft laws, put them through consultation and pass them through parliament. Such delays 
also have an impact on population-based or targeted prevention health policies.  An update of the 
healthcare system legislation is overdue.  
Social insurance premiums, through which the system is financed, fell from a proportion of monthly 
salary of 16% in 1998 to 12.9% in 2008.  The 12.9% is made up of an employee’s contribution of 6.5% 
and the employer’s contribution of 6.35%, of which 0.85% is a “sick leave” component. Despite 
sustained improvement in the level of contributions to the NHIF, such as better coverage in premium 
collections, the system remains short of funds.  
Since 2010 hospitals and other large service providers have come under the control of local authorities 
and councils. Medical staff and nurses are employed by the National Health Insurance System.  
Professionally, staff are accountable to the College which has representation at local level (counties + 
Bucharest, capital city). Renal tertiary services are largely provided privately, while continuing to be 
funded publicly. 
Romania needs a clearer health planning process, and better mapping of care pathways from prevention 
to tertiary care. Some programmes, such as vaccination and immunisation, must have their resources 
ring-fenced; others could be more efficiently and effectively provided if their provision and supply were 
guided by needs assessments.  
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9.3.3  The RRT network  
By 2007 only eleven health care programmes out of thirty remained the direct responsibility of the 
Ministry of [Public] Health, the national renal replacement therapy programme being one of them. 
(Another was control of diabetes which has become a priority programme since 2006.)  
From 2007, annual operational budgets have been established via the National Health Insurance Fund, 
through its “sub-programme” components. The eleventh budget entry is “renal replacement therapy for 
end-stage renal failure”. Budgets for each centre are based largely on the annual average cost/ patient of 
HD and of CAPD and on a historical basis.  
The number of RRT centres in the country more than doubled between 1997 and 2003, from 30 to 70. 
Ten percent of the centres were privatised in 2007, but these included some of the larger ones, so that in 
2008, 36% of RRT patients were treated in private centres. This compares with reported figures of e.g. 
75% in Czech Republic, 85% in Poland and 90% in Hungary. In Romania most of the provider contracts 
involved Greek partners 
234
.    
By 2011 the provision of tertiary services for RRT was entirely privately operated, with teaching units 
and district units distributed throughout the country. Not all districts provide RRT and some patients 
have to travel substantial distances to the nearest teaching unit.  
According to the Nephrology Committee of the Ministry of Health, complete privatisation would 
address the lack of transparency in policy on acceptance for treatment, by lifting the age threshold. 
However privatisation is likely to make access to information for planning and evaluation purposes even 
more difficult, particularly in terms of costs and where they fall. Market-fixing or “patron-client” 
mechanisms have been a feature in this medical field in Romania. (This study could not address aspects 
such as “under-the-table” payments, a phenomenon close to the “take there, give here” described by 
those who studied this concept which is very deeply rooted in some societies 
238
. For example, none of 
the published reports 
122, 177
 explain the observed geographical inequalities.) 
In relation to staffing the most recent available figure for generalist nurses/100,000 population for 
Romania is 830 for 2002. It is believed that numbers of general nurses and the ratio of nurses to 100,000 
population in Romania did not change materially between 1990 to 2002. For comparison, the European 
(EU15) average figures were 829 in 1997 and 990 in 2002, but some developed countries had more than 
2,500 nurses per 100,000.  
  
 
 
180 
The 1996 report of the Romanian Society of Nephrology reported 447 dialysis nurses working in 27 
centres in 1995, giving an average of 2.6 patients/ RRT nurse. In 1997 there were 27.1 fte RRT specialist 
nurses per million population (pmp) for the 14 centres which reported on staff resources, If the stock 
estimate is at 139 pmp, as reported for that year, this gives 5 patients/ RRT nurse. By 2003 this ratio may 
have increased to 6 or 7 patients/ nurse, but this is only an estimate based on changes in reported stock 
and an unchanged number of specialist nurses.  
Despite the substantial increases in the number of RRT facilities in Romania the number of specialist 
nurses remains below the European average according to the Romanian Society of Nephrology. 
 9.3.4  Estimates of RRT ‘stock’ in Romania.  
As in section 9.2.4, this study involved cross-referencing estimates or triangulation from different 
sources and reports.  
i) The renal registry 
The official national ‘stock’ rate for CKD5 on RRT was reported as 250 pmp in 2003 with earlier values 
of 19 (1991) and 57 (1996) pmp. The latest figure can be compared with the corresponding figures for 
England (529 pmp), and the European median (437 pmp) .  
ii) The EDTA-ERA  
A 127 pmp stock rate was reported for haemodialysis (HD) for Romania to this source in 1998 
223
. The 
overall RRT stock rate, including transplant and CAPD patients, was reported to the same source as 139 
pmp
2278
. Further information was requested from the EDTA-ERA in 2008 but was not available.  
iii) The Society of Nephrology 
In data from the Society’s published report for 2004 it seems as though there is a reassuring correlation 
between time series for stock and number of centres: stock rates increased from 55 in 1995 to 127 in 
1997 to 250 for 2003, while number of centres increase from 22 to 30 to 70 in the same years. However 
these figures are based on diminishing numbers of centres reporting to the Society: 22 in 1995, 18 in 
1997 and 14 in 2003 
122
.  
iv) This study: data from the Centre Questionnaires 
The present study involved making an independent estimate of the stock rate using data from responses 
to the centre questionnaire and from the EDTA. In the 3 responding centres the stock rate was estimated 
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at 112 to 119 pmp with centre rates varying from 32 to 222 pmp. The capture-recapture method (CRM) 
was used to deal with the incomplete coverage of facilities.  On the assumption that there was a high 
degree of independence between the data from the responding centres and data from the EDTA, it was 
estimated that the national stock rate in 1997 was 161 to 175 patients per million.  
This estimate is subject to three limitations. One is that because the stock of 616 patients common to the 
EDTA and the Centre Questionnaire were not identifiable by age or gender, no age/gender breakdown 
could be provided for the national estimate. Second, primary questionnaire data were limited to only 3 
units and these may not reflect the national picture.  And third, case ascertainment in the responding 
facilities may have been incomplete. Nonetheless, both estimates are of the same order of magnitude. 
v) National Health Insurance Fund estimates 
In more recent years the NHIF has reported estimated stock levels of CKD5 under RRT as 6,600 patients 
in 2006 and 7,400 in 2007, and it was predicting a figure of 10,000 patients for 2008 
215
. The NHIF 
reported numbers rather than actual rates, but their numbers suggest CKD5 stock rates of: 382, 428 and 
578 pmp in the 15+ population.  
9.3.5  Indirect estimates of unmet need 
How do these figures for stock of patients receiving RRT compare with estimates of the prevalence of 
CKD5?  The 1997 National Survey gave an estimated prevalence rate of 1,222.5 pmp (section 9.2.1). 
Taken at face value, and subtracting the various stock estimates of around 150 to 500 pmp, this suggests 
a very high level of unmet need, of around 750 to 1000 pmp requiring RRT or other nephrological care 
but not getting it. What could be the reasons for such a large difference?  (Note that the base years for 
these estimates differ - 1997 for prevalence of CKD5 vs 2003 for RRT stock.  However the expectation 
would be for CKD5 to  have been going up, not down.) 
It is quite likely that the figure for CKD5 from the National Survey is an overestimate of the true need 
for RRT.  It was seen that other countries in Europe have stock rates of about 500 pmp; only the USA 
and Japan have ever reported figures close to 1,000 pmp and these rates have plateau’d, suggesting that 
needs are largely being met.  The number of cases in the survey was small (n = 12) and so the 
confidence intervals were wide (660 to 2,200 pmp).  Also a proportion of patients receiving RRT will 
not have been counted as stock because they will have been in treatment for less than 90 days. It is 
possible that some patients were considered inappropriate or contraindicated for RRT; and some patients 
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may have been unwilling to accept treatment.  Even in developed societies patients may wait too long 
for a transplant if that this the only practicable modality, and a proportion may die without their needs 
for RRT having been met.  
Thus although there is considerable uncertainty about the figures,  it does seem likely that there is a 
residual gap between prevalence of CKD5 and stock of RRT in Romania, indicating unmet need. 
However these stock figures are of limited value for planning purposes. First, they do not distinguish 
between incident and prevalent patients (or newly accepted and currently in treatment).  If the 
acceptance rates were known, it would be easier to plan for the required capacity. Then there is the 
related but different question of the number of centres required. The location of these centres will need 
to be such as to provide equitable access, conditional on affordability and the optimum treatment 
modality mix. It also seems likely that this gap between need and supply will be subject to substantial 
variation in terms of other factors such as gender and age.  While inequities are at the core of healthcare 
public health, providers of RRT tend to be only secondarily concerned with equity; clinical matters come 
first.     
9.3.6  RRT stock with HT and DM. 
The proportions of precursor conditions in those on RRT in Romania differ from the proportions 
recorded elsewhere, with almost 85-90% of CKD5 on RRT in Romania still due to PRD.   This has been 
reported in EDTA annual reports and published articles
110; 122; 227
.   It may be that while in western 
societies needs for CKD5 on RRT due to a primary renal disease (PRD) have been met, and treatment 
has then been extended to the other predominant underlying conditions such as hypertension (HT) and 
diabetes (DM), in Romania this has yet to occur.  
There are a number of other possible explanations for the small proportion with hypertension as the 
precursor condition in Romanian RRT patients. One could be that in some cases HT develops 
concurrently with the early stages of CKD; this is known as the renal “compensatory” mechanism for the 
loss of kidney function, or secondary HT. The loss of kidney function could be shown only by the 
asymptomatic decrease in GFR in stages CKD1 and 2
56; 58; 68;
 
93;
 
113; 119; 185; 227
 . Alternatively, if the CKD 
stage is not established in a patient with HT until much later in the progression of the CKD, for example 
through a late referral, then there are questions about what ICD codes might have been used: whether 
primary HT with kidney complications or primary CKD with secondary HT. The latter type of coding is 
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much more likely for the Romanian CKD5 patient who might not reach the point of a referral for 
nephrology because another vascular complication of raised blood pressure has come first, such as a 
cardiac event (e.g. a myocardial infarction) or a cerebro-vascular event (stroke). However it is striking 
that in the data from the three sampled units reported in Chapter 7, the modal group in the age 
distribution of RRT patients was 35-44 years, followed by group aged 45-54 years. Thus in 1997 the 
Romanian patients were much younger than their western peers, and below the age at which 
hypertension becomes most prevalent.  This was still the case in 2003 
122; 177
.  The younger the cohort of 
patients, the less likely that: 1) HT is an underlying CKD precursor and 2) the treatment needs for the 
older CKD patients are being met. This could reflect inequalities in provision or acceptance policies 
related to age. However more recently, treatment policies have been reviewed and the age threshold has 
been lifted (see section 9.3.3). 
In the UK in 1970, 2% of those on RRT had diabetes as the underlying cause, and the figure for 
Romania in 1991 was very similar at 1-2%.  Now a quarter of the UK renal replacement therapy treated 
population has diabetes as an underlying cause. By 2003 the proportion in Romania had also grown, but 
by much less, to 10%.  However, the calculated PAR% suggests an estimated figure of 30.5% for 
Romania, implying a large difference between sources in the proportion of acceptance with DM 
nephropathy. This could be either due to a lag in the occurrence and/or detection of diabetic 
nephropathy, to diabetic nephropathy patients not yet actually requiring RRT, or to diabetic nephropathy 
patients accessing RRT late in the progression of their disease and not surviving much into the ‘beyond 
90 days of treatment’ cohort.   Scenarios for the evolution of DM nephropathy could include: a) 
physiological changes are reversible in DM patients, e.g. better prevention of vascular complications and 
DM nephropathy will not reach western levels or b) these changes are irreversible, and DM nephropathy 
will follow the epidemiology of western society. Whichever the direction, the proportion of those on 
RRT needs monitoring to see if this increases or stays at 10%.  The % with PRD and HT may change 
even if the RRT stock rate plateaus. However it seems likely that DM will become the leading precursor 
condition for chronic kidney disease and end-stage renal failure in Romania very soon if the 
epidemiology of the condition follows its expected course. 
One further explanation for RRT patients in Romania having a different mix of precursors to those in 
western societies is late referral to a nephrologist. The argument is that late referrals (at a later CKD 
stage), combined with the younger age of the Romanian RRT patient, leads to poorer outcomes and a 
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shortening of the duration on treatment. In a large cohort Scottish study by Marks (2012) it was found 
that the relationship between RRT initiation and all cause mortality is an important parameter for 
planning RRT, regardless of the age of the patient. In this cohort, patients initially had CKD stages 3b, 4 
or 5 (66% were stage 3b), and after a 6-year follow-up only 5% had started on RRT; 59% had died 
without any RRT, and 36% were alive and had not started RRT, suggesting that CKD develops slowly in 
the later stages, in older patients.  They also showed that the probability of starting on RRT decreases 
with age, but the actual numbers increase. And third, they found a higher individual risk of all cause 
mortality at younger ages when compared with peers in the general population (mortality rate ratios or 
RR), but higher numbers of deaths (attributable risk or mortality rate excess) in older patients, latter 
being expected 
155
.  
There are several possible reasons for this.  There could be a greater contribution to mortality from 
premature cardiovascular disease and non-traditional cardiovascular risk factors in the young than in the 
elderly; 40% of patients had ischaemic heart disease at baseline. Another explanation could be renal 
pathology, i.e. younger people with CKD may progress faster than elderly individuals and there is 
probably more use of conservative care among those greater numbers of elderly with CKD 
155
. When 
some patients are referred late to specialist care, RRT capacity may be full and starting on treatment 
further delayed.  Some patients never reach specialist care until very late because of primary care 
“ignorance” or misdiagnosis. Some patients may not bring their problem to the attention of their GP, or 
even visit the surgery for e.g. routine BP measurements.  
The scale of problems of this kind can be reduced by introducing clinical pathways for secondary 
prevention of CKD, including pathways for treatment of diabetes and hypertension. The UK has 
developed such pathways, for example, with the use of ACE inhibitors in the treatment for hypertension, 
but also in assisting with a slowdown in proteinuria, and thus a slowdown in CKD progression towards 
stages 3 to 5. Such findings, backed up by epidemiologically supported tools such as relative vs. absolute 
risks, are endorsed by established UK public health renal researchers 
8;44;56;60;151;
 
155; 174;180
. 
9.3.7  RRT acceptance 
In terms of acceptance rates, the only primary data were from the centre questionnaires. Rates from each 
of the 14 responding centres varied widely from 11 to 85 pmp per year. The lowest value came from 
centre 2 which has the largest catchment area and the youngest demographic profile in the country (its 
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stock was also lowest at 32 pmp; this centre separately reported also on a 10-year renal biopsy results 
with annual rates of 11 pmp/year and a proportion of 10% of cases being diagnosed with CKD, but no 
staging was reported 
148
). The highest value of 85 pmp was from a north-western centre with a small 
catchment area and a relatively old demographic profile, similar to the population in centre 3. For 
comparison, the European median value is 79 pmp (1992). The latest UK figure from the UK Renal 
Registry gives 110 pmp (by 2012 called ‘take-on rate’ instead of acceptance).  These acceptance rates 
proved difficult to reconcile with the national estimate of 127 pmp as "national 3-year rolling average of 
CKD all stages" in 1996 
177
, unless this was a one-off 100% take-on rate for that year which is not 
possible. The registry report went on to say that "the assumption for requirement is 65 to 75 pmp per 
year, given that the UK has a 78 pmp acceptance rate". These figures were reported by the Romanian 
National Renal Registry without a reference in 1996. However a report for 2003 gives acceptance as 128 
pmp, still higher than the 110 pmp UK Renal Registry reported figure 
160; 227
.  
In this research, the variation in acceptance rates from 11 to 85 pmp suggests a) geographical inequity in 
distribution of resources or, b) a genuinely higher requirement in the western part of the country where 
the population is “older” than in the east. A combination of the two explanations is possible and merits 
further investigation. However, numerators and denominators must be clearly defined by catchment area 
and national level estimates need to be more rigorously determined. 
9.3.8  Treatment modality within stock and acceptance 
The great majority of patients start on HD or CAPD. In Romania, the majority (over 80%) received HD 
as the main modality of treatment 
160; 122; 163; 177;227
. CAPD was introduced in 1995 but it was not until 
after 1998 that it became more established in Romania 
222
.  Primary data collection for this study ended 
in 1998 and trends in modality beyond this date were not available from other sources.  
9.3.9  Costs and budgets 
For 2007, the year prior to privatisation of a third of RRT network, a budget of €93 million was reported 
with no overspending (expenditure accounting for 98.1% of the budget ), with a similar budget for 2008, 
except that €14.5 million (15% of the budget) was ring-fenced for HD equipment purchased in newly 
privatised centres.  Also in 2007 average costs were reported by the NHIF as: €19,510 for hospital HD 
and €13,135 for CAPD. It is difficult to make independent estimates for these figures based on e.g. cost 
per session and number of sessions per year, not only because of shortage of data on costs and rates but 
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also because of exchange rate fluctuations and the unpublished costing methodologies used by the 
Ministry of Health (MoH) until 1998 and NHIF thereafter.  
Reported figures have shown a substantial difference in the cost of HD per patient per year between state 
owned centres and privately run centres.  In 2009 these were €11,000 and €18,400 respectively 215.  
During this period there was a substantial drop in the cost of HD in state owned facilities, whilst private 
centres provided services at costs similar to those reported prior to privatisation. However, these figures 
were at odds with reported costs per dialysis session, quoted by the same source as €118 in a private 
centre and €128 to €148 in a public centre. The difference may be explained through cash flow 
mechanisms and the inclusion and exclusion of some costs, or possibly by fewer sessions per patient in 
the public sector.  
For haemodialysis patients, the costs of treatment of renal anaemia were excluded. This was due to poor 
data on costs of EPO (hu-EPO, genetically recombinant erythropoietin). EPO is very expensive and it is 
not supplied to centres on a regular basis as there is no budget to cover it. Some patients pay out of 
pocket for its procurement and administration. The potential use of it in the treatment of renal anaemia 
was tested in 1995 when EPO was received through donations, and 15-18% of patients benefited for a 3-
4 month series of treatment. At the time of the fieldwork of this study the treatment of anaemia was still 
carried out with PRBC volume (packed red blood cells). No information was available on the effects of 
using EPO, except a reduction in risk of blood-borne infection.   
The cost-effectiveness analysis (CEA) carried out as part of the present study showed that slightly better 
effectiveness (survival) might be achieved under centre haemodialysis but probably at a greater cost. 
Studies elsewhere have found that transplantation is the most cost-effective modality, but transplant 
costs were not documented for the first year post-transplant, and so no such comparison was possible 
using Romanian data.   
The 1997 figures can only serve to focus research questions and formulate hypotheses.  For example, it 
may be the case that HD appears to be slightly less cost-effective than CAPD in Romania; however, this 
needs further exploration, to include elements of treatment access, centre capacity, point in time of 
referral (stage of condition, etc) and quality of care post- access.  These variables should to be taken into 
account when calculating life years gained on each treatment.  
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9.3.10  Treatment outcomes 
Survival and quality of life are the usual measures of outcome in renal patients. Because of the limited 
time for data collection and lack of possibility of follow-up of patient morbidity, this study focused on 
the measurement of 3-year survival which was 68%. The other important finding was that the presence 
of diabetes may not influence survival on RRT in Romania, at least not in the short term (in the 
estimates with follow-up of up to two years).  
The number of centres providing data for the survival analysis was small (only 3) and extrapolation of 
the results to the entire renal population on RRT for the given cohort involves strong assumptions. Also 
the number of patients sampled from each centre was not large enough to detect anything but gross 
differences in outcomes between HD and CAPD.  For outcome measurements to assist modelling and 
planning, longer periods of follow-up and larger samples are needed in order to assess the impact of 
morbidity and co-morbidity over five-, and maybe ten-year periods
233
. In England for example, survival 
rates have been estimated for up to  8 years of treatment
232
 (60% for similar pre-2000 patient cohorts, in 
patients older than the Romanian patients 
122
).  
Reported survival in Romania was better than the European average in 2003. This was surprising in view 
of the Romanian acceptance and stock rates, which reportedly lagged behind most European countries. 
One explanation is that the almost 600% increase in facilities/centres and 700% increase in dialysis 
machines during the period from 1991 to 2003 led to an increase in one year survival because this 
expansion in capacity
110, 
led to an increase in acceptance rates including less severe patients, and hence a 
less severe case-mix among the patient stock
163; 177
. Other explanatory factors could be that the 
Romanian patients are younger than elsewhere, and there may be some advantage in newer 
equipment
114;155; 174
. 
With regard to quality of life, only two Romanian RRT studies published in the literature provide a 
baseline data on this, which is an insufficient basis for policy making and planning. QoL data are best 
derived with a prospective study design with QoL measured at baseline (i.e. at entry to treatment), and 
then at one or more follow-up points, at 6 months and/or 12 months say. In both the Romanian studies, 
scores were calculated at the start and end of a limited study period after an "average of x months of 
follow-up" with a period prevalence cross-sectional application, to both newly accepted and patients in 
stock, of the SF-36 at two points in time. There was no distinction between newly accepted patients and  
patients who had been on RRT for some time, so the methodology cannot take into account any "lead 
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time bias"
142, 143; 147.
 All three studies (two having used the SF-36 and one the KDQL) used the same 
general population norm, established much earlier, during SF-36 validation studies in the Romanian 
general population in the mid-nineties; the KDQL seems to have benchmarked results against the SF-36 
norm 
147
. 
Benchmarking quality of life scores for RRT patients in both these published studies against scores for 
the Romanian general population showed little or no discrepancy despite the different location and 
different years when the studies were carried out. In both Romanian studies QoL for haemodialysis 
patients was slightly worse than that observed in the general population. These Romanian surveys 
provided no results for transplant patients.  
Research with appropriate benchmarking in the UK and the Netherlands has also shown that quality of 
life differs little between transplant patients and the general population. Other differences, e.g. between 
HD and CAPD, have been noted, but some of the differences are statistically significant and others not.    
9.3.11  RRT policies 
The qualitative component of this study included exploration of national and local treatment policies.  
As has been described in section 9.3.2, the health care system changed in 1998 to a social insurance 
model, but the delivery of RRT did not really begin to change until ten years later when 10% of services 
were privatised. Primary data collection for this study ended before then. At that time there were two 
possible sources of data on policy: the National Renal Registry and the Annual Report of the national 
dialysis and transplantation committee at the Ministry of Health. Ministry reports are generally 
inaccessible to the public or scholars.  
Local centres were supposed to have been guided by the ‘old’ (1991) national protocol until 1998, and 
this involved an age ‘limit’ of age 55.  However in practice they also followed local rules and 
regulations. Thus the age threshold began to be lifted at the local level in the early 1990s, as confirmed 
by the local key persons’ interviews.  
The national dialysis and transplantation committee was updating the access to treatment protocol at the 
time of the primary data collection in 1998. The major point addressed was the age limit, which all units 
agreed to increase to at least age 70, although most chose no upper age limit; that was also in line with a 
documented increase in the uptake of older patients.  Treatment protocols were limited to acceptance 
criteria, with nothing explicit on process or outcomes.  
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Transplantation was not covered in the 1991 guidelines.  The Law of Tissues and Transplantation was 
passed by Parliament seven years later (1998) and this referred to general organ transplantation of which 
kidneys were included along with cornea, pancreas, etc. The reference to kidney transplantation was for 
living related transplantation only; reference to cadaver donors was added later in an amendment to the 
Act.  In 1998 two centres were performing transplantation and as of 2003 another two were set up. 
However information on renal transplantation policy was not available and the only information was 
obtained via EDTA-ERA reporting 
108; 110; 126; 133; 227
. 
One element missing from this study was a thorough assessment of the extent of inequity in the delivery 
of RRT services in Romania. Gender differences and geographic variations in acceptance and stock were 
the main inequalities observed.  The association between smoking and CKD  may partially explain the 
gender inequality on RRT, with higher smoking rates in males than females, regardless of location. The 
apparent geographic variation could be explained, in the absence of comparisons based on standardised 
rates, by the older population living in the western part of Romania as documented in Ministry of Health 
chronic disease reports.  
9.4  Modelling 
The stock estimate obtained from the CRM of 173 pmp, with 95% CIs of  169 to 175 pmp (Chapter 8)  
was used as the baseline, with 11 other scenarios for the treatment model, i.e. 2,995 patients in a 
population of  17.3 million-population over 15 years.    
The model was calibrated by comparing different acceptance and mortality scenarios over a ten-year 
period and comparing the final stock with the ‘observed’ figure.  On this basis a plausible set of 
scenarios for acceptance and mortality rates was identified.  However, the parameters used in these 
scenarios are crude and need to be further improved, for example either by refining the existing 
parameters (e.g. age-adjusted mortality or survival),  adding new parameters such as diabetes and non-
diabetes CKD; and/or by disaggregation, eg by gender, if gender inequalities are to be addressed. 
Although the 2003 report suggests improved treatment outcomes (with 1 year survival near or above 
European average) the role of improved outcomes may not be properly reflected in the modelling, 
whether in the first period of validation, or in the projections. The estimated stock with improved 
outcomes (mortality decreased by 25%) gives values of around 9,070 patients for 2006 and the reported 
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figure is significantly lower. (A stock of 9,070 patients implies a stock rate of 527 pmp, closer to the 
European average of 579 pmp 
151
).  
The model would be improved by adding intermediate states, such as various stages of the disease in the 
case of precursors, particularly hypertension and diabetes. In the case of hypertension the international 
classification defines these different stages and in the case of diabetes, the pre-diabetes stage (IFG stage) 
is distinct from an established diagnosis, which can be disaggregated by duration of disease (1 year, 5 
years).   
Pressure on services due to aging, and the issue of age-related treatment thresholds will undoubtedly 
reoccur during Romanian demographic transition to a more elderly population. However, as found by 
Scottish researchers the contrast between relative and absolute risk for both RRT initiation (acceptance 
or take-on rate) and age-specific mortality illustrates the difficulties for planning services 
155; 174
. As we 
have seen, any age-related restrictions on access to treatment were lifted in 1999, but during calibration 
and the next cycle of the model a few scenarios match currently reported number of patients in RRT. On 
the plus side this makes the model a good starting point. 
Equity (in terms of variation in utilisation or access by geography, ethnic mix, age, socio-economic 
factors, gender etc) is not currently an explicit factor in treatment policy, nor is how to improve 
accessibility in a private service in relation to such factors 
122
. Further monitoring through 
epidemiological research could improve information in this area and assist in reducing inequalities if that 
were considered important. Such parameters could also have an impact on the projections and should be 
modelled. 
9.5  Conclusions 
The research question for this study was: how might epidemiological and health care systems data be 
used to inform the planning of services for renal replacement therapy in Romania?  
From national health survey trends it appears that the prevalence of many of the precursor conditions for 
CKD has remained reasonably constant.  The exception is diabetes, and given the time lag before 
diabetic nephropathy evolves into CKD5 it seems reasonable to expect a substantial increase in the 
requirement for RRT associated with this condition. The PAR% suggests that with a 4% prevalence of 
diabetes in the general population, the proportion of diabetic nephropathy on RRT would be expected to 
be close to 30% of the case-mix, whereas in Romania the reported proportion was only 10% in 2003. 
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The information reviewed and obtained through interviews on health care effectiveness, provision, 
policies and guidelines remained insufficient in allowing for the description of some of the quality 
aspects of the RRT services. For example, the effects of the transition from public to private 
management of the dialysis network were important but beyond the scope of this thesis. As a result the 
treatment model included only clinical and epidemiological rather than health care system parameters. 
Further development could incorporate policy elements.   
The treatment model has a simple design; it is based on a spreadsheet model which can be easily used 
for planning service purposes and can also be further developed. Calibration and validation was carried 
out over 10 years. The model explains crudely how the stock of patients varies with fluctuations in 
acceptance and clinical outcomes (mortality or survival on RRT). Due to the wide range of scenarios  
used, some fit the treatment requirement which in turn could be translated to meeting treatment needs as 
long as treatment remains affordable. However, the fluctuations in the prevalence of condition 
precursors, or future trends, need to be further modelled with an epidemiological model. Good quality 
epidemiological information will improve the treatment model.       
In this study an attempt was made to estimate treatment costs using a standard set of methods.  This was 
complicated by the lack of standardisation in administrative data collection and reporting at the local 
level. For example in some areas overhead costs included salaries. Transplantation costs could not be 
directly measured and so the cost-effectiveness analysis was limited to dialysis.  And finally because of 
the small samples available from the responding centres, the cost-effectiveness of HD vs CPD could not 
be reliably established. Yet these data are needed for service planning and budgeting.  
The conduct of the study was hampered by policy turbulence: RRT treatment policy was changing 
within a continuously changing health care system, as the service delivery and organisation of the RRT 
network became privately managed.  
One strength of this study lies in its search for, collection, and use of Romanian data.  Another is its use 
of scenarios consistent with these data in the calibration of the spreadsheet-based treatment model. The 
methodology is generic, and if the second cycle is validated the model can be used for further planning 
in this service area. 
At the same time the use of Romanian data is a major weakness, with questions about its validity, 
especially of the data from secondary sources. Primary data may also be subject to hidden measurement 
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bias, for example around diagnosis coding at registration; and misclassification as well as missing 
values may have also hindered the information quality. However, the international literature made 
possible many comparisons.  
The information base for this decision-support modelling exercise was weak mainly due to incomplete 
data, such as transplantation data or the impossibility of measuring more than one clinical outcome such 
as quality of life. The greatest aid came from using complementary epidemiological tools and methods: 
the population attributable risk percent (PAR%) estimate for cross-checking with the proportion of 
diabetes on RRT, the impact fraction (IF) for estimating levels of acceptance on RRT (incidence), and 
the capture-recapture method (CRM) to improve the quality of the stock (prevalence on RRT) estimate.   
Overall, there appears to be under-provision of care for CKD5 in Romania, particularly for diabetic 
nephropathy.  
9.6  Recommendations for further research 
9.6.1  Epidemiological research needed 
One part of this study was concerned with estimating the burden of CKD, now and in the future. 
Epidemiological studies of CKD and its progression through stages CKD 1 to 4 may give further 
insights into disease progression towards CKD5.  It was clear that estimating the future burden of CKD 
will also depend on better data on levels and trends in the burdens of hypertension and diabetes, and a 
better understanding of the implications of changes in these for CKD.  
For example in the estimates made for this study, disease factors or precursors were assumed to be 
acting in isolation. Interactions, whether competing and compounding, were not taken into account, and 
these merit further attention through long-term cohort studies. Also multi-centre and cross-national 
samples would improve the power and representativeness of findings.  
Another priority for epidemiological research in Romania is the use of more appropriate comparisons, 
i.e. with countries of similar socio-economic characteristics in the region, and with adjustment for 
known confounders, e.g. by using standardised rates to adjust for differences in age structure. 
Comparisons using the data currently available are very difficult to interpret, either due to little 
information on definition of cases, numerators and denominators or due to ambiguous use of terms 
(ESRD, ESRF, CRI and CKD). This proved particularly difficult when comparisons were attempted 
with data from former communist countries. 
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A role has been identified for development of primary prevention strategies to prevent or delay the 
development of hypertension and diabetes, and hence of CKD.  Also there are complementary roles for 
secondary prevention to control existing diabetes and hypertension, including better compliance with 
treatment, especially in the case of the hypertension. However the implications of more effective 
strategies in these areas for quantitative estimates of the future burden of CKD are not clear, and more 
sophisticated epidemiological models are needed for this too.  
9.6.2  Specific factors that affect disease progression and outcomes:   
There are many factors which affect the progression and outcomes of kidney disease. Patient-related 
factors include age, precursor conditions, and type/severity (staging) of CKD.  Socio-economic status 
may be used as an indicator or correlate of a variety of more specific life-style and environmental 
factors. Data from different geographic areas can provide ‘natural experiments’, in which variations in 
risk factors can be related to variation in outcome. 
Service-related factors would include: geography and access, type of facility and e.g. delayed referral. 
Research questions could include:  is access/acceptance on RRT based on requirement, need or other 
factors such as public vs. private provision. Geographic equity may need to be considered for local 
planning purposes and should be a matter for future research. Studies of the impact of time to referral on 
outcome could also provide valuable insights.  
If this kind of information is to become really useful for future service planning, and if factors such as 
gender, age, cancer and diabetes are to be taken into account when updating policy on access to 
treatment, in future studies further use needs to be made of adjusted survival analysis, with much larger 
samples, and longer periods of observation, of up to at least five years. Novel therapeutic methods may 
need to be taken into account in the future as alternative therapies to RRT, including kidney stem cell 
research, xeno-transplantation and gene therapies may also need attention in the future. This is to 
mention only the kidney targeted therapy. Other advances are being made in the treatment of 
hypertension, obesity and diabetes. 
9.6.3  Research on the factors that affect costs. 
Further research on the factors that affect costs is needed to provide a more secure basis for modelling, 
with disaggregated data on transition probabilities, unit costs and opportunity costs. In terms of patient-
related factors, age disease severity and co-morbidity seem likely candidates, but there may also be 
  
 
 
194 
factors related to treatment setting, such as teaching, district or satellite facilities – or again, public vs. 
private. Also there is the question of whether costs should be based on current practice or evidence-
based/ high quality practice. 
However this aspect needs to be addressed on a comparative European basis if Romania wants to align 
its renal services with the standards in the European RRT network.  
Incremental cost effectiveness ratios (ICERs) and CUA (cost-utility analysis) need to become 
established tools in resource allocation in this medical area in Romania.  This has a number of 
methodological implications such as the use of  PPP (purchase power parity) for benchmarking 
purposes. 
Research into the costs and levels of resource use proved difficult in this study. Data from the three 
centres (377 patients out of potentially about 3000 patients at the time), although from three different 
geographical regions, remain insufficient to draw meaningful conclusions related to treatment capacity 
and how efficiently this capacity was used. Better cost data are needed, and  the currently available cost 
data need to be disaggregated.  
Estimates of comparative impact are needed in terms of costs per life-year gained and QALYs, 
Elsewhere such methods have long since replaced resource allocation based on historic levels 
plus/minus increments, and they could help to address inequalities and inequities.  
9.6.4  Research which may impact on quality of service and information: data sources 
The two sections above outline what type of data would be needed in further research. How might these 
data be gathered?  Good data on infrastructure are necessary for good medical practice and good quality 
care, as well as for good research.  Given the levels of disaggregation suggested, large samples will be 
necessary, and with the limited numbers of cases in each treatment centre, it may be necessary to include 
many centres in such studies. This in turn suggests important roles for a better organised National Renal 
Register and a strengthened RRT register. This will require standardised definitions, with explicit 
inclusion and exclusion criteria and validation according to agreed and explicit rules.  
Establishing a Renal Register at country level in accordance with European standards could allow the 
renal Romanian research network to increase its research capacity and improve the quality of research. 
The Romanian Register could be developed as an arm of a local Health Technology Assessment research 
body. The NICE kidney disease pathway could also provide a valuable tool and could be locally 
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adapted. Because it contains best treatment guidance for disease precursors, such as hypertension, such 
a pathway could provide an opportunity for prospective measurement of disease progression through 
stages CKD1 to CKD5.  
Other sources of data, such as population surveys would have their value enhanced by cross-checking or 
triangulating against the renal disease register. Patient safety needs also to be taken into account, as the 
most sensitive and reliable CKD diagnostic through renal biopsy shows a high proportion of incidents: 
9% 
148
. Primary care data and National Health Insurance data could also be of help. 
For good quality information to be produced, several processes need to be written into policies, 
including research and operational policies. Implementation will require skilled software development or 
purchasing, and training of staff in good governance. 
9.6.5  Research to assist evidence-based decisions and policy making  
According to Daniels (2000)
239
 decision processes should be evidence-based, participative, transparent 
and accountable and the term he coined is "accountability for reasonableness".  Such thinking seems to 
have made little headway in Romania, particularly in the healthcare system. Evidence-based decision 
and policy making involves bringing modellers and decision-makers together. For complete engagement, 
patient groups would also need to be brought in.  The modelers would need to build the kinds of model 
that decision-makers understand and trust, and decision makers would need to accept the case for 
evidence-based policy making and engaging with modelers.   
Much more use could also be made of approaches to priority setting such as Hanlon’s P.E.A.R.L., 
stakeholder analyses and focus groups involving patients, and more transparent accountancy and audit 
systems. However it seems likely that the prospects for more rigorous decision-making will be weakened 
by the increasing reliance on privatised provision in the Romanian health’s sector, especially under 
economic austerity.  Certainly the decision to privatise was not evidence-based.  A priori it seems likely 
that the 100% privatisation of the RRT network will mean self-regulated practice, which seems unlikely 
to improve evidence-based decision-making, at least in terms of public health, with no external audit, no 
quality control by independent bodies and only a weak control over physicians through the College of 
Physicians. This means the opposite of "accountability for reasonableness". 
Primary care services are still publicly owned through the social insurance system. Primary care will 
continue to be the key framework for first steps and decisions to be taken in CKD management, such as 
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initial diagnosis of PRD, DM or HT, or referral to a nephrologist. In a cash-strapped system, primary 
care decision-making could go in one of two directions.  For example, activity in primary care could fit 
in with the RRT network’s vision, i.e. GPs would monitor precursor conditions and providing that 
primary prevention, secondary prevention with early detection, and effective treatment for DM and HT 
are effective, this leads to delay or avoidance of kidney damage. Effective prevention ultimately reduces 
the burden of CKD5 leading to RRT. In the absence of effective precursor prevention and combined 
with the aging of the population it may result in an increase of RRT need. The attached economic costs 
will lead to issues related to access to treatment, affordability, unmet need. These can be addressed once 
precursor conditions are addressed.  
To avoid this bleak future, clinicians, researchers, policy makers and service users should establish a 
closer network, conduct high quality research, and implement best practice.  
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APPENDIX 1 
Literature Search Methodology (Medline 1966 to 2011 and list of journals) 
 
 
# End stage renal disease (ESRD) OR failure OR chronic kidney disease stage 5 (CKD5) 
AND: 
 
 
 
# RRT OR haemodialysis OR CAPD OR transplantation AND:- 
 
# definition 
# natural history  
# primary renal disease 
#  hypertension,  
# diabetes 
# obesity 
# smoking 
# outcomes OR 
 
 
# mortality 
# survival 
# quality of life OR economic value of life OR utilities 
# complications 
# co-morbidities 
# acceptance 
# stock 
# computer modelling OR  
# competitive risk analysis  
# decision making 
# costs AND 
# cost analyses OR CEA OR CUA         
# AND sample > 30 
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Journals from which papers were retrieved:- 
 
1 International Journal for Technology Assessment  23. Inquiry 
2 Clinical Investigations in Medicine 24. Contributions in Nephrology 
3 Archives of Internal Medicine 25. American Journal in Public Health 
4 British Medical Journal 26. Kidney International 
5 Statistics in Medicine 27. International Journal of Artificial Organs 
6 Health Care Management Review 28. Journal of American Society of Nephrology 
7 American Journal of Kidney Diseases 29. Peritoneal Dialysis International 
8 Journal for Health Politics, Policy and Law 30. Clinical Nephrology 
9 New England Journal of Medicine 31. Scandinavian Journal of Urology and Nephrology 
10 Annals of Internal Medicine 32. Advances in Peritoneal Dialysis 
11 Journal of the American Medical Association 33. Journal of the Royal Society of Medicine 
12 Journal of Clinical Epidemiology 34 Health Policy 
13 Medical Care 35. Dialysis and Transplantation 
14 Medical Decision Making 36. Health Economics 
15 Journal of Chronic Diseases 37. Clinical therapy 
16 Public Health Repository 38.Social Sciences in Medicine 
17 Social Work in Health Care 39. Journal of Public Health Medicine 
18 Nephrologie 40. American Journal of Cardiology 
 19. Advances in Renal Replacement Therapy 41. Nephron 
 20. Kidney International Supplement 42 Diabetes Care 
 21. Transplantation Proceedings 43. Nephrology, Dialysis and Transplantation (NDT) 
 22. Health Bulletin – Edinburgh  
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APPENDIX 2 
Epidemiological model            
                
       age/sex        
   
 
 
 
            
             
             
                   
   obesity          smoking    
   
 
  
 
  
 
 
 
    
 
  
 
   
             
             
                   
   diabetes          hypertension    
                   
             
             
                
       
Chronic kidney 
disease        
                
             
 
Legend to figure 
Smoking and hypertension No independent relationship Primatesta et al Hypertension 2001; 37: 187-193  
      John U et al QJ Med 2006; 99: 407-415   
            
            
Obesity and hypertension Independent relationship John U et al QJ Med 2006; 99: 407-415 BMI < 25 BMI 30+ 
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          BMI < 25 BMI 30+ 
      Mokdad A et al JAMA  289: 76-79 BMI < 25 BMI 30-39 
            
Smoking and diabetes Independent relationship Willi C et al JAMA 2007; 298: 2654-2664 smokers non-smokers 
            
            
Obesity and diabetes  Independent relationship Colditz et al Ann Int Med 1995; 122: 481-86   
      Mokdad A et al JAMA  289: 76-79 BMI < 25 BMI 30-39 
      
Wannamethee G et al J Ep Comm Hlth 2005: 59:134-
39 BMI < 25 
BMI 27.5-
29.9 
           BMI 30+ 
            
Smoking and PRD  
No independent relationship 
(?) Fox C et al JAMA 2004; 291: 844-50 smokers non-smokers 
            
            
Obesity and PRD  No independent relationship Fox C et al JAMA 2004; 291: 844-50 per unit BMI 
   Independent relationship Hsu C et al. Ann Int Med 2006; 144:21-23 BMI < 25 BMI 30-39 
            
            
            
            
Hypertension & CRD  Independent relationship Fox C et al JAMA 2004; 291: 844-50 140/90 or on medication 
            
            
Diabetes & CRD  Independent relationship Fox C et al JAMA 2004; 291: 844-50 140/90 or on medication 
   non-obese  Hsu C et al. Ann Int Med 2006; 144:21-23 BMI < 25 BMI 30-39 
   Obese         
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APPENDIX 3 
1997 EDTA RRT data: Accepted and Stock of patients - Romania 
NEW patients aged <15 DEATHS DEATHS aged <15 STOCK - Location 
HD  PD  Tx  Total  HD  PD  Tx  Total  HD  PD  Tx  Total  HD  PD  Tx  Total  Centre HD  
Self limited 
care HD  
Home HD  Total  
514  48  16  578  34  1  3  38  173  6 2 181  9 0 0 9 1355  0  0  1355  
34 centres recorded on database  
25 responded as at 3 1/12/97  
This data therefore represents 74% of centres in 
Rumania  
            
 
STOCK - Type of treatment  STOCK - Location - aged <15  STOCK - Type of treatment - <15  Alive & treated by PD  
HD 
Haemo-
filtration  
Haemo-
diafiltration  
Total 
Centre 
HD  
Self limited 
care HD  
Home 
HD  
Total  Total  HD  
Haemo-  
filtration  
Haemo-
diafiltration  
CAPD  
Auto 
PD  
Other  
PD  
Total  
1349 0 6 1355  44  0  0  44  44  0  0  44  128  1  0  129  
 
Alive & treated by PD - aged <15  Alive_with_functioning_graft  Alive with functioning graft - <15  HD to Tx  PD to Tx  
CAPD 
Auto  
PD 
Other  
PD 
Total 
your  
centre 
another  
centre 
another  
country 
Total 
your  
centre 
another  
centre 
another  
country 
Total Total <15 Total <15 
1 0 0 1 67 94 14 175 5 4 0 9 59 5 5 0 
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1997 EDTA data: Stock of patients - Romania continued 
 
 
 
 
 
All Regrafts All_Regrafts_aged_<15 Multiple grafts Tx Total Tx - <15 
Cadaver Living Total Cadaver Living Total 
kidney/ 
pancreas 
kidney  
/liver 
kidney/  
heart 
Total Cadaver Living Total Cadaver Living Total 
1 0 1 0 0 0 0 0 0 0 7 31 38 0 2 2 
 
Total Tx – 15 to 59 Total Tx - ≥60 Total grafts Total grafts - 1st graft Total grafts - regraft 
Cadaver Living Total Cadaver Living Total Cadaver Living Total Cadaver Living Total Cadaver Living Total 
7 29 36 0 0 0 9 88 97 8 88 96 1 0 1 
Source: ERA-EDTA Registry, St Thomas’ Hospital London, England 
 
 
 
 
Tx to HD Tx to PD PD to lID HD to PD Total renal_grafts Total 1st_grafts Total 1st grafts aged <15 
Total  <15  Total  <15  Total  <15  Total  
! 
<15  Cadaver  Living  Total  Cadaver  Living  Total  Cadaver  Living  Total  
22 0 0 0 6 1 17 1 7 31 38 6 31 37 0 2 2 
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Summary table of respondent and non-respondent centres: EDTA and CQ (CQ form in APPENDIX 4) 
Centre No 
of 
pts 
Centre No. 
of 
pts 
Centre No. 
of 
pts 
Centre No. of 
pts. 
1 Centre BH 116 9 Centre AB 47 17 respondent EDTA Buch CD - 25 respondent EDTA MH - 
2 Centre BV 112 10 Centre BN 36 18 respondent EDTA Buch U - 26 respondent EDTA PH - 
3 Centre HD 27 11 Centre CV 23 19 respondent EDTA TM - 27 respondent EDTA SB - 
4 Centre Bucharest F 82 12 Centre SJ 33 20 respondent EDTA CJ1 - 28 respondent EDTA SV - 
5 Centre CT 83 13 Centre Bucharest SFI 175 21 respondent EDTA CJ2 - 29 respondent EDTA VL**  - 
6 Centre DJ 104 14 Centre Bucharest NP 112 22 respondent EDTA MS - 30 non-respondent EDTA or CQ - 
7 Centre IS* 186 15 unusable patient data CQ 23 respondent EDTA AR - EDTA adult (1 to 7; 17 to 30) 1605 
8 Centre OT 26 16 unusable patient data CQ 24 respondent EDTA CS - CQ 1 to 14 (adult ≥ 15 years) 1162 
(1150) 
*Centres 1 to 7 reported to both EDTA and CQ for the 1997 cohort totalling n =710 patients; 94 were excluded due to:-  
a) age <15 (n=48)  
b) incomplete data n=46 (e.g. centre IS reported 186 patients; however, only 146 HD patients had data eligible for analysis; centre BV reported 
112 and 106 were eligible, centre Bucharest SFI reported 175 and 148 were eligible ) and  
c) CAPD and Tx patients were difficult to cross-check for registration with a specific centres and national estimates were used in the treatment 
model. The 7 centre, which reported to both EDTA and CQ, had an estimated pool of 616 to 662 patients and the lowest value and closest to the 
validated estimate was chosen for the CRM (Chapter 6, Section 6.5 and Chapter 10). Cross-check validation of reported numbers with actually 
collected figures was only possible for the 3 sampled centres: Bucharest, Iasi and Brasov  
**some other 13 centres reported figures to the EDTA. These were not available to this study, neither in aggregate numbers, nor in detail. The 
difference of 1605 – 616 = 989 adult patients was used in the CRM 
*** For the CQ data source the difference of 1150- 616 =534 was used in the CRM (Chapter 6, Section 6.5, Table 6.2).  
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APPENDIX 4 
                               
ROMANIA 
Centre (code): 
 
1. year in which the centre was set up   
    
2. number of patients treated (1995, 1996, 1997 - stock/year)   1995 
           1996 
           1997 
3. number of new  patients (1995, 1996, 1997- acceptance)    1995 
           1996 
           1997 
4. distribution of patients according to the modality of RRT treatment 
1995: 
         HD/HDF         CAPD   LRTx 
1996: 
         HD/HDF       CAPD    LRTx 
1997: 
        HD/HDF        CAPD             LRTx 
5. On HD:  total number of stations 
                  total number of (functional) dialysis stations 
       type(s) of machine 
(firm):____________________________________________- 
                  -______________________________-_______________________________ 
Centre Questionnaire (CQ) 
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                   year of purchase:  
        types of membranes used (tick):        fill in: 
                     cellulosic       non-cellulosic                   mixed (%)
            
       dialysate type (tick):                                                    
 
        acetate    bicarbonate 
6. On CAPD:  type of system connection: 
            single bag   twin bag          other 
7. dedicated human resources:    
a. physicians                      
b. nurses           
c. ancillary       
d. other (no.)                                 
e. other (shared)            profile*:                physicians  
                                 nurses  
                      ancillary  
               other  
a_________________-___________________ 
b_________________-___________________ 
c_________________-___________________ 
d__________________-__________________ 
e __________________-__________________ 
 
8.  RRT financial resources (1997 budget)           Lei                
     [US$    ] 
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9.   catchment area for the centre      (population) 
10. total health budget of the main district health authority (1997)  
                Lei   
     [US$             ] 
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APPENDIX 5   
Letter for Centres (CQ and Patient Form data collection) 
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APPENDIX 6 
 
 
 
BASELINE 
PART  A       Centre Code*  
I. Sociodemographic data: 
1. ID 
 
                       (d   d    m     m     y     y     S     p     F     D    D) 
  
2. [age at first RRT (yrs)] 
3. gender (M, F) 
4. first referred to a nephrologist (dd/mm/yy) 
5. type of referral (self, GP, other) 
6. treatment started (date of first entrance)(dd/mm/yy) 
7. socioeconomic status:  
 - education (school) 
 - occupation at entry on RRT  
 - marital status  
 - residency 
 - distance to RRT centre (km) 
 - means of transport 
  
 
 
 
PATIENT FORM- BASELINE 
and FOLLOW-UP  
 
 
 
 
 
 
 
 
 
                     9 5 
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II. Medical data  
1. primary renal disease (PRD)                          
          
2. co-morbidity (underlying morbidity by the time RRT scheme started)    
 
Group                                    [ code] 
3. medication (chronic) at start 
of RRT (tick):                            CV   HAEM     INF     ENDO   NEUR-PSIH  BONE    DIG    PULM   OTHER 
 
 
4. type of first RRT 
 
5. stage of chronic renal insufficiency when RRT started  
- serum creatinine (mg/dL) 
- Ht (%) 
- Hb (g/dL) 
- serum albumin (%) 
- X-ray (plain renal)    (yes/no)  if yes, size of kidneys (cm)    L 
                    R 
6. BP  (mmHg) 
7. Weight (kg)       
8. Height (cm) 
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III RRT: 
HD 
9.  Type of vascular access: 
Cimino-Brescia           Scribner shunt         Shaldon catheter              other  
date performed        attempts          funct (ml/min)         
             (if Cimino-Brescia) 
surgical complications     
CAPD    
10. Type of access: 
    single bag              twin bag other           date performed 
   first access complications   type: 
      Tx 
10. Living related: 
       date performed:   
       postoperative complications 
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1-YEAR FOLLOW-UP (cohorts ’95, ’96 and ’97) 
PART B       Centre code * 
II. Medical data         31 Dec 95-96-97 
 
ID                     
                                                                                   (d   d      m     m     y     y     S     p     F     D    D) 
       occupation (employment status) 
1.  other co-morbidity detected in the first year of treatment  
         medication (chronic)-(tick) 
 
               CV   HAEM     INF     ENDO   NEUR-Psych  BONE    DIG    PULM   OTHER 
 
type of RRT  
2. actual registration with GP (yes/no) 
3.  disease status and biological results at 1 year* 
- total number of HD sessions 
- duration of session (average)                                                      hours          min 
- serum creatinine (mg/dL) 
- Ht (%) 
- Hb (g/dL) 
- serum albumin (%) 
4.  BP  (mmHg) 
5. Weight (kg)       
 
* for these variables: to consider either last measurement (i.e. if done quarterly) or average of last three measurements 
if done monthly) 
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Treatment interruption  
short interruption         
         reason 
from                                      to                   
from          to             
from       to       
                 
transfer         
          date          type of treatment   reason 
          
  date   type of treatment  reason 
 
 
lost to follow-up 
          date 
 
death 
         date   cause  
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2-YEAR FOLLOW-UP (cohorts ’95 and ’96) 
        Centre code * 
II. Medical data                                                                              31 Dec 96-97 
 
ID                     
                                                                                    (d   d      m     m     y     y     S     p     F     D    D) 
       occupation (employment status) 
1.  other co-morbidity detected in the first year of treatment  
          
 
2. medication (chronic)-(tick) 
          CV   HAEM     INF     ENDO   NEUR-PSIH  BONE    DIG    PULM   OTHER 
 
3. type of RRT  
4. actual registration with GP (yes/no) 
5.  disease status and biological results at 2 year* 
- total number of HD sessions 
- duration of session (average)                                            hours          min 
- serum creatinine (mg/dL) 
- Ht (%) 
- Hb (g/dL) 
- serum albumin (%) 
6.  BP  (mmHg) 
7. Weight (kg)       
* * for these variables: to consider either last measurement (i.e. if done quarterly) or average of last three 
measurements if done monthly) 
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VII. Treatment interruption  
short interruption         
         reason 
from                                      to                   
from          to             
from                  to       
                 
transfer         
          date          type of treatment  reason 
          
 
 
lost to follow-up 
          date 
death 
         date   cause  
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3- YEAR FOLLOW-UP (cohort ’95) 
        Centre code * 
II. Medical data                                                                                 31 Dec  ‘97 
 
ID                     
                                                                                    (d   d      m     m     y     y     S     p     F     D    D) 
       occupation (employment status) 
8.  other co-morbidity detected in the first year of treatment  
          
 
9. medication (chronic)-(tick) 
        CV   HAEM     INF     ENDO   NEUR-psych  BONE    DIG    PULM   OTHER 
 
10. type of RRT  
11. actual registration with GP (yes/no) 
12.  disease status and biological results at 2 year* 
- total number of HD sessions 
- duration of session (average)                                                      hours          min 
- serum creatinine (mg/dL) 
- Ht (%) 
- Hb (g/dL) 
- serum albumin (%) 
13.  BP  (mmHg) 
14. Weight (kg)       
* * for these variables: to consider either last measurement (i.e. if done quarterly) or average of last three 
measurements if done monthly) 
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VII. Treatment interruption  
short interruption         
         reason 
from                                      to                   
from          to             
from                   to       
                 
transfer         
          date          type of treatment  reason 
          
 
 
lost to follow-up 
          date 
death 
         date   cause  
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APPENDIX 8   
Accounting Costs 
 
Chapter 6 
Table 0.1:  HD cost/ patient, Romania, 1997 (US$) 
Consumables and drugs 
Item Unit Quantity USD 
Artificial kidney (membrane) Item 1 16.61 
Blood lines (set) Item 1 4.10 
Needles (fistula) Item 2 0.98 
Dialysis set (TOTAL)   21.69* 
Concentrate solution : 
Acid 
Basic 
 
litre 
litre 
 
5 
7 
18.93 
 
Drip line Item 2 0.50 
Syringe    30 ml Item 1 0.62 
Syringe     2 ml Item 4 - 
Syringe     5 ml Item 2 - 
Syringe     10 ml Item 2 - 
Gloves (single use) Pair 2 0.62 
Drugs   5.31 
EPO I.U. Varies 1.07 
Dressings and other materials - - 1.12 
Blood ml 
PRBC** 
 1.16 
Disinfectant 
Puristeril 
 
Ml 
  
0.19 
SUB-TOTAL (I) direct cost 51.31 
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Table 0.2 continued 
 
Other expenditure (cost)/patient USD 
Hospitalisation (average/year) 10.84 
Tests 3.82 
Food 0.58 
Water 0.02 
Equipment –depreciation 2.83 
Water station depreciation 0.61 
Equipment –spares 0.22 
Patient’s transport 6.57 
Rest Room 0.25 
Laundry 0.25 
Electricity 0.42 
Heating 0.14 
Cleaning (materials) 4.84 
Salaries 4.84 
 
SUB-TOTAL (II) 44.50 
 
TOTAL (I + II) HD session 95.81 
*salaries, according with firm they are bought from: 21.00 to 25 USD; **PRBC –packed red blood cells 
Table 0.2: CAPD cost/ patient, Romania, 1997 (USD) 
Consumables Quantity USD 
Tenchkoff catheter 1 56.50 
Catheter extension 2 17.32 
Catheter adapter  2 4.24 
CAPD double bags 1,500 8,625 
Clamps 1,500 840 
“Frekaderm”  52 338 
SUB-TOTAL I 9,881.06 
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Table 0.3: CAPD cost/ patient, Romania, 1997 (US$) - continued 
Other expenses/ patient 
 Unit USD 
Hospitalisation 28 days/y 5,725.25 
Drugs (while hospitalised)  366.31 
Periodical tests  623.33 
SUB-TOTAL  II 6,714.89 
 
TOTAL I + II CAPD 16,595.95 
 
Table 0.4: Monthly Tx maintenance cost/ patient, Romania, 1997 (US$) 
Item USD 
Medical check-up 1.8 
Tests 7.2 
Hospitalisation 36.4 
Drugs 
- Cyclosporine                 (200 tb/month) 
- Azathioprine                  (100 tb/month) 
- Steroids (“Prednison”)  (300 tb/month) 
 
547.50 
36.00 
13.50 
TOTAL cost/month 632.40 
TOTAL cost / year 7,588.80 
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APPENDIX 9    Cost Form 
Costing 1 Unit of output: HD session (then a.e.c.), CAPD session 1 and monthly (then AC)  
                         'Tx pre-, Tx, post- episodes of care (a.e.c.)    
 2 Resources to be identified (Ingredients list; sublists by modality)   
 3 Values to be attached; find marginal costs and perform the survival analysis   
 4 Model building       
 5 Sensitivity analysis         
        
Itemised list RRT             
         
 1 STAFF  2 AMBULANCES   
  doctors nephrology    Driver   
   urology    Petrol  
   ICU    Maintenance  
   vascular surgery    Deprec  
   internal medicine      
   haematology   TC ambulance Opp. driver  
   Radiology   (cost/journey)  
   other specialty      
         
  psychologist       
  dietitian       
  nurses Centre 3 BUILDINGS   
   Ward    deprec  
   Theatre    maintenance  
   Other    rent  
       electricity  
  ancillary Centre    dialysis ward  
  /catering Rx    phone line  
   Lab    heating  
   Ward      
   Kitchen      
   Other   T. overhead Opp. building  
         
  pharmacy Chemist      
   Assistant      
         
  lab Biologists      
   Chemistry 4 ADMIN   
       accountants  
  technical comp Engineers    mgt  
   technicians    receptionists  
       personnel  
         
  TC staff  Opp staff   Overhead admin Opp admin  
         
5 DIALYSIS    6 CAPD   
 EQUIPMENT (HD)    EQUIPMENT Y-bag  
  machine     other  
  PTFE graft     disinfectant  
  shunt     clamps  
  catheter Shaldon    dressings  
   Other    TC equipment  
  dialyser see list      
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  aa line       
  vv line  7 DRUGS (I)   
  aa access    fluids saline .9%  
  vv access     saline 10%  
  uni-access     saline 20%  
  shunt connector    glucose 20%  
  aa loop     dialysate 1(conc) 
  vv loop     dialysate 2(conc) 
  Single use needles    KCl 7.4%  
  Single use gloves   other (drugs) heparine  
  syringe 2ml     protamine sulphate 
  5 ml     vit K  
  10 ml     Ca gluc 10%  
  30 ml     cardiac  
  other syringe     antibiotics  
  disinfectant     vascular (BP)  
  dressings     blood  
  water purif.     EPO  
       alfa-calcidiol  
       steroids  
       sedatives  
       insuline  
       antialgics  
  TC HD equipm     TC drugs (I)  
      other (fluids) WATER  
         
         
8 ROUTINE    9 SPECIAL   
 INVESTIGATIONS     INVESTIGATIONS   
  Hb     fibroscopy  
  Ht     haemocult  
  Ret     HLA Ag  
  L     other special  
  Tr       
  BT     TC special  
  CT       
  PTT, Howell       
  Urea(s)       
  Creat(s)  
1
0 PATIENT   
  Uric ac.     drugs  
  Na+     transport  
  K+       
  Ca 2+     TC patient  
  PO4
3-     (transfer costs) 
  HCO3
-       
  Fe       
  Transf       
  Acid phosph..       
  Alk. phosph       
 
 
 
 
 
243 
 
  ALAT       
  ASAT       
  Ag HBs       
  Ab VHC       
  HIV       
  Billirubin       
  Electrophoresis       
  Glycaemia       
  Lipids       
 Rx Plain X-ray kidney       
  Chest X-ray       
  Bones X-ray       
  Films       
  Solutions       
 Other ECG       
  Oscillometry       
  Eye test       
  EMG       
  EEG       
  Neurological       
  ENT       
         
  TC Routine       
         
         
11 HOSPITAL   11 HOSPITAL   
 DRUGS (II)     DRUGS (II)   
 antibiotics     cont'd   
  Ampicyllin    beta blockers 1   
  Ceftriaxon     propranolol  
  Vancomycin    beta blockers 2   
  Amoxicillin     metoprolol  
  Cefuroxim     astemisol  
  Cetirizin    others   
  Nicetamide     captopril  
  Neomycin     clonidin  
 cardiac Deslanosid    Ca blockers   
  Dopamine     nifedipin  
  epinefrine     verapamil  
  etilefrine    Blood   
  frusemide     carbocromen  
  lydocain     ticlopidine  
  nitroglycerin     thrombine  
  nipride    sedatives   
  propafenone     clemastin  
 vascular (BP)     clopromazine  
  aminophyllin     diazepam  
  carbazocrom     phenobarbital  
  DH-ergotoxin    steroids hydrocortisone 
  etamsilat     hemisuccinate  
  papaverine      
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       other  
      insuline   
       humulin  
       others  
      Pain medication   
       algocalmin  
       piafen  
         
       TC DRUGS (II)  
         
               
        
List of dialysers (Source: http//:www.hdcn.com) tick one or 
more Dialysate (tick)    
Althin    Acetate    
Asahi    bicarbonate    
Baxter        
Cobe        
Fresenius        
Gambro        
Gambro/HOS        
Minntech        
N.M.C.        
Organon        
Terumo        
Toray        
        
Membrane        
Cellulosic        
non-cellulosic         
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APPENDIX 10 
 
 
Interview questions - key persons at national level 
 
- Q1. Awareness of resource allocation for RRT in the health service  
 - How does the Programme receive its budget? 
- Q2. Awareness on proportions spent: within programmes, among programmes, among 
other medical specialities which ‘compete’ with nephrology: 
 - what are the resource distribution policies? 
 -is geographical equity a consideration? 
- Q3. WHAT are the competitive specialities?  
 -enumerate 
- Q4. How will be the PROVISION of RRT be affected in the context of changes in the 
health service (from tax based to public insurance)? 
- Q5. Awareness of the application of national treatment and access protocols:  
 -who makes them   
 -what do they consist of (i.e. including transplantation legislation, etc.)? 
 -do the protocols include policies about prioritisation between groups of patients 
where  service provision is insufficient (e.g. age, PRD, etc.?) 
 - what are the policies and instruments relating to adherence to protocols at the local 
 level? 
- Q6. Awareness of application of any other local protocols (i.e. at district level: who makes 
them? are they applied along with the national protocols? are they applied instead of the 
national protocols?   
- Q7. Plausible policy scenarios to be examined at the modelling stage: 
 - is the extension of the use of satellite units (teaching, district) plausible as part of a 
 future service  configuration? 
 -if none of these are considered for service extension, what are the constraints 
(money,  human resources, etc.?) 
 
NATIONAL KEY PERSONS INTERVIEWS 
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Interview questions -key persons at local level (Cohort of 1997) 
 
Treatment and access protocols: 
 - Q1. adherence to national treatment protocol (dialysis committee); if not, why? 
 - Q2. local protocol concerning treatment:  
 access,  
 duration of typical HD session, and 
 number of sessions per week on individual patients (range and durations).  
- Q3. catchment area:  
 individual patient’s distance from centre  
 means of transport for each patient 
- Q4. adherence to the EDTA/ERA, if yes: 
 year  
 1997 data  
Budget and expenses 
- Q5. financial flow and costs of the unit: fiscal year of 1997 
- Q6. provide ‘itemised’ list 
- Q7. provide subsequently the sub-lists by modality of treatment, in order to be valued 
- Q8. overheads  
 HOW are they measured, and 
 WHAT are their components? 
- Q9. hospitalization costs: clinical notes and values attached to hospitalization ingredients 
- Q 10. any identifiable priority areas for renal replacement therapy in Romania? (open 
question) 
 
# Q1-5 and partially Q9 (on clinical notes): Centre’s Clinical Director; #Q5-9: Centre’s accountant and 
hospital’s accountant, #Q10  : all levels of management: clinical director, pharmacy and supplies, nurse 
manager, accountant, other. 
 
LOCAL KEY PERSONS INTERVIEWS 
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APPENDIX 11  The treatment model (spreadsheet) 
 
1,150 CQ 1997 (53%) 
        
 
1,659 
EDTA Q 
1997 (74%) incl. paediatric units 
      
 
1,605 
EDTA Q 
1997 (70%) excl. paediatric units 
      
 
2,995 
NUE from 
CRM 
(resulting in 
both sources 
covering 71% 
of all national 
stock) 95% CI from2,869 to 3,121 
      
 
3,170 (Ref 16)  (100%) 
        
BASELINE 
          a 
 
mortality 13% on HD, 5% on CAPD and 4% on Tx 
      
 
CRM Chapter 4 (Section 4.3.2) and Chapter 7 
   
mle nue 
 
 
=from $x12 to $x31 
         
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1205 646 1944 1404 1945 1405 749 3647 3646 3645 
1999 865 1389 749 2241 1628 2242 1629 866 4216 4216 4215 
2000 968 1551 840 2501 1826 2502 1827 969 4717 4716 4715 
2001 1059 1691 921 2728 2002 2729 2003 1060 5158 5157 5156 
2002 1139 1815 992 2928 2157 2929 2158 1140 5546 5546 5545 
2003 1209 1924 1056 3103 2295 3104 2296 1210 5889 5889 5888 
2004 1272 2019 1112 3257 2418 3258 2419 1273 6193 6192 6191 
2005 1327 2104 1162 3393 2527 3394 2528 1328 6461 6461 6460 
2006 1376 2178 1207 3513 2624 3514 2625 1377 6699 6699 6698 
2007 1420 2244 1247 3619 2711 3620 2712 1421 6911 6911 6910 
2008 1458 2301 1282 3712 2788 3713 2789 1459 7098 7098 7097 
2009 1493 2353 1315 3795 2858 3796 2859 1494 7266 7266 7265 
2010 1524 2399 1343 3869 2920 3870 2921 1525 7415 7415 7414 
2011 1551 2440 1369 3935 2976 3936 2977 1552 7550 7549 7548 
2012 1576 2476 1392 3993 3026 3994 3027 1577 7668 7668 7667 
2013 1598 2509 1413 4046 3071 4047 3072 1599 7776 7776 7775 
2014 1618 2537 1432 4092 3112 4093 3113 1619 7872 7871 7870 
2015 1636 2563 1449 4134 3149 4135 3150 1637 7959 7958 7957 
2016 1652 2587 1464 4172 3183 4173 3184 1653 8038 8038 8037 
248 
 
Scenario Baseline a (continued) 
=(a+b+1)(a+c+1)(b)(c)/(a+1)2 (a+2) 
     var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
2.1272E+12 561660.314 421492365.7 5047 71 3574 3785 
3.80017E+12 750562.323 651000230.4 5837 76 4138 4364 
5.95374E+12 939368.024 911384250.7 6533 81 4635 4874 
8.51417E+12 1123303.22 1191667454 7145 85 5072 5322 
1.13852E+13 1298938.88 1481712574 7684 88 5457 5717 
1.44746E+13 1464632.45 1773992114 8159 90 5798 6065 
1.77015E+13 1619739.84 2063046432 8580 93 6099 6373 
2.09811E+13 1763477.76 2343591406 8953 95 6365 6646 
2.42506E+13 1895991.3 2612581215 9282 96 6602 6887 
2.74705E+13 2018047.54 2868816017 9576 98 6812 7102 
3.0565E+13 2128797.72 3108129825 9834 99 6997 7291 
3.3571E+13 2231169.56 3334951459 10066 100 7164 7461 
3.64228E+13 2324130.74 3545484685 10273 101 7313 7613 
3.91346E+13 2409231.71 3741946413 10458 102 7446 7749 
4.16618E+13 2485951.36 3922060595 10622 103 7564 7869 
4.40565E+13 2556513.19 4090191015 10771 104 7671 7978 
4.62749E+13 2620254.44 4244078519 10903 104 7766 8075 
4.83592E+13 2678754.16 4386968894 11023 105 7852 8163 
5.03213E+13 2732706.55 4520142574 11133 106 7931 8243 
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Baseline continued 
b 
 
mortality 50% increase 
        
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1149 615 1853 1338 1854 1339 749 3313 3312 3311 
1999 865 1273 687 2054 1493 2055 1494 866 3544 3544 3543 
2000 968 1375 747 2217 1623 2218 1624 969 3716 3716 3715 
2001 1059 1457 796 2350 1731 2351 1732 1060 3842 3842 3841 
2002 1139 1525 838 2459 1821 2460 1822 1140 3932 3933 3932 
2003 1209 1580 873 2548 1897 2549 1898 1210 3997 3998 3997 
2004 1272 1626 902 2622 1961 2623 1962 1273 4043 4044 4043 
2005 1327 1663 927 2683 2015 2684 2016 1328 4074 4075 4074 
2006 1376 1695 949 2734 2062 2735 2063 1377 4097 4098 4097 
2007 1420 1721 966 2776 2101 2777 2102 1421 4109 4109 4108 
2008 1458 1743 982 2812 2135 2813 2136 1459 4118 4118 4117 
2009 1493 1763 996 2843 2165 2844 2166 1494 4123 4124 4123 
2010 1524 1779 1007 2869 2190 2870 2191 1525 4124 4125 4124 
2011 1551 1792 1018 2891 2213 2892 2214 1552 4124 4125 4124 
2012 1576 1805 1027 2911 2232 2912 2233 1577 4123 4124 4123 
2013 1598 1815 1035 2927 2249 2928 2250 1599 4120 4120 4119 
2014 1618 1824 1042 2942 2265 2943 2266 1619 4119 4120 4119 
2015 1636 1832 1048 2955 2278 2956 2279 1637 4115 4116 4115 
2016 1652 1839 1053 2966 2290 2967 2291 1653 4111 4112 4111 
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=(a+b+1)(a+c+1)(b)(c)/(a+1)2 (a+2) 
     var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
1.75538E+12 561660.314 421492365.7 4165 65 3247 3438 
2.68517E+12 750562.323 651000230.4 4125 64 3479 3669 
3.69642E+12 939368.024 911384250.7 4056 64 3652 3840 
4.72406E+12 1123303.22 1191667454 3964 63 3778 3964 
5.72402E+12 1298938.88 1481712574 3863 62 3870 4054 
6.66933E+12 1464632.45 1773992114 3760 61 3935 4117 
7.5467E+12 1619739.84 2063046432 3658 60 3982 4161 
8.34292E+12 1763477.76 2343591406 3560 60 4014 4191 
9.0718E+12 1895991.3 2612581215 3472 59 4038 4212 
9.70965E+12 2018047.54 2868816017 3385 58 4050 4222 
1.02881E+13 2128797.72 3108129825 3310 58 4060 4230 
1.08137E+13 2231169.56 3334951459 3243 57 4066 4235 
1.1268E+13 2324130.74 3545484685 3178 56 4067 4234 
1.1683E+13 2409231.71 3741946413 3122 56 4068 4234 
1.20494E+13 2485951.36 3922060595 3072 55 4068 4232 
1.23685E+13 2556513.19 4090191015 3024 55 4064 4227 
1.26739E+13 2620254.44 4244078519 2986 55 4064 4226 
1.29333E+13 2678754.16 4386968894 2948 54 4061 4221 
1.31674E+13 2732706.55 4520142574 2913 54 4057 4217 
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Baseline continued 
 
c 
 
mortality 25% decrease 
        
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1234 661 1990 1437 1991 1438 749 3821 3820 3819 
1999 865 1450 781 2339 1698 2340 1699 866 4590 4589 4588 
2000 968 1646 891 2655 1937 2656 1938 969 5312 5311 5310 
2001 1059 1824 991 2942 2155 2943 2156 1060 5988 5987 5986 
2002 1139 1985 1083 3202 2354 3203 2355 1140 6619 6618 6617 
2003 1209 2132 1167 3438 2536 3439 2537 1210 7210 7209 7208 
2004 1272 2265 1243 3653 2702 3654 2703 1273 7762 7761 7760 
2005 1327 2386 1313 3848 2854 3849 2855 1328 8276 8275 8274 
2006 1376 2496 1377 4026 2993 4027 2994 1377 8757 8756 8755 
2007 1420 2597 1436 4188 3121 4189 3122 1421 9207 9206 9205 
2008 1458 2688 1489 4336 3237 4337 3238 1459 9626 9625 9624 
2009 1493 2771 1539 4470 3345 4471 3346 1494 10017 10015 10014 
2010 1524 2848 1584 4593 3443 4594 3444 1525 10380 10378 10377 
2011 1551 2917 1626 4705 3534 4706 3535 1552 10719 10718 10717 
2012 1576 2981 1664 4808 3617 4809 3618 1577 11037 11035 11034 
2013 1598 3039 1699 4902 3694 4903 3695 1599 11332 11331 11330 
2014 1618 3093 1731 4988 3764 4989 3765 1619 11606 11604 11603 
2015 1636 3141 1761 5066 3829 5067 3830 1637 11859 11857 11856 
2016 1652 3186 1789 5139 3889 5140 3890 1653 12097 12095 12094 
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=(a+b+1)(a+c+1)(b)(c)/(a+1)2 (a+2) 
     var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
2.33501E+12 561660.314 421492365.7 5540 74 3745 3965 
4.50326E+12 750562.323 651000230.4 6917 83 4505 4751 
7.54963E+12 939368.024 911384250.7 8284 91 5219 5488 
1.1473E+13 1123303.22 1191667454 9628 98 5888 6178 
1.62153E+13 1298938.88 1481712574 10944 105 6513 6822 
2.16949E+13 1464632.45 1773992114 12229 111 7098 7425 
2.78035E+13 1619739.84 2063046432 13477 116 7643 7987 
3.44186E+13 1763477.76 2343591406 14686 121 8153 8512 
4.14346E+13 1895991.3 2612581215 15860 126 8629 9002 
4.87521E+13 2018047.54 2868816017 16994 130 9075 9461 
5.62144E+13 2128797.72 3108129825 18086 134 9489 9888 
6.37946E+13 2231169.56 3334951459 19129 138 9876 10285 
7.13571E+13 2324130.74 3545484685 20126 142 10235 10655 
7.88891E+13 2409231.71 3741946413 21082 145 10572 11001 
8.6295E+13 2485951.36 3922060595 22002 148 10886 11325 
9.35613E+13 2556513.19 4090191015 22875 151 11178 11626 
1.00578E+14 2620254.44 4244078519 23698 154 11449 11905 
1.07362E+14 2678754.16 4386968894 24473 156 11700 12163 
1.13967E+14 2732706.55 4520142574 25213 159 11936 12406 
 
 
 
Baseline ends 
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SCENARIO 1: Increase acceptance by 10% at 10 years             
a 
           
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1205 646 1944 1404 1945 1405 749 3647 3646 3645 
1999 867 1392 751 2245 1632 2246 1633 868 4225 4225 4224 
2000 974 1559 845 2515 1837 2516 1838 975 4744 4744 4743 
2001 1070 1709 931 2756 2023 2757 2024 1071 5211 5211 5210 
2002 1157 1843 1008 2973 2192 2974 2193 1158 5634 5634 5633 
2003 1236 1965 1079 3169 2346 3170 2347 1237 6017 6017 6016 
2004 1307 2075 1144 3347 2487 3348 2488 1308 6367 6366 6365 
2005 1373 2176 1203 3509 2616 3510 2617 1374 6686 6685 6684 
2006 1433 2268 1258 3658 2735 3659 2736 1434 6979 6979 6978 
2007 1489 2353 1309 3795 2846 3796 2847 1490 7251 7251 7250 
2008 1541 2431 1357 3921 2949 3922 2950 1542 7503 7502 7501 
2009 1589 2504 1400 4039 3044 4040 3045 1590 7736 7736 7735 
2010 1634 2572 1442 4149 3134 4150 3135 1635 7955 7955 7954 
2011 1677 2637 1480 4253 3218 4254 3219 1678 8161 8161 8160 
2012 1717 2697 1517 4350 3298 4351 3299 1718 8356 8355 8354 
2013 1755 2755 1552 4443 3373 4444 3374 1756 8540 8539 8538 
2014 1791 2809 1585 4531 3446 4532 3447 1792 8716 8716 8715 
2015 1826 2862 1617 4616 3515 4617 3516 1827 8885 8885 8884 
2016 1860 2912 1648 4697 3582 4698 3583 1861 9048 9047 9046 
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Scenario 1 continued 
 
=(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
2.1272E+12 561660.314 421492365.7 5047 71 3574 3785 
3.8325E+12 753753.876 655155331.6 5850 76 4147 4373 
6.0933E+12 950313.026 927353462.9 6571 81 4662 4902 
8.87303E+12 1146719.72 1229111535 7219 85 5125 5377 
1.21217E+13 1340292.44 1553010258 7805 88 5544 5806 
1.57751E+13 1529006.44 1892191341 8337 91 5925 6195 
1.9775E+13 1711962.9 2241678456 8822 94 6271 6549 
2.40481E+13 1887958.44 2595999495 9264 96 6588 6873 
2.85647E+13 2057704.18 2953772621 9671 98 6880 7171 
3.32897E+13 2221500.82 3313301829 10047 100 7150 7446 
3.81549E+13 2378442.53 3670460079 10395 102 7399 7701 
4.31357E+13 2529022.28 4024407870 10719 104 7631 7937 
4.82478E+13 2674827.54 4377328521 11022 105 7849 8160 
5.34502E+13 2815449.08 4726941932 11308 106 8054 8368 
5.87301E+13 2951386.56 5073315444 11576 108 8247 8565 
6.40857E+13 3083114.57 5416662333 11831 109 8430 8752 
6.95649E+13 3212375.14 5760784455 12076 110 8605 8930 
7.51189E+13 3338257.87 6102635826 12309 111 8773 9101 
8.0771E+13 3461720.72 6444235450 12534 112 8934 9266 
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Scenario 1 continued 
 
b 
 
mortality 50% increase 
        
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1149 615 1853 1338 1854 1339 749 3313 3312 3311 
1999 867 1277 689 2059 1497 2060 1498 868 3554 3554 3553 
2000 974 1384 752 2232 1634 2233 1635 975 3745 3745 3744 
2001 1070 1474 805 2378 1751 2379 1752 1071 3892 3892 3891 
2002 1157 1552 853 2503 1854 2504 1855 1158 4012 4012 4011 
2003 1236 1618 894 2610 1943 2611 1944 1237 4104 4105 4104 
2004 1307 1677 931 2705 2023 2706 2024 1308 4186 4186 4185 
2005 1373 1729 963 2788 2094 2789 2095 1374 4252 4252 4251 
2006 1433 1775 993 2863 2158 2864 2159 1434 4310 4311 4310 
2007 1489 1817 1020 2931 2217 2932 2218 1490 4363 4363 4362 
2008 1541 1856 1045 2993 2271 2994 2272 1542 4410 4411 4410 
2009 1589 1892 1068 3051 2321 3052 2322 1590 4456 4456 4455 
2010 1634 1926 1090 3106 2369 3107 2370 1635 4502 4502 4501 
2011 1677 1957 1110 3157 2413 3158 2414 1678 4543 4543 4542 
2012 1717 1988 1129 3206 2455 3207 2456 1718 4584 4585 4584 
2013 1755 2017 1148 3253 2496 3254 2497 1756 4627 4627 4626 
2014 1791 2045 1166 3299 2535 3300 2536 1792 4669 4669 4668 
2015 1826 2073 1184 3344 2573 3345 2574 1827 4712 4712 4711 
2016 1860 2100 1200 3387 2609 3388 2610 1861 4752 4753 4752 
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=(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
1.75538E+12 561660.314 421492365.7 4165 65 3247 3438 
2.71273E+12 753753.876 655155331.6 4141 64 3489 3680 
3.79754E+12 950313.026 927353462.9 4095 64 3680 3870 
4.94967E+12 1146719.72 1229111535 4027 63 3828 4016 
6.1475E+12 1340292.44 1553010258 3958 63 3948 4134 
7.34118E+12 1529006.44 1892191341 3880 62 4042 4226 
8.54773E+12 1711962.9 2241678456 3813 62 4123 4306 
9.72863E+12 1887958.44 2595999495 3748 61 4190 4371 
1.08955E+13 2057704.18 2953772621 3689 61 4249 4429 
1.20519E+13 2221500.82 3313301829 3637 60 4302 4480 
1.31866E+13 2378442.53 3670460079 3593 60 4350 4527 
1.43124E+13 2529022.28 4024407870 3556 60 4396 4572 
1.54527E+13 2674827.54 4377328521 3530 59 4442 4618 
1.65627E+13 2815449.08 4726941932 3504 59 4483 4658 
1.76804E+13 2951386.56 5073315444 3485 59 4525 4699 
1.88154E+13 3083114.57 5416662333 3474 59 4568 4742 
1.99606E+13 3212375.14 5760784455 3465 59 4609 4784 
2.11281E+13 3338257.87 6102635826 3462 59 4653 4827 
2.22855E+13 3461720.72 6444235450 3458 59 4693 4867 
 
 
 
 
 
257 
 
 
 
 
 
 
Scenario 1 continued 
 
c 
 
mortality 25% decrease 
        
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1234 661 1990 1437 1991 1438 749 3821 3820 3819 
1999 867 1453 783 2344 1702 2345 1703 868 4600 4600 4599 
2000 974 1655 896 2670 1948 2671 1949 975 5341 5340 5339 
2001 1070 1842 1001 2971 2177 2972 2178 1071 6046 6045 6044 
2002 1157 2015 1099 3250 2389 3251 2390 1158 6712 6711 6710 
2003 1236 2176 1190 3509 2588 3510 2589 1237 7350 7349 7348 
2004 1307 2324 1276 3749 2773 3750 2774 1308 7952 7950 7949 
2005 1373 2463 1356 3973 2947 3974 2948 1374 8527 8526 8525 
2006 1433 2593 1430 4183 3109 4184 3110 1434 9072 9071 9070 
2007 1489 2715 1501 4379 3263 4380 3264 1490 9593 9592 9591 
2008 1541 2830 1567 4564 3407 4565 3408 1542 10089 10088 10087 
2009 1589 2938 1630 4738 3544 4739 3545 1590 10565 10564 10563 
2010 1634 3039 1690 4902 3674 4903 3675 1635 11019 11017 11016 
2011 1677 3136 1747 5058 3797 5059 3798 1678 11453 11451 11450 
2012 1717 3228 1801 5206 3915 5207 3916 1718 11871 11869 11868 
2013 1755 3316 1852 5348 4027 5349 4028 1756 12272 12271 12270 
2014 1791 3399 1902 5483 4135 5484 4136 1792 12657 12655 12654 
2015 1826 3480 1950 5613 4239 5614 4240 1827 13030 13028 13027 
2016 1860 3557 1995 5737 4338 5738 4339 1861 13383 13381 13380 
 
 
 
258 
 
 
 
 
 
 
 
 
=(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
2.33501E+12 561660.314 421492365.7 5540 74 3745 3965 
4.54385E+12 753753.876 655155331.6 6936 83 4516 4762 
7.7221E+12 950313.026 927353462.9 8327 91 5248 5518 
1.19404E+13 1146719.72 1229111535 9715 99 5945 6237 
1.72054E+13 1340292.44 1553010258 11079 105 6605 6917 
2.35362E+13 1529006.44 1892191341 12439 112 7237 7567 
3.08427E+13 1711962.9 2241678456 13759 117 7832 8179 
3.91204E+13 1887958.44 2595999495 15070 123 8403 8766 
4.82625E+13 2057704.18 2953772621 16339 128 8942 9321 
5.82594E+13 2221500.82 3313301829 17583 133 9458 9851 
6.89934E+13 2378442.53 3670460079 18797 137 9950 10355 
8.04528E+13 2529022.28 4024407870 19991 141 10422 10840 
9.2551E+13 2674827.54 4377328521 21143 145 10871 11301 
1.05242E+14 2815449.08 4726941932 22264 149 11301 11743 
1.18527E+14 2951386.56 5073315444 23363 153 11715 12168 
1.32338E+14 3083114.57 5416662333 24432 156 12113 12576 
1.46663E+14 3212375.14 5760784455 25459 160 12495 12967 
1.61527E+14 3338257.87 6102635826 26468 163 12864 13346 
1.76715E+14 3461720.72 6444235450 27422 166 13215 13705 
 
 
259 
 
 
 
 
 
 
 
 
 
SCENARIO 2: Increase acceptance by 30% every 10 years           
a 
           
         
mle nue 
 
            
 
A B C a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1205 646 1944 1404 1945 1405 749 3647 3646 3645 
1999 867 1399 754 2256 1640 2257 1641 868 4266 4266 4265 
2000 974 1578 856 2545 1860 2546 1861 975 4861 4860 4859 
2001 1070 1745 951 2815 2067 2816 2068 1071 5439 5438 5437 
2002 1157 1903 1041 3069 2263 3070 2264 1158 6004 6004 6003 
2003 1236 2052 1127 3310 2449 3311 2450 1237 6561 6560 6559 
2004 1307 2195 1209 3540 2628 3541 2629 1308 7116 7115 7114 
2005 1373 2332 1288 3761 2800 3762 2801 1374 7670 7669 7668 
2006 1433 2464 1365 3974 2968 3975 2969 1434 8228 8227 8226 
2007 1489 2593 1440 4183 3131 4184 3132 1490 8793 8792 8791 
2008 1541 2720 1514 4387 3291 4388 3292 1542 9368 9367 9366 
2009 1589 2845 1587 4588 3449 4589 3450 1590 9957 9955 9954 
2010 1634 2968 1658 4787 3605 4788 3606 1635 10558 10557 10556 
2011 1677 3091 1730 4985 3761 4986 3762 1678 11180 11179 11178 
2012 1717 3213 1801 5183 3916 5184 3917 1718 11821 11820 11819 
2013 1755 3337 1873 5382 4072 5383 4073 1756 12488 12487 12486 
2014 1791 3460 1945 5581 4228 5582 4229 1792 13173 13171 13170 
2015 1826 3585 2018 5783 4386 5784 4387 1827 13890 13888 13887 
2016 1860 3712 2091 5987 4546 5988 4547 1861 14636 14634 14633 
 
260 
 
 
 
 
 
=(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
2.1272E+12 561660.314 421492365.7 5047 71 3574 3785 
3.90816E+12 753753.876 655155331.6 5965 77 4188 4416 
6.39669E+12 950313.026 927353462.9 6898 83 4776 5022 
9.66388E+12 1146719.72 1229111535 7862 89 5349 5611 
1.37672E+13 1340292.44 1553010258 8865 94 5908 6187 
1.87539E+13 1529006.44 1892191341 9911 100 6460 6754 
2.46999E+13 1711962.9 2241678456 11018 105 7009 7320 
3.16477E+13 1887958.44 2595999495 12191 110 7558 7884 
3.96998E+13 2057704.18 2953772621 13440 116 8110 8454 
4.89479E+13 2221500.82 3313301829 14773 122 8670 9029 
5.94801E+13 2378442.53 3670460079 16205 127 9238 9615 
7.14502E+13 2529022.28 4024407870 17754 133 9821 10216 
8.49764E+13 2674827.54 4377328521 19413 139 10416 10829 
1.00297E+14 2815449.08 4726941932 21218 146 11032 11463 
1.17542E+14 2951386.56 5073315444 23169 152 11666 12117 
1.37038E+14 3083114.57 5416662333 25299 159 12327 12797 
1.58863E+14 3212375.14 5760784455 27577 166 13004 13495 
1.83555E+14 3338257.87 6102635826 30078 173 13713 14227 
2.11346E+14 3461720.72 6444235450 32796 181 14452 14988 
 
 
 
 
 
261 
 
 
 
 
Scenario 2 continued 
b 
 
mortality 50% increase 
        
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1149 615 1853 1338 1854 1339 749 3313 3312 3311 
1999 867 1283 692 2070 1505 2071 1506 868 3592 3592 3591 
2000 974 1402 761 2262 1655 2263 1656 975 3844 3844 3843 
2001 1070 1510 825 2435 1793 2436 1794 1071 4081 4081 4080 
2002 1157 1608 883 2593 1920 2594 1921 1158 4304 4304 4303 
2003 1236 1699 938 2741 2039 2742 2040 1237 4523 4524 4523 
2004 1307 1786 990 2880 2153 2881 2154 1308 4743 4743 4742 
2005 1373 1869 1040 3014 2261 3015 2262 1374 4963 4963 4962 
2006 1433 1949 1088 3143 2366 3144 2367 1434 5188 5188 5187 
2007 1489 2027 1136 3270 2469 3271 2470 1490 5420 5421 5420 
2008 1541 2106 1183 3396 2571 3397 2572 1542 5665 5665 5664 
2009 1589 2182 1229 3520 2671 3521 2672 1590 5916 5916 5915 
2010 1634 2260 1275 3645 2772 3646 2773 1635 6182 6182 6181 
2011 1677 2338 1322 3771 2873 3772 2874 1678 6461 6461 6460 
2012 1717 2417 1368 3898 2974 3899 2975 1718 6752 6752 6751 
2013 1755 2497 1415 4027 3077 4028 3078 1756 7061 7061 7060 
2014 1791 2578 1463 4158 3181 4159 3182 1792 7384 7384 7383 
2015 1826 2661 1512 4292 3287 4293 3288 1827 7726 7726 7725 
2016 1860 2746 1561 4429 3394 4430 3395 1861 8084 8083 8082 
 
 
 
 
 
 
262 
 
 
 
 
 
 
=(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
1.75538E+12 561660.314 421492365.7 4165 65 3247 3438 
2.77116E+12 753753.876 655155331.6 4230 65 3526 3719 
4.00115E+12 950313.026 927353462.9 4315 66 3778 3972 
5.44162E+12 1146719.72 1229111535 4427 67 4014 4210 
7.07539E+12 1340292.44 1553010258 4556 67 4236 4436 
8.91607E+12 1529006.44 1892191341 4712 69 4454 4657 
1.09743E+13 1711962.9 2241678456 4896 70 4672 4879 
1.32548E+13 1887958.44 2595999495 5106 71 4891 5103 
1.5783E+13 2057704.18 2953772621 5343 73 5114 5330 
1.86036E+13 2221500.82 3313301829 5615 75 5345 5567 
2.17563E+13 2378442.53 3670460079 5927 77 5587 5815 
2.52272E+13 2529022.28 4024407870 6269 79 5836 6070 
2.91344E+13 2674827.54 4377328521 6656 82 6099 6341 
3.34966E+13 2815449.08 4726941932 7086 84 6376 6625 
3.83506E+13 2951386.56 5073315444 7559 87 6664 6921 
4.38144E+13 3083114.57 5416662333 8089 90 6970 7236 
4.99214E+13 3212375.14 5760784455 8666 93 7290 7565 
5.67939E+13 3338257.87 6102635826 9306 96 7628 7914 
6.44778E+13 3461720.72 6444235450 10006 100 7982 8279 
 
 
 
 
263 
 
 
 
 
Scenario 2 continued 
 
c 
 
mortality 25% decrease 
        
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1234 661 1990 1437 1991 1438 749 3821 3820 3819 
1999 867 1459 787 2354 1710 2355 1711 868 4642 4641 4640 
2000 974 1675 907 2701 1971 2702 1972 975 5467 5466 5465 
2001 1070 1880 1022 3032 2221 3033 2222 1071 6294 6293 6292 
2002 1157 2076 1133 3349 2463 3350 2464 1158 7131 7130 7129 
2003 1236 2266 1240 3655 2696 3656 2697 1237 7975 7974 7973 
2004 1307 2450 1344 3951 2922 3952 2923 1308 8830 8829 8828 
2005 1373 2628 1446 4239 3143 4240 3144 1374 9703 9702 9701 
2006 1433 2802 1545 4520 3359 4521 3360 1434 10592 10590 10589 
2007 1489 2974 1643 4796 3571 4797 3572 1490 11498 11496 11495 
2008 1541 3142 1739 5067 3780 5068 3781 1542 12427 12425 12424 
2009 1589 3308 1834 5335 3987 5336 3988 1590 13384 13381 13380 
2010 1634 3473 1929 5601 4193 5602 4194 1635 14368 14366 14365 
2011 1677 3636 2023 5865 4397 5866 4398 1678 15378 15375 15374 
2012 1717 3800 2116 6129 4601 6130 4602 1718 16424 16421 16420 
2013 1755 3964 2211 6393 4806 6394 4807 1756 17508 17505 17504 
2014 1791 4128 2305 6658 5011 6659 5012 1792 18625 18621 18620 
2015 1826 4294 2400 6925 5218 6926 5219 1827 19788 19784 19783 
2016 1860 4460 2496 7194 5426 7195 5427 1861 20991 20987 20986 
 
 
 
 
 
264 
 
 
 
 
 
 
=(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
2.33501E+12 561660.314 421492365.7 5540 74 3745 3965 
4.62587E+12 753753.876 655155331.6 7061 84 4556 4805 
8.09008E+12 950313.026 927353462.9 8724 93 5371 5648 
1.29433E+13 1146719.72 1229111535 10531 103 6190 6494 
1.94185E+13 1340292.44 1553010258 12504 112 7017 7348 
2.77105E+13 1529006.44 1892191341 14645 121 7852 8210 
3.80349E+13 1711962.9 2241678456 16967 130 8697 9083 
5.06531E+13 1887958.44 2595999495 19512 140 9561 9975 
6.57766E+13 2057704.18 2953772621 22269 149 10439 10881 
8.3695E+13 2221500.82 3313301829 25260 159 11336 11807 
1.04673E+14 2378442.53 3670460079 28518 169 12255 12755 
1.29093E+14 2529022.28 4024407870 32077 179 13201 13731 
1.57366E+14 2674827.54 4377328521 35950 190 14175 14736 
1.89745E+14 2815449.08 4726941932 40141 200 15174 15767 
2.26881E+14 2951386.56 5073315444 44720 211 16208 16834 
2.6933E+14 3083114.57 5416662333 49723 223 17281 17941 
3.17569E+14 3212375.14 5760784455 55126 235 18385 19080 
3.72514E+14 3338257.87 6102635826 61042 247 19536 20267 
4.34701E+14 3461720.72 6444235450 67456 260 20726 21495 
 
 
 
 
265 
 
 
 
 
 
SCENARIO 3: Increase acceptance by 50% every 10 years           
a 
           
         
mle nue 
 
            
 
A B C a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1205 646 1944 1404 1945 1405 749 3647 3646 3645 
1999 867 1406 758 2267 1647 2268 1648 868 4306 4305 4304 
2000 974 1598 866 2577 1883 2578 1884 975 4983 4982 4981 
2001 1070 1784 972 2877 2112 2878 2113 1071 5680 5679 5678 
2002 1157 1966 1075 3171 2337 3172 2338 1158 6407 6406 6405 
2003 1236 2145 1178 3460 2560 3461 2561 1237 7169 7168 7167 
2004 1307 2324 1280 3748 2782 3749 2783 1308 7975 7974 7973 
2005 1373 2502 1382 4036 3004 4037 3005 1374 8830 8829 8828 
2006 1433 2682 1485 4326 3229 4327 3230 1434 9745 9743 9742 
2007 1489 2864 1590 4620 3456 4621 3457 1490 10720 10718 10717 
2008 1541 3050 1696 4920 3688 4921 3689 1542 11773 11771 11770 
2009 1589 3240 1806 5226 3925 5227 3926 1590 12906 12904 12903 
2010 1634 3435 1917 5541 4168 5542 4169 1635 14130 14127 14126 
2011 1677 3636 2032 5865 4418 5866 4419 1678 15452 15449 15448 
2012 1717 3844 2151 6200 4676 6201 4677 1718 16885 16882 16881 
2013 1755 4059 2274 6547 4944 6548 4945 1756 18445 18441 18440 
2014 1791 4282 2402 6907 5221 6908 5222 1792 20131 20127 20126 
2015 1826 4514 2535 7281 5510 7282 5511 1827 21970 21964 21963 
2016 1860 4756 2672 7671 5809 7672 5810 1861 23963 23957 23956 
 
 
 
 
 
266 
 
 
 
 
 
 
       =(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
2.1272E+12 561660.314 421492365.7 5047 71 3574 3785 
3.98011E+12 753753.876 655155331.6 6075 78 4226 4457 
6.72168E+12 950313.026 927353462.9 7248 85 4896 5148 
1.05384E+13 1146719.72 1229111535 8574 93 5585 5859 
1.56741E+13 1340292.44 1553010258 10093 100 6304 6602 
2.23912E+13 1529006.44 1892191341 11833 109 7058 7380 
3.10266E+13 1711962.9 2241678456 13841 118 7855 8204 
4.19473E+13 1887958.44 2595999495 16158 127 8701 9077 
5.56793E+13 2057704.18 2953772621 18850 137 9605 10011 
7.27446E+13 2221500.82 3313301829 21955 148 10569 11007 
9.39437E+13 2378442.53 3670460079 25595 160 11610 12084 
1.2005E+14 2529022.28 4024407870 29830 173 12730 13242 
1.52182E+14 2674827.54 4377328521 34766 186 13940 14491 
1.91562E+14 2815449.08 4726941932 40526 201 15246 15842 
2.39798E+14 2951386.56 5073315444 47266 217 16663 17307 
2.98913E+14 3083114.57 5416662333 55184 235 18205 18900 
3.71007E+14 3212375.14 5760784455 64402 254 19872 20623 
4.5917E+14 3338257.87 6102635826 75241 274 21689 22501 
5.66484E+14 3461720.72 6444235450 87906 296 23660 24537 
 
 
267 
 
 
 
 
 
Scenario 3 continued 
 
b 
 
mortality 50% increase 
        
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1149 615 1853 1338 1854 1339 749 3313 3312 3311 
1999 867 1290 696 2080 1513 2081 1514 868 3629 3629 3628 
2000 974 1421 772 2292 1678 2293 1679 975 3949 3949 3948 
2001 1070 1546 845 2493 1836 2494 1837 1071 4278 4278 4277 
2002 1157 1667 915 2688 1990 2689 1991 1158 4624 4624 4623 
2003 1236 1785 985 2879 2142 2880 2143 1237 4991 4991 4990 
2004 1307 1903 1055 3069 2294 3070 2295 1308 5385 5385 5384 
2005 1373 2022 1125 3261 2445 3262 2446 1374 5807 5807 5806 
2006 1433 2142 1196 3455 2599 3456 2600 1434 6264 6264 6263 
2007 1489 2265 1268 3654 2756 3655 2757 1490 6761 6761 6760 
2008 1541 2392 1342 3858 2917 3859 2918 1542 7302 7302 7301 
2009 1589 2522 1418 4068 3083 4069 3084 1590 7891 7891 7890 
2010 1634 2658 1497 4287 3254 4288 3255 1635 8535 8534 8533 
2011 1677 2798 1578 4513 3431 4514 3432 1678 9234 9233 9232 
2012 1717 2945 1663 4750 3615 4751 3616 1718 10001 10000 9999 
2013 1755 3098 1751 4996 3807 4997 3808 1756 10838 10837 10836 
2014 1791 3257 1843 5253 4007 5254 4008 1792 11750 11749 11748 
2015 1826 3424 1939 5522 4216 5523 4217 1827 12749 12747 12746 
2016 1860 3598 2040 5804 4434 5805 4435 1861 13839 13837 13836 
 
 
 
 
268 
 
 
 
 
 
=(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
1.75538E+12 561660.314 421492365.7 4165 65 3247 3438 
2.82781E+12 753753.876 655155331.6 4316 66 3562 3757 
4.2229E+12 950313.026 927353462.9 4554 67 3881 4081 
5.98067E+12 1146719.72 1229111535 4866 70 4208 4414 
8.16759E+12 1340292.44 1553010258 5259 73 4551 4766 
1.08549E+13 1529006.44 1892191341 5737 76 4915 5139 
1.41469E+13 1711962.9 2241678456 6311 79 5304 5540 
1.81434E+13 1887958.44 2595999495 6989 84 5722 5970 
2.30118E+13 2057704.18 2953772621 7791 88 6175 6436 
2.89415E+13 2221500.82 3313301829 8735 93 6666 6943 
3.61417E+13 2378442.53 3670460079 9847 99 7201 7495 
4.48855E+13 2529022.28 4024407870 11153 106 7784 8097 
5.55298E+13 2674827.54 4377328521 12686 113 8420 8754 
6.84139E+13 2815449.08 4726941932 14473 120 9112 9468 
8.41327E+13 2951386.56 5073315444 16583 129 9870 10251 
1.03219E+14 3083114.57 5416662333 19056 138 10698 11107 
1.26414E+14 3212375.14 5760784455 21944 148 11600 12038 
1.54641E+14 3338257.87 6102635826 25340 159 12587 13058 
1.88959E+14 3461720.72 6444235450 29322 171 13665 14172 
 
 
 
 
 
269 
 
 
 
 
Scenario 3 continued 
 
c 
 
mortality 25% decrease 
        
         
mle nue 
 
            
 
A B c a+b a+c a+b+1 a+c+1 a+1 =($e12*$f12)/$b12 =[($g12*$h12)/$i12] =$k12-1 
1997 616 989 534 1605 1150 1606 1151 617 2996 2996 2995 
1998 748 1234 661 1990 1437 1991 1438 749 3821 3820 3819 
1999 867 1466 790 2365 1718 2366 1719 868 4685 4685 4684 
2000 974 1694 917 2732 1994 2733 1995 975 5594 5593 5592 
2001 1070 1918 1043 3094 2267 3095 2268 1071 6556 6555 6554 
2002 1157 2141 1168 3453 2539 3454 2540 1158 7579 7578 7577 
2003 1236 2362 1293 3810 2811 3811 2812 1237 8668 8667 8666 
2004 1307 2584 1418 4168 3083 4169 3084 1308 9828 9827 9826 
2005 1373 2807 1545 4528 3358 4529 3359 1374 11074 11072 11071 
2006 1433 3034 1673 4893 3636 4894 3637 1434 12411 12408 12407 
2007 1489 3263 1803 5263 3919 5264 3920 1490 13848 13845 13844 
2008 1541 3497 1935 5640 4207 5641 4208 1542 15395 15392 15391 
2009 1589 3736 2071 6025 4502 6026 4503 1590 17067 17063 17062 
2010 1634 3981 2210 6421 4804 6422 4805 1635 18872 18868 18867 
2011 1677 4233 2353 6827 5116 6828 5117 1678 20828 20823 20822 
2012 1717 4493 2501 7247 5436 7248 5437 1718 22944 22938 22937 
2013 1755 4762 2653 7681 5768 7682 5769 1756 25246 25239 25238 
2014 1791 5041 2811 8130 6111 8131 6112 1792 27735 27728 27727 
2015 1826 5329 2975 8595 6467 8596 6468 1827 30439 30430 30429 
2016 1860 5629 3145 9079 6837 9080 6838 1861 33380 33371 33370 
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=(a+b+1)(a+c+1)(b)(c)/(a+1)2 
(a+2) 
      var NUE 
    
95% CI 
       
=($g12*$h12*$c12*$d12) =$i12*$i12 =($b12+2)*$n12 =$m12/$o12 =SQRT($p12) 
=$L12-
1.96*$q12 =$L12+1.96*$q12 
9.76244E+11 380689 235265802 4150 64 2869 3121 
2.33501E+12 561660.314 421492365.7 5540 74 3745 3965 
4.71297E+12 753753.876 655155331.6 7194 85 4599 4850 
8.47106E+12 950313.026 927353462.9 9135 96 5496 5779 
1.40419E+13 1146719.72 1229111535 11424 107 6447 6764 
2.19364E+13 1340292.44 1553010258 14125 119 7458 7810 
3.27333E+13 1529006.44 1892191341 17299 132 8534 8923 
4.71191E+13 1711962.9 2241678456 21020 145 9681 10110 
6.59704E+13 1887958.44 2595999495 25412 159 10911 11383 
9.03142E+13 2057704.18 2953772621 30576 175 12233 12750 
1.21384E+14 2221500.82 3313301829 36635 191 13652 14219 
1.60632E+14 2378442.53 3670460079 43764 209 15181 15801 
2.09915E+14 2529022.28 4024407870 52160 228 16834 17510 
2.71468E+14 2674827.54 4377328521 62017 249 18618 19355 
3.48032E+14 2815449.08 4726941932 73627 271 20550 21353 
4.42756E+14 2951386.56 5073315444 87272 295 22642 23516 
5.59973E+14 3083114.57 5416662333 103380 322 24917 25869 
7.04173E+14 3212375.14 5760784455 122236 350 27377 28412 
8.81383E+14 3338257.87 6102635826 144427 380 30049 31174 
1.09918E+15 3461720.72 6444235450 170568 413 32957 34179 
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Legend 
       1997 EDTA and 1998 CQ (CRM) 
    5,447 reported by Mircescu et al for 2003 (2004) 
  6,600 reported by NHIF 2006 
    7,400 reported by NHIF 2007 
    10,000 estimated by NHIF 2008 
  
  
end of second cycle estimates in all 
scenarios 
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List of acronyms 
 
ACEI Angiotensin Converting Enzyme Inhibitor 
ADPKD Autosomal Dominant Polycystic Kidney Disease 
BMI Body Mass Index 
BUN Blood Urea Nitrogen 
CADTx Cadaver Donor Transplant 
CAPD Continuous Ambulatory Peritoneal Dialysis 
CBA Cost Benefit Analysis 
CBR Cost Benefit Ratio 
CCPD Continuous Cyclical Peritoneal Dialysis 
CEA Cost Effectiveness Analysis 
CER Cost Effectiveness Ratio 
CGN Chronic Glomerulonephritis 
CHD Coronary Heart Disease 
CKD Chronic Kidney Disease 
CRF Chronic Renal Failure 
CRI Chronic Renal Insufficiency 
CRM Capture-Recapture Method 
CUA Cost Utility Analysis 
CVD Cardio Vascular Disease 
DM Diabetes Mellitus 
ERA-EDTA European Renal Association- European Dialysis and 
Transplant Association 
EPO Erythropoietin 
ER Emergency Room 
ESRD End-Stage Renal Disease 
ESRF End-Stage Renal Failure 
FY Fiscal Year 
e-GFR Estimated-Glomerular Filtration Rate 
GN Glomerulonephritis 
GP General Practitioner 
Hb Haemoglobin 
HD Haemodialysis 
HDF Haemo-dia-filtration 
HHD Home Haemodialysis 
HLA Human Leukocyte Antigen 
HRQOL Health Related Quality of Life 
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HT Hypertension 
ICD-9 or 10 International Classification of Diseases 9
th
 or 10
th
 version 
ICER Incremental Cost-Effectiveness Ratio 
IDDM Insulin Dependent Diabetes Mellitus 
IPD Intermittent Peritoneal Dialysis 
JNC VI Joint National Committee on Hypertension 6
th
 revision 
KDQ Kidney Disease Questionnaire 
KDQOL Kidney Disease Quality of Life 
KPS Karnofsky Performance Scale 
LRDTx  Living Related Donor Transplant 
LYG Life Years Gained 
MDRD Modification of Diet in Renal Disease (Study)(USA) 
MI Myocardial Infarction 
MLE Maximum Likelihood Estimate 
MoH Ministry of Health 
MPGN Membrano-proliferative glomerulo-nephritis 
N or n Number of observed/ defined values 
NHANES National Health and Nutrition Examination Survey (USA) 
NHIF National Health Insurance Fund 
NHP Nottingham Health Profile 
NIDDM Non-Insulin Dependent Diabetes Mellitus 
NUE Nearly Unbiased Estimate 
OR Odds Ratio 
PRCV Packed Red Cells Volume 
PD Peritoneal Dialysis 
Pmp per million population 
PRD Primary Renal Disease 
PTFE Poly-Tetra-Fluoro-Ethylen (graft) 
PVD Peripheral Vascular Disease 
QALY Quality Adjusted Life Year 
QI Quetelet Index 
QOL Quality of Life 
QWB Quality of Well Being (Index) 
RCT Randomised Controlled Trial 
RQLP Renal Quality of Life Profile 
RR Risk Rate; Risk Ratio; Rate Ratio (contextual) 
RRT Renal Replacement Therapy 
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SF-36 Short Form- 36 Questionnaire 
SAR Standardised Acceptance Ratio 
SIP Sickness Impact Profile 
SSR Standardised Stock Ratio 
Tx Transpalant 
U Unit of measure (e.g. IU: international unit) 
UK United Kingdom 
USRDS United States Renal Data System 
VAS Visual Analogue Scale 
WHO World Health Organisation 
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